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 Abstract 
 
Background: Moderate alcohol consumption has been associated with a lower risk of type 
2 diabetes in various populations. However, the underlying mechanisms are not entirely 
clear. The aims of this thesis were 1) to substantiate the evidence of the association between 
alcohol consumption and type 2 diabetes in observational research and 2) to examine 
physiological mechanisms in randomized trials with specific attention to adiponectin, 
inflammation and insulin sensitivity which may mediate the association between alcohol 
consumption and type 2 diabetes. 
 
Methods: Two prospective cohort studies, one among 38,031 U.S. men (age: 45-75 y) of 
the Health Professionals Follow up Study (HPFS) and one among 35,625 Dutch men and 
women (age: 20-70 y) of the European Prospective Investigation into Cancer and Nutrition 
(EPIC)-NL cohort. Four randomized, crossover trials of eight to twelve weeks with 
consumption of 25-30 g alcohol/day in the form of vodka with orange juice, beer, or white 
wine (twice) compared to orange juice, alcohol free beer, white grape juice or water among 
24 young men, 24 premenopausal and 36 and 22 postmenopausal women, respectively. 
 
Results: A 7.5 g/day increase in alcohol consumption over four years was associated with 
lower diabetes risk among initial non-drinkers (hazard ratio [HR]: 0.78; 95% confidence 
interval (CI): 0.60, 1.00) and drinkers initially consuming <15 g/d (HR: 0.89; 95% CI: 0.83, 
0.96) but not among men initially drinking ≥15 g/d (HR: 0.99; 95% CI: 0.95, 1.02) 
(Pinteraction < 0.01) in U.S. men. Among Dutch subjects with ≥3 out of 4 low-risk lifestyle 
behaviors, moderate alcohol consumption was associated with a lower risk of type 2 
diabetes compared with abstention (HR: 0.56; 95% CI: 0.32, 1.00). 
In the randomized crossover trials, alcohol consumption consistently increased 
circulating adiponectin levels by about 10% compared to abstention (P < 0.05) regardless 
of beverage type, gender or age. These increases were evident after a minimum of three 
weeks of alcohol consumption. Moderate alcohol consumption also increased expression of 
the gene encoding adiponectin in adipose tissue and lowered serum fasting insulin and 
triglyceride levels (all P < 0.05). An integrated approach of large-scale profiling of proteins 
and genes revealed that moderate alcohol consumption for four weeks altered gene 
expression profiles of white blood cells and circulating markers related to inflammation in 
men (all P < 0.05). However, we did not observe an attenuated inflammatory response after 
a low-dose in vivo endotoxin bolus, despite increased high-density lipoprotein cholesterol 
and apolipoprotein levels after four weeks of alcohol consumption compared to abstention. 
Six minutes of oral white wine exposure without swallowing substantially (-20%; P < 0.05) 
and temporarily (~20 min) decreased circulating free fatty acid concentrations compared 
with oral water exposure. 
 
 Conclusions: Moderate alcohol consumption was associated with a lower risk of type 2 
diabetes compared with abstention. The association persisted among subjects already at low 
risk based on combined favorable lifestyle behaviors. Also, increases in alcohol 
consumption among initially rare and light drinking men were associated with higher 
adiponectin levels and lower risk of type 2 diabetes. Increased adiponectin levels, anti-
inflammatory effects and decreased insulin and triglyceride levels, may partially explain the 
inverse association between moderate alcohol consumption and type 2 diabetes. 
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Alcohol consumption: what’s (in) a drink? 
The term ‘alcohol’ in alcohol consumption commonly refers to ethanol or ethyl alcohol, a 
2-carbon alcohol, which is the dominant bioactive compound in all alcoholic beverages. It 
is safe to say that alcohol is both a tonic and a poison. The difference lies mostly in the 
dose. Moderate alcohol consumption is associated with lower total mortality (1), 
cardiovascular diseases (2;3) and type 2 diabetes (4) but also with increased breast cancer 
risk among women (5) compared with abstention. Excessive alcohol consumption is 
associated with an increased risk of injuries and accidents (6;7), liver diseases (8;9), several 
forms of cancer (5), alcohol dependence and alcoholism. The quantity of alcohol consumed 
thus determines how it affects overall health and well-being.  
 
In 2006, the Dutch Health Council stated that “People who consume alcohol are well 
advised to limit their intake; adult men should drink no more than two standard Dutch units 
per day, and adult women no more than one unit. Binge drinking should be avoided. 
Alcohol consumption is inadvisable for the under-eighteens, and for pregnant women, 
women who are seeking to become pregnant and women who are breastfeeding” (10). 
According to the 2005 United States Department of Agriculture (USDA) Dietary 
Guidelines (11), moderate drinking is considered to be no more than one drink per day for 
women and no more than two drinks/day for men. Guidelines for sensible drinking set by 
the U.K. government in 1995 are 3 to 4 units or less for men and 2 to 3 units or less for 
women (12). 
In the Netherlands a standard unit of beer (250 mL), wine (100 mL) and spirits (35 
mL) all contain around 10 g of pure alcohol. In the United States typical serving sizes 
consist of one 12-ounce bottle of beer, one 5-ounce glass of wine, or 1.5 ounces of 80-proof 
distilled liquor equaling around 14 to 15 g of alcohol per serving (13) whereas a standard 
unit of alcohol in the United Kingdom equals 8 g of alcohol. Thus, at the upper limits, 
moderate drinking would be between 10 to 20 g of alcohol/day for women and 20 to 30 
g/day for men, depending which guideline one uses. 
Given differences in first-pass metabolism, volume of distribution, and overall 
body size between men and women (14), women experience toxic effects at approximately 
half the daily dose of alcohol of men. This notion is reflected in sex-specific limits that 
these above mentioned guidelines endorse. 
 
 
Diabetes mellitus: etiology 
Diabetes mellitus, often simply referred to as diabetes, is a disorder characterized by 
hyperglycemia (chronic elevated blood glucose levels) from defects in insulin secretion, 
insulin sensitivity, or both. These high blood glucose levels produce the classical symptoms 
of polyuria (frequent urination), and polydipsia (increased thirst). Diabetes is associated 
with increased morbidity and mortality. Complications include retinopathy, neuropathy and 
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renal failure. Several forms of diabetes can be distinguished. Type 1 diabetes mellitus, also 
known as insulin-dependent diabetes, is caused by defects in pancreatic function leading to 
an inability to produce sufficient amount of insulin. This type of diabetes is often diagnosed 
at early age and accounts for less then 5% of the diabetes cases.  
Type 2 diabetes mellitus, formerly non-insulin-dependent diabetes mellitus or 
adult-onset diabetes, is the most common form of diabetes and accounts for approximately 
90 to 95% of the cases of diabetes. As of 2000 at least 171 million people worldwide suffer 
from diabetes, or 2.8% of the population (15). Type 2 diabetes is a metabolic disorder that 
is characterized by high blood glucose in the context of insulin resistance and abnormal 
insulin secretion. It is caused by a combination of an impairment of the β-cells to release 
sufficient insulin (β-cell dysfunction) and an impaired metabolic response of peripheral 
tissues to circulating insulin (insulin resistance). 
The underlying mechanisms leading to insulin resistance and β-cell dysfunction 
are still subject of research. Recently, obesity has been associated with a chronic low-grade 
inflammatory state of adipose tissue (16;17) in which circulating concentrations of 
inflammatory mediators such as tumor necrosis factor alpha (TNF-α) interleukin-6 (IL-6) 
and C-reactive protein (CRP) are increased (18). Low-grade inflammatory changes have 
been shown to precede type 2 diabetes by many years (19;20).  
Besides elevated glucose concentrations, circulating free fatty acid (FFA) 
concentrations are also increased in obese persons, which lead to a reduction of glucose 
uptake in adipose tissue and skeletal muscles and in a stimulation of glucose output from 
the liver. In response to elevated glucose and FFA concentrations various tissues and cell 
types have been shown to release inflammatory mediators.  
Finally, adipose tissue is known to secrete various signaling peptides – the 
adipokines – influencing insulin sensitivity, inflammation and food intake (21). The most 
abundant adipokine is adiponectin. Adiponectin is thought be involved in glucose and lipid 
metabolism (22). Higher adiponectin levels have been consistently associated with a lower 
risk of type 2 diabetes (23) and cardiovascular disease (24). Moreover, adiponectin is 
positively associated with insulin sensitivity (25) and inversely with inflammatory markers 
(26).  
 
 
Modifiable lifestyle factors 
Although genetic elements are involved in the development of pre-diabetes and type 2 
diabetes, the rapid changes in incidence rates during the last decades suggest a particularly 
important role for lifestyle related factors. Compelling evidence from epidemiologic studies 
and lifestyle interventions indicate that the current worldwide diabetes epidemic is largely 
due to changes in diet and lifestyle (27). The majority (~90%) of incidence type 2 diabetes 
cases may be prevented by a healthy lifestyle of which excess adiposity is by far the most 
important risk factor for diabetes (28-30). Other components of a low-risk lifestyle being 
physically active (31;32), refraining from smoking (33) and eating a diverse and healthy 
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diet rich in fruits, vegetables, whole grains, nuts and legumes and low in red and processed 
meats, sugar-sweetened beverages and sodium (34-37).  
Besides these four modifiable lifestyle factors, moderate alcohol consumption could be 
regarded as a fifth low-risk factor to reduce the risk of type 2 diabetes.  
 
 
State of the art evidence on alcohol consumption and type 2 diabetes 
risk 
Substantial epidemiological evidence of at least 20 prospective studies (28;30;38-68) from 
different geographical regions and large and diverse cohorts described in several meta-
analyses (4;69-73) links moderate alcohol consumption with a lower risk of type 2 diabetes. 
The population size and diversity and length of follow-up all vary greatly from study to 
study which adds to the robustness and generalizability of the findings. Most studies 
describe a J-shaped or U-shaped curve, whereby light to moderate drinkers have less risk 
than abstainers and heavy drinkers. The strength of the association described in these meta-
analyses varies between the 10 and 40%. Maximum risk reduction is observed when 
consuming alcohol at about 25 g/day. No risk reduction was reported at consumption levels 
greater than 50 g/day for both men and women (4;69-73). 
The ethanol itself, rather than specific components of various alcoholic beverages, 
appear to be the major factor in conferring health benefits. However, the alcohol-containing 
beverage which is most frequently consumed in specific populations, will be associated 
with the greatest benefit in that population; e.g. wine is the most common source of alcohol 
in Dutch postmenopausal women and wine is therefore of most benefit (57) whereas if 
spirits or beer are consumed the most these beverages appear to have the strongest 
associations (45;61). 
 
Factors modifying the relation between alcohol consumption and type 2 
diabetes 
Besides several lifestyle factors that are associated with diabetes risk itself, other factors 
have the potency to modify the relation between alcohol consumption and diabetes risk. 
Two examples of such factors include drinking pattern and genetic predisposition. 
 
Drinking pattern 
Drinking pattern is an important factor in the relation, because the way alcohol is consumed 
has differential effects given the same volume: drinking moderate amounts per occasion 
and at regular frequency (4-7 days/week) decreases risk of type 2 diabetes (45;55) whereas 
binge drinking or episodic drinking (5 or more alcoholic beverages at a single occasion) 
increases the risk (46;59). 
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Genetic predisposition 
Polymorphisms in genes that oxidize alcohol may also affect the relation between alcohol 
consumption and type 2 diabetes risk. The major enzymes involved are alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Ethanol is oxidized to 
acetaldehyde in a reversible reaction catalyzed by the class I ADH isoenzymes (e.g. 
ADH1a, ADH1b, ADH1c) located in the cytosol of hepatocytes. Subsequently, 
acetaldehyde is then oxidized to acetate and water in a nonreversible reaction catalyzed by 
the mitochondrial class II ALDH2. Functional relevant polymorphisms are found in the 
genes encoding ADH1b and ADH1c, the latter affecting ethanol degradation rates and 
alcohol intake in Caucasian populations (74). Thus, such a polymorphism could modify the 
association of alcohol consumption with disease risk but with an effect anticipated only 
among drinkers. Indeed, it appears that the alcohol dehydrogenase 1c gene (ADH1C) 
modifies the relation between alcohol consumption and diabetes among drinkers (75) 
although some inconsistency exists (76).  
 
Underlying mechanisms based on observational studies and 
randomized trials 
 
Improved insulin sensitivity 
There is substantial observational evidence that links alcohol consumption to improved 
insulin sensitivity either in a linearly inverse association (77-85) or a U-shaped relationship 
(47;76;86;87). This association even presents in subjects with confirmed type 2 diabetes 
(88). Furthermore, alcohol consumption is also inversely associated with glycemic control 
among type 2 diabetes patients (89) and complications of type 1 (90) and type 2 diabetes 
such as cardiovascular diseases and mortality (91).  
Despite a large amount of observational studies showing a positive association 
between moderate alcohol consumption and insulin sensitivity, there is limited evidence 
from clinical trials that supports this finding. So far, eleven studies have examined the 
effects of moderate alcohol consumption on fasting glucose and insulin levels or (in)direct 
markers of insulin sensitivity in subjects without diabetes (92-102) (Table 1.1). Only one 
study reported lower steady-state plasma glucose (SSPG; a measure of insulin resistance) 
(102) in a subgroup of people after eight weeks of red wine or vodka consumption, 
equaling 30 g of alcohol/day. Another study reported lower fasting insulin and triglyceride 
levels, another independent risk factor for type 2 diabetes (94), after eight weeks of alcohol 
consumption in the form of 15 and 30 g pure alcohol and juice per day. The majority of 
studies, however, did not show changes in fasting levels of glucose and insulin or insulin 
sensitivity. It appears that the alcohol’s effects on insulin sensitivity are only observed after 
prolonged periods of consumption (8 weeks) and are more pronounced in older, more 
insulin-resistant populations (94;102) or in subjects with type 2 diabetes (103-106). 
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Increased circulating adiponectin levels 
Second, alcohol consumption has been associated with higher circulating adiponectin 
concentrations (82;107-109) even in diabetic subjects (88). Adiponectin was demonstrated 
to be an independent risk factor of insulin sensitivity and type 2 diabetes based on 10 
prospective cohort studies (23). It is also inversely associated with markers of inflammation 
(26). More importantly, increased adiponectin concentrations may explain up two one third 
of the association between alcohol consumption and type 2 diabetes (110).  
Also in several randomized trials, predominantly performed in males, moderate 
alcohol consumption increased plasma total adiponectin concentrations (97;99-101;111) 
and even the high-molecular weight (HMW) adiponectin isomer (100). Especially the latter 
of adiponectin has been proposed as the most active metabolic form (112-114). 
 
Anti-inflammatory effects 
Third, moderate alcohol consumption has various effects on the immune system (115) and 
is associated with lower levels of inflammatory markers (116-118). In concord with insulin 
sensitivity and adiponectin levels, the association between alcohol consumption and 
inflammatory markers even persists among men with type 2 diabetes (88;119).  
Data from randomized trials on inflammatory markers after prolonged moderate 
alcohol consumption are scare but do suggest lower levels of CRP (120;121) and certain 
cytokines (122) although not consistently (123). Furthermore, moderate alcohol 
consumption also has several acute effects on white blood cells. Also several lines of 
evidence suggest that acute moderate alcohol consumption inhibits the pluripotent 
transcription factor nuclear receptor regulatory factor kappa B (NF-κB) in white blood cells 
(124;125). Activation of this transcription factor is a pivotal step in the induction of 
inflammatory cytokines, chemokines and growth factors. 
 
Beneficial postprandial effects 
Recent evidence showed that alcoholic beverages as such are capable of reducing peak 
blood glucose concentrations and the overall postprandial glucose response when consumed 
with or before a carbohydrate-containing meal (126;127). Besides lowered glycemic 
responses, acute alcohol consumption also decreased serum FFA levels (128) also in 
subjects with type 2 diabetes (129). 
 
 
Rationale and outline of this thesis 
There is ample evidence from observational research linking moderate alcohol consumption 
to a reduced risk of type 2 diabetes. However, several aspects have not yet been studied. 
Also, the physiological mechanisms that account for this observation are not completely 
understood. We thus aimed to: 
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1) further substantiate the existing literature of prospective cohort studies on alcohol 
consumption and risk of type 2 diabetes by investigating the temporality of the relation 
between alcohol intake and type 2 diabetes risk and by examining this association among 
subjects already at low risk of diabetes due to individual and joint contribution of healthy 
lifestyle behaviors 
 
2) examine physiological mechanisms in short-term intervention studies of alcohol 
consumption that potentially mediate the association between alcohol consumption and 
type 2 diabetes. Of particular interest is the effect of alcohol consumption on adiponectin 
concentrations, low-grade inflammatory processes and to a lesser extent insulin sensitivity. 
 
Prospective cohort studies 
A new approach to explore the causality of the alcohol–diabetes relation is to examine the 
temporality of the association; in other words: does the introduction or removal of alcoholic 
beverages lead to a change in risk? In chapter 2 we examine the effect of changes in 
alcohol consumption on subsequent changes in risk of type 2 diabetes during twenty years 
of follow-up. Furthermore, we look at associations between a four-year change in alcohol 
consumption and its effect on circulating levels of adiponectin and hemoglobin A1c 
(HbA1c).  
 
As previously described in this chapter approximately 90% of the incident type 2 diabetes 
cases could have been prevented by adhering to several low-risk lifestyle behaviors. It is 
uncertain whether alcohol consumption could still decrease the risk of diabetes even if 
people already pursue several of these healthy lifestyle behaviors and may consequently be 
considered as an independent risk factor. Therefore, we evaluate in chapter 3 the 
association between alcohol consumption and type 2 diabetes in the context of single and 
multiple favorable lifestyle behaviors. 
 
Randomized crossover trials 
Despite the consistent decreased risk of type 2 diabetes associated with moderate alcohol 
consumption in observational studies the majority of the short-term alcohol-feeding trials 
do not find changes in insulin sensitivity, an important predictor of type 2 diabetes, even 
after prolonged moderate alcohol consumption. In chapter 4 we try to confirm a previously 
observed finding of improved insulin sensitivity in postmenopausal women. Additionally, 
we investigate the effects of white wine on the expression of the gene encoding adiponectin 
(ADIPOQ) and on corresponding circulating protein levels of adiponectin, an important 
biochemical predictor of type 2 diabetes.  
 
Moderate alcohol consumption has several acute effects on gene expression of white blood 
cells but longer term effects on gene expression are largely unknown. In chapter 5 we thus 
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explore the effects of four weeks of moderate vodka consumption on changes in associated 
gene expression of leukocytes (white blood cells) and several circulating proteins. 
 
Although prolonged moderate alcohol consumption increases circulating adiponectin levels 
acute alcohol consumption in moderation does not increase postprandial adiponectin levels. 
This suggests that longer periods of consumption are needed to increase adiponectin levels. 
Therefore, we describe in chapter 6 weekly changes in two forms of plasma adiponectin 
levels during 3 weeks of moderate beer consumption in normal-weight premenopausal 
women.  
 
Since a low-grade inflammation is thought to play an important role in the development of 
type 2 diabetes, we tried to mimic an acute low-grade inflammatory status by challenging 
young men with a low-dose endotoxin bolus to see whether the inflammatory response is 
attenuated after moderate vodka consumption. These results are described in chapter 7. 
 
Besides prolonged and postprandial effects of moderate alcohol consumption, pre-prandial 
effects of alcohol consumption (e.g. mere tasting of alcohol before ingestion) might also 
affect glucose and lipid metabolism. These pre-prandial effects belong to a so called 
cephalic phase and are important in triggering gastric and intestinal responses. Therefore, in 
chapter 8 we investigate the effects of pre-prandial oral white wine exposure on several 
markers of glucose and lipid metabolism to investigate whether alcohol induces cephalic 
phase responses. 
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Background: Alcohol consumption has been associated with lower risk of diabetes, but 
whether changes in alcohol consumption over time influence future diabetes risk is unclear. 
 
Objective: The objective of this study was to investigate the association of four-year 
changes in alcohol consumption with subsequent risk of type 2 diabetes. 
 
Design: We prospectively examined 38,031 middle-aged men from the Health 
Professionals Follow-up Study free of diagnosed diabetes or cancer in 1990. Alcohol 
consumption was reported on food frequency questionnaires and updated every four years. 
 
Results: A total of 1,905 cases of type 2 diabetes occurred during 428,497 person-years of 
follow-up. A 7.5 g/day (~half a glass) increase in alcohol consumption over four years was 
associated with lower diabetes risk among initial nondrinkers (multivariable hazard ratio 
[HR]: 0.78; 95% confidence interval [CI]: 0.60, 1.00) and drinkers initially consuming <15 
g/day (HR: 0.89; 95% CI: 0.83, 0.96) but not among men initially drinking ≥15 g/day (HR: 
0.99; 95% CI: 0.95, 1.02; Pinteraction < 0.01). A similar pattern was observed for levels of 
total adiponectin and hemoglobin A1c, with a better metabolic profile among abstainers and 
light drinkers who modestly increased their alcohol intake, compared with men who either 
drank less or among men who were already moderate drinkers and increased their intake. 
Likewise, compared to stable light drinkers (0-4.9 g/day), light drinkers who increased their 
intake to moderate levels (5.0-29.9 g/day) had a significantly lower risk of type 2 diabetes 
(HR: 0.75; 95% CI: 0.62, 0.90). 
 
Conclusions: Increases in alcohol consumption over time were associated with lower risk 
of type 2 diabetes among initially rare and light drinkers. This lower risk was evident 
within a four-year period following increased alcohol intake.  
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Introduction 
Alcohol consumption has been consistently associated with a reduced risk of type 2 
diabetes compared with abstention or excessive consumption (1;2). Most prospective 
studies measure alcohol consumption at only one point in time which assumes intake is 
fairly stable over time. However, alcohol consumption is dynamic, especially over longer 
periods of follow-up (3). Importantly, changes in alcohol consumption over time have been 
associated with subsequent changes in risk of cardiovascular diseases (4-6) and mortality 
(7) although some inconsistency exists (8;9). Variability in intake over time thus highlights 
the constraints of single measures of alcohol consumption. 
To our knowledge, no observational studies have examined the association between 
changes in alcohol consumption over time and future risk of type 2 diabetes, despite the 
importance of such studies both in assessing the robustness of the alcohol-diabetes 
association and in addressing a topic of direct clinical importance – what happens when 
individuals adopt or cease drinking? Short-term randomized trials of alcohol have shown 
changes in insulin sensitivity and adiponectin concentrations within six to eight weeks, 
suggesting changes in subsequent risk of diabetes could plausibly occur with a short latency 
(10-12). Therefore, we attempted to examine whether initiation of light to moderate alcohol 
consumption is associated with a lower subsequent risk of type 2 diabetes, and likewise 
whether reduction in alcohol consumption is associated with higher type 2 diabetes risk. 
To accomplish these aims, we examined men enrolled in the Health Professionals 
Follow-up Study (HPFS), an ongoing prospective cohort of men who have repeatedly 
reported their alcohol consumption over time and in whom validated diagnoses of diabetes 
have been ascertained for two decades. 
 
 
Methods 
Study population 
The HPFS is a prospective investigation of 51,529 U.S. male health professionals aged 40 - 
75 y at baseline in 1986 who returned a mailed questionnaire about diet and medical 
history. Participants subsequently provided diet, lifestyle, and medical information on 
biennial questionnaires. We excluded men with missing data on body mass index (BMI) 
and physical activity at baseline. We also excluded men who had implausible nutritional 
information (≥70 missing food items or estimated daily energy intake <800 or >4200 kcal). 
Furthermore, we excluded men who deceased or had diagnosed diabetes or cancer (except 
non melanoma skin caner) before follow-up for these analyses started (i.e., in 1990). After 
these exclusions 38,031 participants remained for the analyses.  
To assess the association between changes in alcohol intake and biochemical 
markers of glycemia, we examined a subset of men in this cohort who participated in a 
nested case-control study of coronary heart disease. In 1994, 18,825 participants provided 
blood samples. Men who provided samples were somewhat younger but were otherwise 
similar to those who did not provide samples. We matched 266 men with incident coronary 
| Chapter 2 
 34
heart disease until 2000 and an additional 188 cases from 2000 to 2004 with controls 
matched for age, date of blood draw, and smoking status on a 1:2 basis, as described 
previously (13;14). All participants gave written informed consent, and the Harvard school 
of public health human subjects committee review board approved the study protocol. 
 
Assessment of alcohol consumption 
In 1986, men reported their alcohol consumption on a semi quantitative food frequency 
questionnaire (FFQ) (15;16) that included ,separate items  for beer, white wine, red wine, 
and liquor. Participants were asked how often, on average over the past year, they 
consumed each beverage. We calculated total alcohol intake by multiplying the average 
consumption of each beverage by the published alcohol content of the specified portion size 
based on periodically updated U.S. Department of Agriculture food composition tables and 
then summing across beverages (17). The FFQ was administered again every 4 years, with 
an item for light beer added in 1994. We assessed the validity of self-reported alcohol 
consumption by comparing estimated alcohol intake from the FFQ with the intake derived 
from two 7-day dietary records among 127 participants who returned questionnaires in 
1986 and 1987 and resided in or near Boston, Massachusetts. The Spearman rank 
correlation coefficient between alcohol intake estimated from the FFQ and corresponding 
intake from diet records was 0.86 (18). 
 
Assessment of lifestyle factors 
Lifestyle factors were assessed biennially using questionnaires including BMI, smoking, 
physical activity, and medical conditions. Participants reported physical activity as the 
average time engaged in specific activities during the previous year. Reported weights have 
been shown to correlate well with measured weights, (16) and the assessment of physical 
activity was previously validated (19). We obtained energy intake, coffee consumption and 
energy-adjusted intakes of dietary fiber, glycemic load, trans fat, and the ratio between 
polyunsaturated and saturated fat from a semi quantitative FFQ (20). Glycemic load was 
calculated by multiplying the amount of carbohydrates by the average glycemic index as 
previously described (21). 
 
Ascertainment of type 2 diabetes  
Incident cases of type 2 diabetes were identified by self report and confirmed by a validated 
supplementary questionnaire detailing symptoms, diagnostic laboratory test results and 
diabetes treatment. The diagnosis was confirmed if participants reported at least one of the 
following: treatment with insulin or oral hypoglycemic medication, at least one classic 
symptom (excessive thirst, polyuria, weight loss, or hunger) plus elevated plasma glucose 
level, or at least two elevated plasma glucose concentrations on two different occasions in 
the absence of symptoms. Elevated plasma glucose concentration was defined as at least 
≥140 mg/dL (≥7.8 mmol/L), plasma glucose ≥200 mg/dL [≥11.1 mmol/L] nonfasting, or 
plasma glucose ≥200 mg/dL [≥11.1 mmol/L] after ≥2 hours during an oral glucose 
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tolerance test before 1998; for cases diagnosed in 1998 and later, the fasting plasma glucose 
threshold was lowered to ≥126 mg/dL (≥7.0 mmol/L) (22). The validity of self reported 
diabetes has been confirmed with medical record review in a sample (23). 
 
Measurement of biochemical variables 
Blood samples were collected in liquid EDTA tubes, placed on ice packs, stored in 
Styrofoam containers, returned to our laboratory via overnight courier, and centrifuged and 
aliquoted for storage in liquid nitrogen freezers (−130°C or colder). Plasma total 
adiponectin concentrations were measured by competitive radio-imunoassay (Linco 
Research Inc, St Charles, MO, U.S.A.) for cases and controls ascertained through 2000 (N 
= 798). Hemoglobin A1c (HbA1c) concentrations were measured by turbidimetric 
immunoinhibition for cases and controls through 2004 (N = 1,365). 
 
Statistical analysis 
Each individual contributed person-time from the return of the 1990 questionnaire to the 
date of diagnosis of type 2 diabetes, date of diagnosis of cancer or death, or January 31, 
2006, which ever came first. We used Cox proportional hazards models to calculate hazard 
ratios (HR) and 95% confidence intervals (CI). We used change in alcohol consumption 
updated every 4 years as a time-varying covariable, using an Anderson-Gill data structure 
(24). Thus, we used the change in alcohol consumption between the 1986 and 1990 
questionnaires to determine the risk for type 2 diabetes during the period from 1990 to 
1994, the change in alcohol consumption based on the 1990 and 1994 questionnaires for the 
period from 1994 to 1998, and so on. In these analyses, men contributed person-time only 
during each four-year period in which they provided data on alcohol consumption. We 
skipped contributions of person-time for individuals with missing information on alcohol 
consumption during follow-up for that specific period. In multivariate models, we adjusted 
for age (five categories), BMI (eight categories: <23.0, 23.0-23.9, 24.0- 24.9, 2.5-26.9, 2.7-
28.9, 29.0-30.9, 31.0-34.9, or ≥35.0 kg/m2), physical activity (quintiles), smoking status 
(never, former, current 1-14 cigarettes/day, current 15-24 cigarettes/day or current ≥25 
cigarettes/day), family history of type 2 diabetes (yes or no), incident and prevalent 
cardiovascular disease (stroke, myocardial infarction, coronary artery bypass surgery or 
angina), hypertension, and hypercholesterolemia, dietary glycemic load, fiber intake, trans 
fat intake, ratio of polyunsaturated to saturated fat (all four in quintiles and energy-
adjusted), coffee intake (quintiles) and total energy intake (continuous). All variables were 
treated as time-varying covariates in our models. Linear trends across (change in) alcohol 
consumption categories were tested by treating the median value of each category as a 
continuous variable. 
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Concentrations of total adiponectin and HbA1c per 7.5 g/day increment in alcohol intake 
over four years (i.e., 1990-1994) were calculated with a mixed analysis of variance model 
that included the same terms as the Cox regression model and a term for case-control status 
with clustering on case-control triads. The models were stratified by alcohol intake in 1990. 
For these analyses, we excluded men with missing data on alcohol intake and with a history 
of type 2 diabetes in 1994, leaving 697 and 1,188 men for the adiponectin and HbA1c 
analyses, respectively. 
 
 
Results 
In 1990, the first update on alcohol consumption, most subjects (55%) reported only modest 
change in alcohol consumption compared to four years earlier (Table 2.1). The median 
change in alcohol consumption was 0 g/day. No consistent trends where seen in potential 
confounders among men who decreased or increased their alcohol consumption. 
 
Overall alcohol consumption and risk of type 2 diabetes 
During 428,497 person-years of follow-up among 38,031 men, we documented 1,905 cases 
of newly diagnosed type 2 diabetes. We first examined alcohol consumption in grams per 
day and risk of diabetes. Compared with abstention, HRs of type 2 diabetes after 
multivariable adjustment were 1.04 (95% CI: 0.92, 1.18) for alcohol consumption of 0.1 to 
4.9 g/day, 0.81 (95% CI: 0.69, 0.94) for 5 to 9.9 g/day, 0.70 (95% CI: 0.59, 0.84) for 10 to 
14.9 g/day, 0.71 (95% CI: 0.60, 0.84) for 15 to 29.9 g/day, 0.54 (95% CI: 0.44, 0.67) for 30 
to 49.9 g/day and 0.50 (95% CI: 0.36, 0.69) for alcohol consumption of 50 or more grams 
per day (Ptrend < 0.0001). 
 
Four-year changes in amount of alcohol intake and risk of type 2 diabetes 
The effect of a 7.5 g/day (~half a glass) change in alcohol intake on subsequent change in 
diabetes risk differed between initial alcohol consumption levels (Pinteraction < 0.01) (Table 
2.2). Such an increment had the largest association with risk on men who were initially 
nondrinkers at the beginning of any four-year period of change (HR: 0.78; 95% CI: 0.60, 
1.00). This was followed by men who initially consumed <1 glass/day (HR: 0.89; 95% CI: 
0.83, 0.96). Four-year change in alcohol intake was not associated with subsequent diabetes 
risk among men who consumed ≥1 glass/day at the beginning of the four-year period (HR: 
0.99; 95% CI: 0.95, 1.02). In a secondary analysis, we repeated the analysis excluding men 
with any missing alcohol data during follow-up. This slightly strengthened the association 
of changes in alcohol intake with risk among initial nondrinkers (HR: 0.71; 95% CI: 0.52, 
0.98) but had little effect on initial <1 glass/day drinkers (HR: 0.89; 95% CI: 0.82, 0.96) 
and ≥1 glass/day drinkers (HR: 0.99; 95% CI: 0.95, 1.04). To minimize potential bias 
related to total abstention from alcohol consumption due to poor health, we also excluded 
all current nondrinkers at the beginning of each follow-up period, with little effect on the 
HRs (data not shown). Finally, we examined whether changes in BMI and physical activity 
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over time could partially explain the observed relation. We assessed this effect by including 
levels of BMI and physical activity assessed at both the beginning and end of each four-
year period used to calculate change in alcohol consumption, while retaining all other 
variables in the model. This did not materially influence our results (results not shown).  
 
 
Table 2.3: Hazard ratios of type 2 diabetes according to updated 4-year changes in initial 
and current drinking category (N = 38,031). 
 Alcohol drinking category four years later (g/day)  
Initial alcohol 
drinking category 
(g/day) 
Light 
(0-4.9) 
Moderate 
(5.0-29.9) 
Heavier 
(≥30.0) 
Ptrend1 
Light (0-4.9)     
Hazard ratio2 1.00 (referent) 0.75 (0.62, 0.90) 0.35 (0.11, 1.10) < 0.001 
Person-years 169,623 31,723 1,127  
No. of cases 875 125 3  
Moderate (5.0-29.9)     
Hazard ratio2 1.09 (0.92, 1.30) 0.74 (0.65, 0.83) 0.59 (0.45, 0.77) < 0.001 
Person-years 27,841 134,942 16,050  
No. of cases 159 496 60  
Heavier (≥30.0)     
Hazard ratio2 0.78 (0.44, 1.38) 0.67 (0.52, 0.88) 0.50 (0.40, 0.63) 0.08 
Person-years 2,089 15,036 30,067  
No. of cases 12 65 110  
1 Ptrend was derived from tests of linear trend across increasing categories of alcohol use by treating the median 
value of each category as a continuous variable.  
2 Multivariable-adjusted hazard ratios (95% confidence intervals) were calculated using Cox proportional hazards 
model and adjusted for the covariates listed in table 2. 
 
 
The association between changes in alcohol consumption and diabetes risk among the three 
strata of initial drinkers did not substantially differ by subgroups of BMI. The 
multivariable-adjusted relative risks for diabetes associated with a 7.5 g/day increase in 
alcohol among initial nondrinkers, <1 and ≥1 drink/day consumers were 0.66 (95% CI: 
0.42-1.04), 0.85 (95% CI: 0.76, 0.94) and 0.98 (95% CI: 0.93, 1.04) for men with a BMI 
<28.3 kg/m2 (median BMI of incident diabetes cases) and 0.86 (95% CI: 0.65, 1.14), 0.92 
(95% CI: 0.84, 1.02) and 0.99 (95% CI: 0.93, 1.04) for men with a BMI of ≥28.3 kg/m2, 
respectively (Pinteraction = 0.48). 
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Table 2.4: Associations of a 7.5 g/day increment in alcohol consumption from 1990-1994 
on subsequent total adiponectin (N = 697) and hemoglobin A1c (HbA1c) levels (N = 1,188), 
classified by alcohol consumption in 1990. 
 
Mean increment in glycemic marker per 7.5 g/day increase 
in alcohol consumption from 1990-1994 
Alcohol consumption  
in 1990 (g/day) Total adiponectin (µg/mL) HbA1c (%) 
Non (0)   
Mean increment1 1.2 ± 0.3 -0.04 ± 0.02 
No. of participants 151 267 
   
<1 drink/day (0.1-14.9)   
Mean increment1 0.5 ± 0.3 -0.02 ± 0.02 
No. of participants 355 610 
   
≥1 drink/day (≥15.0)   
Mean increment1 -0.6 ± 0.3 0.01 ± 0.01 
No. of participants 191 311 
   
Pinteraction2 0.002 0.02 
1 Values are mean increments (± SEM) per 7.5 g/day increment in alcohol consumption over four years and were 
calculated with a mixed analysis of variance model that included terms for age, body mass index, physical activity, 
smoking status, family history of type 2 diabetes, hypertension, hypercholesterolemia, cardiovascular disease, 
dietary glycemic load, fiber intake, trans fat intake, ratio of polyunsaturated fat and saturated fat (all energy-
adjusted), coffee intake, total energy intake and case-control status.  
2 Pinteraction was derived by adding an interaction term between the 7.5 g/day increment of alcohol consumption 
(continuous), and initial alcohol consumption in 1990 (categorical) in the mixed analysis of variance model. 
 
 
Four-year changes in type of drinker and risk of type 2 diabetes 
Compared to stable light drinkers (0-4.9 g/day), initial light drinkers who increased their 
intake to moderate levels (5.0-29.9 g/day) had a significantly lower risk of type 2 diabetes 
(HR: 0.75; 95% CI: 0.62, 0.90) (Table 2.3). Conversely, moderate drinkers who reduced 
their intake to none or light did not have a lower risk of diabetes (HR: 1.09; 95% CI: 0.92, 
1.30) after multivariable adjustments compared to stable light drinkers. However, stable 
moderate drinkers had significantly lower risk of diabetes compared to stable light drinkers 
(HR: 0.74; 95% CI: 0.65, 0.83). Furthermore, all current moderate alcohol consumption 
categories were associated with at least a 25% lower risk of type 2 diabetes compared to 
stable light drinkers, regardless of initial alcohol consumption category (Pinteraction = 0.55). 
No further risk reductions were observed among initial light or moderate drinkers who 
increased their consumption over ≥30.0 g/day. Similar results were obtained when we 
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reanalyzed the data excluding people who abstained from alcohol or who had missing 
alcohol data during follow-up (data not shown).  
 
Four-year change in amount of alcohol intake and effect on markers of glycemia 
To test the robustness of our findings, we next examined the four-year change in alcohol 
consumption from 1990-1994 on markers of glycemia collected in 1994, stratified by initial 
alcohol consumption in 1990 (Table 2.4). A similar interaction between change in alcohol 
and baseline alcohol intake as in the main analysis was observed for levels of total 
adiponectin and HbA1c among non-diabetic men. For example, a 7.5 g/day increment in 
alcohol intake, between 1990-1994, was associated with a 1.2 ± 0.3 µg/mL (mean ± SEM) 
higher adiponectin level in 1994 among men who were nondrinkers at baseline, a 0.5 ± 0.3 
µg/mL higher adiponectin level among <1 glass/day drinkers, and a 0.6 ± 0.3 µg/mL lower 
level among ≥1 glass/day drinkers at baseline (Pinteraction = 0.002). For HbA1c, the inverse 
association between change in alcohol intake in 1990-1994 and HbA1c concentration was 
also strongest among nondrinkers compared to <1 glass/day drinkers and ≥1 glass/day 
drinkers in 1990 (Pinteraction = 0.02). 
 
 
Discussion 
In this large prospective cohort study, we found that four-year changes in alcohol 
consumption assessed repeatedly over time were followed by subsequent changes in risk of 
type 2 diabetes. The lower risk associated with an increase in alcohol consumption was 
dependent on initial drinking levels, with no benefit associated with increased intake among 
men already drinking moderately. This pattern of lower risk associated with increased 
alcohol consumption solely among abstainers and light drinkers was further supported by 
associations of change in alcohol intake with total adiponectin and HbA1c. 
Our results extend previous epidemiological studies that have reported an inverse 
association between moderate alcohol consumption and the longer term risk of type 2 
diabetes (1;2). Recent studies have shown that alcohol consumption is associated with 
lower risk of type 2 diabetes even among low-risk individuals (lean, active non-smokers) 
(25;26) and when adjusted for multiple lifestyle factors based on BMI, physical activity 
level, smoking habits and diet quality (27-29). Comparisons of different beverage types 
generally suggest that ethanol rather than the type of alcoholic beverage is responsible for 
this association (23;30). Furthermore, variation in the ADH1C gene, a gene that encodes the 
alcohol dehydrogenase 1C enzyme that oxidizes ethanol, appears to modify the association 
between alcohol consumption and type 2 diabetes risk, providing further epidemiological 
support for the causal nature of the relationship between alcohol consumption and diabetes 
risk (31).  
The plausibility of these observational results is supported by short-term 
randomized controlled trials on changes in alcohol consumption (25-30 g/day) (10;11) In 
these studies, moderate drinking significantly improved insulin sensitivity after six to eight 
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weeks. Also, clinical trials in a variety of populations have shown that alcohol consumption 
increases adiponectin, (11;12;32;33) a hormone secreted by adipose tissue that appears to 
improve insulin sensitivity. Indeed, adiponectin appears to explain approximately 25 to 
30% of the inverse association between alcohol consumption and type 2 diabetes in women 
(34). Lastly, longer-term randomized trials of three to twelve months among diabetic 
individuals have shown that assignment to alcohol consumption lowers fasting glucose (35) 
and HbA1c (36). 
These findings from randomized trials suggest that the effects of alcohol intake on 
glycemia have a short latency, as they appear within weeks of assignment to alcohol. Our 
results are consistent with this finding, the more beneficial metabolic parameters and the 
lower subsequent risk of diabetes associated with an increase in alcohol consumption was 
evident in the next follow-up period. Our results further imply that the effect may be 
transient, as a decrease in consumption was accompanied by a modest increase in risk. 
Finally, our results highlight that any benefit of alcohol on glycemia and risk of diabetes is 
restricted to moderate drinking, and increases among those already drinking moderately 
confer no lower risk. 
Several limitations warrant consideration. We relied on self-reported alcohol 
consumption. However, validation studies in these health professionals comparing self-
administered questionnaire with intake assessed by detailed diet records showed 
correlations above 0.8 and mean and standard deviation values almost identical by the two 
methods (18). Second, we do not know why men changed their intake. However, we 
restricted our analysis to men without history of diabetes and cancer and adjusted for 
cardiovascular disease, hypertension and hypercholesterolemia. Third, we do not know 
when during each four-year interval the change in alcohol consumption occurred, a 
limitation that reflects the fact that the administered FFQ specifically queries alcohol 
consumption in the previous year. Therefore, we cannot definitely evaluate whether the 
change in intake on type 2 diabetes risk is immediate. We do know however, that the 
change in alcohol preceded the diagnosis of diabetes. Fourth, we performed our analysis in 
male health professionals and results may therefore not be readily generalizable to other 
populations. However, within this homogenous group of highly educated men potential 
confounding due to social economic status is substantially reduced. Fifth, we could not 
evaluate changes in beverage types, given the more limited use of any particular beverage 
compared with total alcohol use. We have previously found that all beverage types were 
inversely associated with type 2 diabetes in this cohort (24). Finally, as with any 
observational study, unaccounted factors associated with changes in alcohol consumption 
and risk of type 2 diabetes may introduce an unknown degree of residual confounding, 
despite the substantial number of potentially confounding factors we included. 
In conclusion, in this cohort of male health professionals increases in alcohol 
consumption over time were associated with correspondingly lower four-year risk of type 2 
diabetes, although this association was limited to rare and light drinkers at baseline. This 
suggests that the effect of alcohol consumption on diabetes risk has a relatively short 
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latency time but may also be transient and reversible. Our results also highlight that 
individuals already consuming alcohol in moderation did not receive further benefit from 
increased consumption. Although our results might be seen as suggesting that some 
individuals should consider adopting regular and moderate intake of alcohol, our findings – 
even if proven to be causal - are limited to a single outcome of diabetes. Decisions and 
recommendations about changes in alcohol consumption should, as with alcohol 
consumption in general, consider the full range of risks and benefits to an individual, 
including the consistent harms to the individual and society of drinking that exceeds 
recommended limits. 
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Background: It has been suggested that the inverse association between alcohol and type 2 
diabetes could be explained by moderate drinkers’ healthier lifestyles. 
 
Objective: We studied whether moderate alcohol consumption is associated with a lower 
risk of type 2 diabetes among adults with combined low-risk lifestyle behaviors. 
 
Design: We prospectively examined 35,625 adults of the Dutch European Prospective 
Investigation into Cancer and Nutrition (EPIC)-NL cohort aged 20 - 70 years and free of 
diabetes, cardiovascular disease and cancer at baseline (1993-1997). Besides moderate 
alcohol consumption (women: 5.0-14.9 g/day; men: 5.0-29.9 g/day), we defined low-risk 
levels of four lifestyle behaviors: optimal weight (BMI <25 kg/m2), physically active (≥30 
minutes of physical activity/day), current non-smoker and a healthy diet (upper two 
quintiles of the DASH diet). 
 
Results: During a median of 10.3 years, we identified 796 incident cases of type 2 diabetes. 
Compared with teetotalers, hazard ratios of moderate alcohol consumers for risk of type 2 
diabetes in low-risk lifestyle strata after multivariable adjustments were 0.35 (95% CI: 0.17, 
0.72) when of a normal weight, 0.65 (0.46, 0.91) when physically active, 0.54 (0.41, 0.71) 
when nonsmoking and 0.57 (0.39, 0.84) when consuming a healthy diet. When ≥3 low-risk 
lifestyle behaviors were combined, the hazard ratio for incidence of type 2 diabetes among 
moderate alcohol consumers after multivariable adjustments was 0.56 (0.32, 1.00).  
 
Conclusion: In subjects already at lower risk of type 2 diabetes on the basis of multiple 
low-risk lifestyle behaviors, moderate alcohol consumption was associated with an 
approximately 40% lower risk compared with abstention. 
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Introduction 
Several studies have demonstrated that type 2 diabetes can largely be prevented through a 
healthy lifestyle (1;2). Components of such a lifestyle include maintaining a normal body 
weight (1), being physically active (3), refraining from smoking (4) and eating a healthy 
diet (5). Moderate alcohol consumption has consistently been associated with a decreased 
risk of type 2 diabetes in prospective cohort studies compared with abstention or excessive 
consumption (6;7). Much of this association is thought to be attributable to an improved 
insulin sensitivity due to moderate alcohol consumption (8;9). Therefore, moderate alcohol 
consumption could be considered a fifth favorable behavioral lifestyle factor to lower the 
risk of type 2 diabetes.  
Despite this evidence, some have suggested that the observed inverse association 
between alcohol and disease such as type 2 diabetes can be explained by the fact that 
moderate drinkers have a healthier lifestyle in general (10). Previous studies on the relation 
between alcohol consumption, lifestyle and type 2 diabetes have only considered individual 
lifestyle behaviors, (11-13) but low-risk lifestyle habits are often inter-correlated and may 
be most effective when present in combination. 
Little is known about the association between type 2 diabetes risk and alcohol 
consumption in the context of healthy lifestyle behaviors, especially when multiple low-risk 
lifestyle habits are combined. We therefore examined the association of alcohol intake with 
risk of type 2 diabetes in strata of separate lifestyle behaviors based on body mass index 
(BMI), physical activity level, smoking and adherence to the Dietary Approach to Stop 
Hypertension (DASH) diet and in strata of combined low-risk lifestyle behaviors in a 
prospective population-based study of men and women (of which almost half were 
postmenopausal at baseline). 
 
 
Methods 
Study population 
The EPIC-NL cohort is the Dutch contribution to the European Prospective Investigation 
into Cancer and Nutrition (EPIC) and consists of the Prospect and MORGEN cohort. Both 
cohorts were jointly set up within the context of EPIC between 1993 and 1997, recruiting 
predominantly Caucasian 40,011 subjects. This cohort is described in more detail elsewhere 
(14). In short, Prospect is a prospective cohort study of 17,357 women aged 49 - 70 who 
participated in the breast cancer screening between 1993 and 1997. The Monitoring Project 
on Risk Factors for Chronic Diseases (MORGEN)-cohort consists of 22,654 men and 
women aged 20 - 59 years who were recruited from three Dutch towns (Amsterdam, 
Doetinchem and Maastricht). From 1993 to 1997, each year a new random sample of 
~5,000 subjects was examined. Of the total cohort of 40,011 persons, 615 subjects reported 
diabetes and 915 and 1,560 participants reported cardiovascular disease or cancer 
respectively at baseline and were therefore excluded. Furthermore, we excluded 192 
subjects with missing data on alcohol consumption and diet, 138 persons with missing data 
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of other lifestyle behaviors, 36 individuals with unrealistic energy intakes (<600 kcal/day or 
>5000 kcal/day) and 930 individuals without consent for linkage to disease registries, 
leaving 35,625 subjects for the present study. The Prospect-EPIC study was approved by 
the Institutional Review Board of the University Medical Center Utrecht and the MORGEN 
project was approved by the Medical Ethical Committee of TNO, the Netherlands. All 
participants signed informed consent prior to study inclusion. 
 
General assessments 
At baseline, participants filled in a general questionnaire on demographic characteristics 
and risk behaviors for presence of chronic diseases. The general questionnaires from both 
cohorts were largely similar. Coding of this information was standardized and merged into 
one uniform database. Body weight, height, waist and hip circumferences were measured. 
Physical activity was assessed using a questionnaire, validated in an elderly population 
(15). The Cambridge Physical Activity Index (CPAI) was used to allocate individuals to 
four ordered categories: inactive, moderately inactive, moderately active and active, as 
previously described (16). Because we could not calculate a total physical activity score for 
14% of all participants, we imputed missing scores by single imputation using linear 
regression modeling (SPSS MVA procedure) with other lifestyle factors (e.g. smoking, 
BMI) and the outcome (type 2 diabetes). Smoking was defined as never, past or current. 
Daily nutritional intake was obtained from a food frequency questionnaire (FFQ) 
containing questions on the usual frequency of consumption of 79 main food items during 
the year preceding enrolment. This questionnaire allows the estimation of the average daily 
consumption of 178 foods. The FFQ was validated against 12 monthly 24-hour recalls in a 
representative group before the start of the study (17;18). 
We constructed the DASH diet score as previously described (19). The score is 
based on 8 components: high intake of fruits, vegetables (except potatoes and legumes), 
nuts and legumes, low-fat dairy products, and whole grains and low intake of sodium, 
sweetened beverages, and red and processed meats. The original DASH diet limits 
saturated fat intake, which would be in part reflected by a de-emphasis on red and 
processed meats in our score. For each of the components, we classified subjects into sex-
specific quintiles according to their intake ranking. Component score for fruits, vegetables, 
nuts and legumes, low-fat dairy products, and whole grains is the sex-specific’s quintile 
ranking. For example, quintile 1 is assigned 1 point and quintile 5, 5 points. For sodium, 
red and processed meats, and sweetened beverages, low intake was desired. Therefore, the 
lowest quintile was given a score of 5 points and the highest quintile, 1 point. We then 
summed up the component scores to obtain an overall DASH score ranging from 8 (lowest 
adherence) to 40 (highest adherence).  
Education was categorized into three groups; low, average and high. Low 
education attainment included those with primary education up to those completing 
intermediate vocational education, average educational attainment included those with 
higher secondary education and high educational attainment included those with higher 
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vocational education and university. Women were assumed to be post-menopausal when 
they reported not having menstrual periods for at least a year. Serum HDL-cholesterol was 
measured in a 6.5% random sample of the baseline cohort using an automated enzymatic 
procedure on a Vitros 250 (Johnson & Johnson, Rochester, NY, U.S.A.). 
 
Assessment of alcohol intake 
Alcohol consumption was assessed by the general questionnaire and FFQ. The validity of 
this alcohol consumption assessment is good as confirmed by a Spearman correlation of 
0.87 for women and 0.74 for men between the FFQ and twelve 24-hour recalls (17). 
Through the general questionnaire subjects were asked whether they had ever consumed 
alcohol. If so, they were asked the number of units of alcohol-free beer, beer, white wine, 
red wine, port/sherry/vermouth and spirits consumed. Subjects indicated their consumption 
frequency on a daily/weekly/monthly/yearly scale or as never consumed. Alcohol 
consumption at baseline was determined by multiplying the alcohol percentage of each 
beverage by the standard ethanol weight content (5% for beer, 18.5% for fortified wine, 
12.5% for red wine, 12% for white wine and 40% for liquor; means from the average sorts 
of beverages). 
 
Ascertainment of type 2 diabetes 
The ascertainment of type 2 diabetes has been described in more detail elsewhere (20). The 
incidence of type 2 diabetes was first assessed by self-report in follow-up questionnaires 
and a urine dipstick test in the Prospect cohort only. Also data on diagnosis of type 2 
diabetes were obtained from the Dutch Centre for Health Care Information, which holds a 
standardized computerized register of hospital discharge diagnoses [all diagnosis were 
coded according to the International Classification of Diseases, Ninth revision (ICD-9, 
ICD codes 250)] (21). The records from this database were linked to the EPIC-NL cohort 
with a validated probabilistic method (22). All potential cases of type 2 diabetes have been 
verified against medical records of the general practitioners and pharmacists. For 89% of all 
potential diabetes cases verification information was available. Of these potential diabetes 
cases 72% were verified as having type 2 diabetes and were used as such in the analysis. 
The remaining 28% was verified as not having type 2 diabetes or having another type of 
diabetes like gestational diabetes and were therefore included in our analysis as non-cases. 
 
Definition of low-risk lifestyle behaviors and alcohol categories 
We used the World Health Organization cut-off for healthy weight (BMI <25 kg/m2). 
Results were essentially the same when we defined low risk for BMI as 18.5 to <25 kg/m2 
(data not shown). We used waist circumference as a surrogate measure for healthy weight. 
Low risk level was defined as a waist circumference of less than 88 cm in women or 92 cm 
in men (Adult Treatment Panel III criteria) (23). We dichotomized the population based on 
the four categories of CPAI into physically active (≥30 minutes of combined recreational, 
household, and occupational physical activity/day; CPAI categories: moderately active, 
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active) and physically inactive (<30 minutes of combined daily recreational, household, and 
occupational physical activity/day; CPAI categories: inactive, moderately inactive). In 
terms of cigarette smoking participants were categorized in current non-smokers 
(never/former) or current smokers. For the DASH diet score categories were: low 
adherence (lower 3 quintiles; composite score range of 8 to 25), or high adherence (upper 2 
quintiles; composite score range of 26 to 40). Alcohol categories were divided in four 
alcohol groups in line with the 2005 U.S. DA Dietary Guidelines (24) as follows: 
teetotalers (lifelong abstainers), light (0-4.9 g/day for both women and men; includes 
former drinkers), moderate (between 5.0 to 14.9 g/day for women; 5.0 to 29.9 g/day for 
men) and heavier consumers (≥15.0 g/day for women; ≥30.0 g/day for men). 
 
Statistical analysis 
Follow up time was calculated from date of enrolment into the study to the date of diabetes 
diagnosis or date of death, all other participants were censored at the end of follow up 
(January 2006). We used Cox proportional hazards model to calculate relative risk for each 
alcohol consumption category using teetotalers as a reference and 95% confidence intervals 
(95% CI), adjusted for age (continuous), BMI, (continuous), physical activity (inactive; 
moderately inactive; moderately active; active), smoking (never, former and current), 
adherence to the DASH diet (quintiles), parental history of type 2 diabetes (present or not), 
education (high, middle, low), postmenopausal status (premenopausal, postmenopausal, 
perimenopausal and surgical postmenopausal), cohort (Prospect-EPIC-NL or MORGEN-
EPIC-NL) and daily energy intake (continuous) and stratified by gender. To determine 
effects of alcohol consumption and individual lifestyle behaviors, the association of alcohol 
consumption with type 2 diabetes was first estimated stratified by each lifestyle factor 
separately. Secondly, to determine the effects of alcohol consumption and combined low-
risk lifestyle factors on type 2 diabetes incidence, participants could score one point for 
each low-risk lifestyle: BMI <25 kg/m2, physically active, current non-smoker, and upper 
two quintiles of the DASH diet. They could have a score ranging from 0 (no low-risk 
behaviors) to 4 (all low-risk behaviors). Statistical interaction of alcohol consumption with 
gender and with lifestyle behaviors was assessed based on likelihood ratio tests in models 
with and with out the cross-product terms in the multivariable model. Statistical analyses 
were performed using the SAS statistical software package (SAS version 9, SAS Institute, 
Cary, NC, U.S.A.). 
 
 
Results 
In both men and women, teetotalers smoked less and were less highly educated compared 
to alcohol consumers (Table 3.1). Less than 2.0% of the women reported drinking >45 
g/day (>3 drinks/day) and 2.2% of the men reported drinking >75 g/day (>5 drinks/day). To 
validate the self-reported alcohol intake, we determined the relation between alcohol intake 
and HDL-cholesterol in a 6.5% sub-cohort. This analysis showed a linear association (P < 
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0.001) between alcohol intake and HDL-cholesterol concentrations in both men (N = 604) 
and women (N = 1,719) (β ± SD: 0.062 ± 0.005 mmol/l per 5 g alcohol/day in women and 
0.043 ± 0.007 mmol/l per 10 g alcohol/day in men) adjusted for all confounders from the 
multivariable model.  
During a median follow-up of 10.3 person-years (360,661 person-years) we 
verified 618 female and 178 male incident cases of type 2 diabetes. Compared with female 
teetotalers hazard ratios (HRs) for type 2 diabetes were 0.75 (95% confidence interval (CI): 
0.61, 0.91) for light, 0.48 (95% CI: 0.36, 0.63) for moderate and 0.54 (95% CI: 0.40, 0.73) 
for heavier drinkers after multivariable adjustment. Among males, HRs were 0.98 (95% CI: 
0.53, 1.80) for light, 0.79 (95% CI: 0.43, 1.44) for moderate and 0.71 (95% CI: 0.37, 1.38) 
for heavier drinkers compared with male teetotalers after multivariable adjustment. Because 
we did not find a gender-based difference (Pinteraction = 0.50) between alcohol consumption 
and type 2 diabetes, we combined men and women in further analyses. In the entire 
population, HRs for type 2 diabetes were 0.78 (95% CI: 0.64, 0.95) for light, 0.55 (95% CI: 
0.43, 0.69) for moderate and 0.57 (95% CI: 0.44, 0.74) for heavier alcohol consumers 
compared with teetotalers after multivariable adjustment. 
Prevalence of low-risk lifestyle behaviors was, 47.1% for having an optimal 
weight, 68.7% for having an optimal waist circumference, 62.3% for being physically 
active, 69.3 for not smoking and 38.5% for having a high diet quality. After multivariable 
adjustments, HRs for risk of type 2 diabetes in high-risk strata of lifestyle behaviors were 
6.11 (95% CI: 4.74, 7.83) for BMI, 5.96 (95% CI: 5.02, 7.08) for waist circumference, 1.06 
(95% CI: 0.92, 1.22) for physical activity, 1.19 (95% CI: 1.01, 1.40) for smoking and 1.18 
(95% CI: 1.01, 1.37) for the DASH diet compared to the low-risk levels of each lifestyle 
behavior. When analyzing physical activity over the four categories in the multivariable 
adjusted model more pronounced associations were observed: Each increase in physical 
activity category was significantly associated with a 7% lower risk of type 2 diabetes after 
multivariable adjustments (Ptrend < 0.05). Results were essentially the same when we 
excluded imputed values for physical activity. 
Compared with teetotalers, HRs of moderate alcohol consumers for risk of type 2 
diabetes in low-risk lifestyle strata after multivariable adjustments were 0.35 (95% CI: 0.17, 
0.72) when having an optimal weight or 0.45 (95% CI: 0.28, 0.72) when having an optimal 
waist circumference, 0.65 (95% CI: 0.46, 0.91) when being physical active, 0.54 (95% CI: 
0.41, 0.71) when being a non-smoker and 0.57 (95% CI: 0.39, 0.84) when consuming a 
healthy diet (Table 3.2). Results were essentially the same when we excluded imputed 
values for physical activity: 0.67 (95% CI: 0.46, 0.98). Comparable results were found for 
moderate alcohol consumers in subgroups reporting less healthy lifestyle behaviors. 
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There were significant interactions between alcohol consumption categories and 
physical activity and between alcohol consumption categories and smoking, but these were 
mainly due to the lower risks of heavier drinkers who smoke or are physically inactive. 
Interactions between alcohol consumption categories and other dichotomous lifestyle 
behaviors were not significant (Table 3.2). 
In order to have adequate power to investigate the impact of combined low-risk 
lifestyle factors across categories of alcohol consumption, we grouped participants with 
three or all four (38.2%), two (35.5%), and one or none (26.3%) low-risk lifestyle behaviors 
together. When ≥3 low-risk lifestyle behaviors were combined, HR for incidence of type 2 
diabetes among moderate alcohol consumers after multivariable adjustments was 0.56 (95% 
CI: 0.32, 1.00) (Table 3.3). Results were essentially the same but more precise when we 
used the low-risk level for waist circumference instead of the low-risk level of BMI with 
the combined lifestyles analysis: 0.60 (95% CI: 0.37, 0.97). Similar associations were found 
among moderate alcohol consumers reporting less low-risk lifestyle habits. We observed no 
effect modification of the association of gender with combined low-risk lifestyle behaviors 
(Pinteraction = 0.23) or alcohol and combined low-risk lifestyle behaviors (Pinteraction = 0.17) 
after multivariable adjustment. 
When analyzing data for each cohort separately almost identical HRs, tough less 
precise, were observed among moderate alcohol consumers with ≥3 low-risk lifestyle 
behaviors combined. The HR for the Prospect cohort was 0.54 (95% CI: 0.27, 1.08) 
whereas the HR for the MORGEN cohort was 0.59 (95% CI: 0.22, 1.57) after multivariable 
adjustment. Again, when low-risk level of BMI was replaced with the low-risk level of 
waist circumference in the combined score, virtually the same HRs were observed among 
moderate alcohol consumers with ≥3 low-risk lifestyle behaviors combined when results 
from the multivariate model were split up according to cohort: Prospect cohort: 0.55 (95% 
CI: 0.30, 1.00); MORGEN cohort: 0.61 (95% CI: 0.28, 1.32).  
 
 
Discussion 
This prospective study shows that moderate alcohol consumption is associated with a 
reduced risk of developing type 2 diabetes, regardless of other favorable behavioral 
lifestyles. Among participants already at lower risk of developing type 2 diabetes based on 
the combined effect of body weight, physical activity level, smoking habits, and diet 
quality, moderate alcohol consumption was associated with a lower risk for the incidence of 
type 2 diabetes. 
Our results confirm that moderate alcohol consumption reduces the risk of type 2 
diabetes in the presence of individual low-risk lifestyle behaviors, such as BMI, physical 
activity and smoking, which is in line with 3 previous observational studies (11-13). In 
addition, they show that moderate alcohol consumption remains to be associated with a 
lower risk of type 2 diabetes among those with multiple low-risk lifestyle behaviors 
combined. These findings indicate that the relation between alcohol consumption and type 
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2 diabetes is not likely to be explained by a healthier lifestyle of moderate drinkers in 
general. 
Our findings of joint moderate alcohol consumption and healthy lifestyle 
behaviors are comparable with findings of Mukamal et al for risk of coronary heart disease 
(25). In their study, men with 4 healthy lifestyle behaviors, who drank alcohol in 
moderation (5.0 to 29.9 g/day) remained to have a significant lower risk for myocardial 
infarction as compared with abstainers. Therefore, the associations of alcohol consumption 
with both type 2 diabetes and coronary heart disease do not seem to be confounded by 
healthier lifestyles of moderate drinkers. 
In our cohort, heavier drinkers had lower risks of developing type 2 diabetes 
compared with teetotalers. Even heavier drinkers with a less favorable lifestyle behavior 
(based on smoking status, physical activity, and diet), had lower risks of developing type 2 
diabetes compared with teetotalers with the favorable lifestyle behavior (Table 2). These 
findings warrant clarification. A reduction in the risk of developing type 2 diabetes is 
observed for an alcohol intake up to 50 g/day (6;7). However, the upper limit for moderate 
drinking in the current study was based on the 2005 U.S. DA Dietary Guidelines (24), 
directed at prevention of all chronic diseases rather than on maximum risk reduction of type 
2 diabetes. These relatively low cutoffs, particularly for women, could explain the low-risks 
observed among the heavier drinkers.  
Clearly, the observations for heavier drinkers must be considered in the light of 
potential harmful effects of excessive alcohol intake and greater risk of certain cancers such 
as breast and rectum (26). Heavy or excessive drinking should always be discouraged, 
whereas moderate alcohol consumption could be regarded as a complement, rather than an 
alternative, to other low-risk lifestyle habits. Guidelines and personal advice on alcohol 
consumption should consider the full range of benefits and risks to the individual.  
The association between alcohol consumption and type 2 diabetes tended to be 
stronger in women than in men, which is consistent with previous meta-analyses (6;7). 
However, studies in these meta-analyses that reported results for both men and women did 
not find this trend. Men in this cohort were substantially younger than women and only 
about one-fourth of the entire cohort consisted of men. Subsequently, there were fewer 
incident cases of type 2 diabetes in men than in women, which may explain the weaker 
association between alcohol intake and incidence type 2 diabetes in men.  
There are several biologically plausible mechanisms to explain an inverse 
association between moderate alcohol consumption and type 2 diabetes. In 2 short-term 
randomized controlled crossover trials of women without diabetes, alcohol consumption of 
30 and 25 g/day decreased insulin resistance and triglycerides concentrations (8;9). Besides 
these effects, moderate alcohol consumption increases both gene expression and circulating 
protein levels of adiponectin (9). Adiponectin is positively associated with insulin 
sensitivity and inversely associated with inflammation and type 2 diabetes (27). Recently it 
has been suggested that adiponectin may explain about 25 to 30% of the inverse association 
between alcohol consumption and type 2 diabetes in women (28). 
Alcohol, lifestyles and type 2 diabetes | 
 63 
Some limitations of our study warrant consideration. First, a FFQ was used for 
nutritional assessment including alcohol intake. Self-reported alcohol intake is generally 
being underreported (29). However, there was a high correlation between alcohol 
consumption from the FFQ and the twelve 24-hour recalls and between alcohol 
consumption and serum HDL-cholesterol levels. This suggests sufficient validity for 
ranking participants on alcohol consumption. Also, we could not take drinking pattern 
(regular versus episodic/binge drinking) into account. However, among moderately 
drinking middle-aged and older women, binge drinking does not occur frequently (30). It is 
therefore unlikely that this influenced the results in this cohort of predominantly middle-
aged and older women. Furthermore, we did not take into account beverage type in the 
association between alcohol and type 2 diabetes. However, a previous study in one of the 
cohorts presented here showed that beverage type did not influence this association (20). 
Second, we used only baseline measurements to characterize individuals and did 
not take into account possible changes in alcohol consumption or other lifestyle behaviors 
over follow-up. People who are already ill or have poor health might be more likely to 
change their diet and could therefore drink less or even quit drinking as a result of this. 
However, we repeated the analyses excluding people with type 2 diabetes within the first 
two years of follow-up and the association persisted (data not shown). We excluded those 
with prevalent cardiovascular diseases and cancer at baseline. In addition, we used lifetime 
abstainers as a reference category without occasional or former drinkers to rule out “the 
sick quitter” hypothesis (31). Therefore, our results are unlikely to be confounded by such 
reverse causality.  
Third, although we adjusted for several known potential confounders, we cannot 
completely rule out the possibility of residual confounding. Finally, presence of type 2 
diabetes goes often undetected, and may be preclinical up to nine to twelve years (32). 
Undetected diabetes cases in our cohort may have been misclassified as nondiabetic 
individuals, which resulted in the attenuation of associations. 
In summary, this study supports the presence of an inverse association between 
moderate alcohol consumption and incidence of type 2 diabetes in a mixed population and 
extends this association to subjects already at low-risk based on their multiple low-risk 
lifestyle behaviors. Moderate alcohol consumption (approximately 0.5 to 1 drink/day for 
women and 0.5 to 2 drinks/day for men) appears to reduce the risk of type 2 diabetes, 
independently of other lifestyle behaviors. 
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Background: Moderate alcohol consumption has consistently been associated with a 
decreased risk of type 2 diabetes compared with abstaining and excessive drinking but 
whether it improves insulin sensitivity remains uncertain. 
 
Objective: To determine whether six weeks of daily, moderate alcohol consumption 
increases expression of the gene encoding adiponectin (ADIPOQ) and plasma levels of the 
protein, and improves insulin sensitivity in postmenopausal women. 
 
Methods: In a randomized, open-label, crossover trial conducted in the Netherlands, 36 
apparently healthy postmenopausal women who were regular alcohol consumers, received 
250 mL white wine (~25 g alcohol/day) or 250 mL of white grape juice (control) daily 
during dinner for six weeks. Randomization to treatment allocation occurred according to 
BMI. Insulin sensitivity and ADIPOQ mRNA and plasma adiponectin levels were 
measured at the end of both periods. Insulin sensitivity was estimated using the homeostasis 
model assessment of insulin resistance (HOMA-IR). Levels of ADIPOQ mRNA in 
subcutaneous adipose tissue were determined by RT-PCR. 
 
Results: All participants completed the study. Six weeks of white wine consumption 
reduced fasting insulin (mean ± SEM 40.0 ± 3.4 vs. 46.5 ± 3.4 pmol/L; P < 0.01) and 
HOMA-IR (1.42 ± 0.13 vs. 1.64 ± 0.13; P = 0.02) compared with 6 weeks of grape juice 
consumption. ADIPOQ mRNA levels (1.09 ± 0.15 vs. 0.98 ± 0.15; P = 0.04) and plasma 
levels of total (13.1 ± 0.8 vs. 12.0 ± 0.8 μg/mL; P < 0.001) and high-molecular weight 
(HMW) adiponectin (9.9 ± 1.2 vs. 8.8 ± 1.2 μg/mL; P = 0.02) significantly increased after 
alcohol consumption compared with juice consumption. Changes in ADIPOQ mRNA levels 
correlated with changes in plasma levels of total adiponectin (ρ = 0.46; P < 0.01). Both 
fasting triglyceride (8.2%; P = 0.04) and LDL-cholesterol levels (7.8%; P < 0.0001) 
decreased whereas HDL-cholesterol increased (7.0%; P < 0.0001) after prolonged 
moderate alcohol intake. No notable adverse events were reported. 
 
Conclusions: Moderate alcohol consumption for six weeks improves insulin sensitivity, 
adiponectin levels and lipid profile in postmenopausal women. Furthermore, these data 
suggest a transcriptional mechanism leading to the alcohol-induced increase in adiponectin 
plasma levels. 
 
Trial registration: Clinicaltrials.gov ID no.: NCT00285909. 
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Introduction 
Moderate alcohol consumption has consistently been associated with a decreased risk of 
type 2 diabetes compared with abstaining and excessive drinking (1;2). The reason for the 
lower risk of type 2 diabetes is not entirely clear but a plausible explanation seems to be 
improved insulin sensitivity (3). However, so far only one randomized controlled trial 
among postmenopausal women has confirmed this notion (4). Other studies, mainly 
performed among young male populations, failed to detect such effects (5-12). 
Adiponectin, an adipose tissue-derived hormone, is thought to play an important 
role in the regulation of insulin sensitivity and glucose and lipid metabolism (13). Its 
plasma levels are positively associated with insulin sensitivity (14) and are inversely 
associated with impaired glucose metabolism and type 2 diabetes (15-17). Furthermore, 
observational studies revealed an association between moderate alcohol consumption, 
adiponectin concentrations and insulin sensitivity (18;19). Randomized controlled trials 
also showed a significant increase of both circulating levels of total and high-molecular 
weight (HMW) adiponectin (8;11;12) after a period of moderate alcohol consumption 
compared with abstention. 
However, the mechanism by which moderate alcohol consumption increases 
adiponectin levels is unknown. Synthesis of adiponectin is controlled by peroxisome 
proliferator-activated receptor γ (PPARγ) activation, which functions as a transcriptional 
regulator (20). Low doses of alcohol have been shown to alter the expression of genes 
encoding tissue plasminogen activator (PLAT) and plasminogen activator inhibitor type-1 
(PAI-1 also known as SERPINE1) (21). Like adiponectin, these markers are affected by 
moderate alcohol consumption and activated by PPARγ (22).  
Consequently, we investigated whether moderate alcohol consumption affects 
gene expression of the gene encoding adiponectin (ADIPOQ) and levels of the protein, and 
whether it improves insulin sensitivity in postmenopausal women. 
 
 
Methods 
Study protocol 
The study used a randomized, open-label, placebo-controlled, crossover design, consisting 
of two 6-week periods, each preceded by a 1 week of washout. Participants consumed 250 
mL of white wine (25 g alcohol; Chardonnay; Jean d’Alibert, Rieux, France) or alcohol-
free white grape juice (Albert Heijn, Zaandam, the Netherlands) daily for 6 weeks during 
dinner. The study was conducted at TNO (a Dutch acronym for applied scientific research) 
Quality of Life, in Zeist, the Netherlands. The primary objective of the study was to 
investigate the effect of moderate alcohol consumption on PPARγ activity and risk markers 
of metabolic disease and took place from March through June 2006. Participants were 
instructed to maintain their habitual body weight, food pattern and physical activity pattern 
and were told to refrain from any alcoholic products during the entire study (including 
washout periods) except for alcoholic beverages supplied by TNO. Of the 77 women who 
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were screened, 40 were eligible to participate. A total of 36 women were randomly selected 
and initiated the study. Allocation to treatment order was randomized according to BMI. 
Both white wine and white grape juice contained 300kJ/100mL (~70 kcal/100mL). Blood 
and adipose tissue sampling was done on the last day of each treatment period after an 
overnight fast. Compliance was monitored by weekly measurement of urinary ethyl 
glucuronide (EtG), a direct phase II metabolite of ethanol formed by action of UDP- 
glucuronosyl transferase. EtG has been reported to be a superior marker with 100% 
sensitivity as a biomarker of recent drinking (23). It persists in the urine up to ~75 - 85 h 
after last intake. Additional measures of compliance were increase of HDL-cholesterol, 
daily questionnaires, and return of empty bottles. 
 
Participants 
Postmenopausal women were recruited from a pool of volunteers of TNO Quality of Life 
and by advertisements in local newspapers. Eligible participants consumed between 5 and 
21 units of alcohol per week, were apparently healthy and had an absence of menses for at 
least two years, a BMI between 18.5 and 35 kg/m2 and no family history of alcoholism. 
Participants gave written informed consent and received a compensation for their 
participation. An independent medical ethical committee (The Medical Ethical Committee 
University Medical Centre Utrecht) approved the research protocol. 
 
Outcomes measures 
Primary endpoints were markers of insulin sensitivity such as homeostasis model 
assessment of insulin resistance (HOMA-IR), glucose, insulin, HbA1c and free fatty acids 
(FFA) and several adiponectin-related measures such as ADIPOQ mRNA levels and plasma 
levels of total and HMW adiponectin. Secondary variables included lipid profile 
(triglycerides, HDL-and LDL-cholesterol) HbA1c and FFA and correlations between 
specific outcome measures. 
 
Analyses and assessment 
Ethyl glucuronide was determined in morning urine samples. Urinary samples were diluted 
about twenty times using an internal standard solution. The resulting solution was analyzed 
using a triple quadrupole Ultra Performance LC/MS in MRM mode (Waters, Saint-Quentin 
En Yvelines Cedex, France) with a detection limit of 50 ng/mL. Cut-off limit to assess 
compliance during juice intervention for urinary EtG values was set at >0.25 mg/mL 
(positive sample), to obtain a high sensitivity but avoid positive results due to unintentional 
ethanol exposure. Cut-off limit during wine intervention was set at EtG values <0.5 mg/mL 
(2.2 μmol/L) (negative sample) as proposed by Bottcher et al. (24). Blood samples were 
obtained from the anticubital vein of the forearm and collected in tubes containing clot 
activator for serum and in ice-chilled tubes containing or Potassium Ethylene Diamine 
Tetra Acid (K3EDTA) for plasma (Vacutainer Systems, Becton Dickinson, Plymouth, 
U.K.). Blood was centrifuged for 15 minutes at 2.000 g at 4°C, within 15 - 30 minutes after 
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collection and stored at -80°C. All biochemical determinations in blood were performed at 
TNO Quality of Life using Olympus analytical equipment and reagents except for 
adiponectin. Plasma total adiponectin concentrations were determined by 
radioimmunoassay (RIA) method (Linco Research, Inc., St. Charles, MO, U.S.A.) with a 
mean intra-assay coefficient of variation of 5.0% and plasma high molecular weight 
(HMW) adiponectin levels by a novel Enzyme-linked immunosorbent assay (ELISA) 
(Linco Research) with a mean intra-assay coefficient of variation of 14.1%. LDL-
cholesterol was calculated by the Friedewald formula. Subcutaneous adipose tissue was 
sampled from the buttock by means of a Strauss cannula, outer diameter 1.5 mm and stored 
at -70°C until further analysis. Total RNA was extracted from adipose tissues with TRIzol 
reagent (Invitrogen, Breda, The Netherlands); 1 mg total RNA was then reverse-transcribed 
with iScript (Bio-Rad,Veenendaal, The Netherlands). cDNA was PCR-amplified with 
Platinum Taq DNA polymerase (Invitrogen) on a Bio-Rad iCycler or MyIQ PCR machine. 
Expression were standardized to levels of acidic ribosomal protein ARBP (25). Primer 
sequences used were ADIPOQ forward: TATCCCCAACATGCCCATTCG, ADIPOQ 
reverse: TGGTAGGCAAAGTAGTACAGCC, PPARG forward: 
TCCATGCTGTTATGGGT-GAA, PPARG reverse: TCAAAGGAGTGGGAGTGGTC, 
ARBP forward: CGGGAAGGCTGTGGTGCTG and ARBP reverse: 
GTGAACACAAAGCCCACA-TTCC. 
 
Statistical analyses 
Statistical analyses were performed using the SAS statistical software package (SAS 
version 8, SAS Institute, Cary, NC, U.S.A.). All variables were compared between 
treatments with a mixed analysis of variance model that included terms for treatment, 
period and the interaction between period and treatment (indicating possible carryover 
effects). Body weight was included in the model as a random factor to adjust for changes of 
body weight. Correlation coefficients were computed according to Spearman rank order to 
assess associations between intervention-induced changes in outcome measures. Based on a 
study by Arvidsson et al. (26) a sample size of 36 should be sufficient to detect a 20% 
difference in ADIPOQ mRNA levels with a power of 80% and accepting a two-sided a of 
0.05. Data are presented as means and SEM unless otherwise specified. Statistical 
significance was defined as P < 0.05.  
 
 
Results 
General results 
All 36 postmenopausal women completed the study. Participants were slightly overweight 
(BMI 25.4 ± 3.3 kg/m2). Mean glucose, insulin, triglycerides and cholesterol concentrations 
before the intervention indicated that participants were euglycemic and normolipidemic 
(Table 4.1). 
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Table 4.1: Characteristics of 36 postmenopausal women before intervention after an 
overnight fast. 
Variable Baseline 
Age (years) 56.5 ± 4.2 
Weight (kg) 71.4 ± 10.0 
BMI (kg/m2) 25.4 ± 3.3 
Glucose (mmol/L) 5.5 ±0.4 
Insulin (pmol/L) 37.4 ± 12.6 
Triglycerides (mmol/L) 1.21 ± 0.54 
HDL-cholesterol (mmol/L) 1.67 ± 0.27 
LDL-cholesterol (mmol/L) 3.88 ± 0.60 
Total cholesterol (mmol/L) 6.11 ± 0.72 
Alkaline phosphatase (U/L) 76.1 ± 19.3 
Alanine aminotransferase (U/L) 15.3 ± 8.2 
Aspartate aminotransferase (U/L) 20.8 ± 7.4 
γ-Glutamyltranspeptidase (U/L) 21.3 ± 11.4 
Follicle-stimulating hormone (IU/L) 108.5 ± 41.3 
Data are means ± SD 
 
 
Compliance with treatments was assessed by weekly urinary EtG revealing two 
positive samples during the juice-drinking period and six negative samples during the wine-
drinking period out of the 468 samples analyzed (overall compliance of 98.3%). Another 
indicator for compliance was the 7.0% increase in HDL-cholesterol after wine compared 
with juice consumption (Table 4.2).  
No significant (P > 0.05) carryover effects, as assessed by an interaction between 
treatment and period effect, were observed for any outcome measures. Treatment means of 
variables and P values estimated from models with period effects were very similar to those 
obtained from models without period effect, and we report the results of the latter. Mean 
body weight was 0.7 kg higher (P < 0.001) at the end of the alcohol drinking period (Table 
4.2). Results were adjusted for this difference in body weight, but did not essentially change 
them. Therefore, unadjusted results are presented here. 
 
Insulin sensitivity 
Fasting serum insulin concentrations decreased (12.3%; P < 0.01) and HbA1c percentages 
(P < 0.09) tended to decrease after six weeks of moderate alcohol consumption compared 
with abstention. Insulin sensitivity, as expressed by the HOMA-IR index, also improved by 
11.9 % (P = 0.02) after white wine consumption. However, there were no differences 
between serum glucose and free fatty acid concentrations after the two treatment periods 
(Table 4.2).  
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Table 4.2: Markers of insulin sensitivity, adiponectin and lipid profile in 36 
postmenopausal women measured at the end of a 6 week period of consuming white grape 
juice or white wine after an overnight fast. 
Data are means ± SEM. 
1 P values obtained from a mixed ANOVA model that included terms for treatment, period and the interaction 
between period and treatment (to assess carryover effects). 
 
 
Adiponectin 
There was a significant increase in the relative ADIPOQ mRNA levels in subcutaneous 
adipose tissue (27.7%; P = 0.04) after alcohol consumption compared with grape juice. 
Consistently, the ratio of PPARG/ARBP mRNA levels tended to increase as well although 
not significantly (P = 0.13) after the alcohol treatment. Both plasma protein levels of total 
adiponectin (10.6%; P < 0.001) and HMW adiponectin (15.8%; P = 0.02) increased 
significantly after consuming white wine, rather than juice, for 6 weeks (Table 4.2).  
 
 
Lipid profile 
Besides a significant increase in HDL-cholesterol, changes in lipid profile were further 
characterized by significant decreases in LDL-cholesterol (7.8%; P < 0.001) and 
triglycerides (8.2%; P = 0.04) levels after the wine-drinking period compared with the 
juice-drinking period (Table 4.2). 
Variable Grape juice White wine P value1 
Markers of insulin sensitivity    
   HOMA-IR score 1.64 ± 0.13 1.42 ± 0.13 0.02 
   Insulin (pmol/L) 46.5 ± 3.4 40.0 ± 3.4 < 0.01 
   Glucose (mmol/L) 5.4 ± 0.1 5.4 ± 0.1 0.72 
   HbA1c (%) 6.0 ± 0.04 5.9 ± 0.04 0.09 
   Free fatty acids (mmol/L) 0.43± 0.04 0.44 ± 0.04 0.67 
   Weight (kg) 70.4 ± 1.7 71.1 ± 1.7 < 0.001 
    
Adiponectin    
   ADIPOQ/ARBP (arbitrary units) 0.98 ± 0.15 1.09 ± 0.15 0.04 
   PPARG/ARBP (arbitrary units) 0.67 ± 0.09 0.73 ± 0.09 0.13 
   Total adiponectin (μg/mL) 12.0 ± 0.8 13.1 ± 0.8 < 0.001 
   High-molecular weight adiponectin (μg/mL) 8.8 ± 1.2 9.9 ± 1.2 0.02 
    
Lipid profile    
   Triglycerides (mmol/L) 1.18 ± 0.08 1.03 ± 0.08 0.04 
   HDL-cholesterol (mmol/L) 1.57 ± 0.04 1.68 ± 0.04 < 0.0001 
   LDL-cholesterol (mmol/L)  3.84 ± 0.12 3.51 ± 0.12 < 0.0001 
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Correlations 
Changes in ADIPOQ mRNA levels due to alcohol consumption correlated positively with 
changes in PPARG mRNA levels (ρ = 0.76; P < 0.001) and with changes in the plasma 
protein level of total adiponectin (ρ = 0.46; P < 0.01), but not with changes in plasma levels 
of HMW adiponectin (ρ = -0.25; P = 0.15). No significant correlations were found between 
changes in HOMA-IR and changes in total (ρ = 0.27; P = 0.11) or HMW (ρ = -0.18; P = 
0.29) adiponectin plasma levels. Furthermore, changes in HDL-cholesterol correlated 
significantly with changes in total adiponectin (ρ = 0.47; P < 0.01) but not with HMW 
adiponectin levels (ρ = 0.13; P = 0.44). 
 
 
Discussion 
The primary findings of this study are that daily moderate alcohol intake improves insulin 
sensitivity and lipid profile in postmenopausal women. Furthermore, ADIPOQ mRNA 
levels in subcutaneous adipose tissue along with plasma levels of total and HMW 
adiponectin increased after moderate alcohol consumption. Moreover, changes in ADIPOQ 
mRNA levels correlated with changes in plasma total adiponectin indicating that prolonged 
moderate alcohol intake increases circulating adiponectin via increased gene expression. 
However, improvements in insulin sensitivity were not associated and with increased 
plasma adiponectin levels (HMW and total) after moderate alcohol consumption in these 
women. 
A strength of this study is its randomized crossover design. In addition, we 
assessed compliance to study treatment several times in different ways throughout the study 
and observed no significant deviations. Several limitations warrant consideration. A slightly 
lower body weight was observed after the juice intervention compared with the alcohol 
intervention. However, lower body weight is associated with improved insulin sensitivity 
and thus could have only affected the results towards no alcohol-induced improvement in 
insulin sensitivity. In the present study, only subcutaneous adipose tissue samples were 
used to determine ADIPOQ mRNA levels. Studies have demonstrated that ADIPOQ 
mRNA levels were higher (27;28) or not different (29) in subcutaneous compared with 
visceral adipose tissue in lean and obese subjects. Furthermore, studies in human adipose 
tissue showed increased (30) as well as indifferent (31) ADIPOQ mRNA and in vitro 
protein secretion levels of adiponectin from subcutaneous compared with omental 
adipocytes. Subcutaneous adipose tissue thus, appears to be at least of equal importance as 
omental adipose tissue for circulating plasma adiponectin levels. 
The observed changes in insulin sensitivity after prolonged moderate alcohol 
intake are in accordance with a study by Davies et al. (4) in which moderate alcohol 
consumption in postmenopausal women for 8 weeks decreased fasting insulin and 
triglycerides levels, both independent risk factors for type 2 diabetes, and improved insulin 
sensitivity. However, other clinical trials did not find a change in fasting insulin levels (5) 
and triglyceride levels (32;33) nor in insulin sensitivity after moderate alcohol consumption 
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(6-12), whereas levels of total adiponectin (8;10;12) and HMW adiponectin (11) did 
increase. Differences in the designs used in these clinical trials are numerous. However, 
studies that did observe an effect on markers of insulin sensitivity after moderate alcohol 
consumption were all performed in middle-aged (4), relatively insulin resistant (8) or 
diabetic subjects (34;35). This suggests that the effect of moderate alcohol intake on insulin 
sensitivity is more pronounced in subjects with (slightly) impaired glucose tolerance rather 
then young and glucose tolerant subjects. Moreover, most interventions that did not observe 
a link between alcohol and insulin sensitivity lasted only 30 (7;9) or even fewer (8;10-12) 
days of consecutive alcohol consumption, while this study and of Davies et al. (4) and Shai 
et al. (34) comprised of 6, 8 and 12 weeks respectively. This indicates that a longer duration 
of alcohol consumption may be needed to exert an effect on insulin sensitivity. Finally, the 
relation between moderate alcohol intake and insulin sensitivity might be influenced by 
gender since the association between alcohol consumption and type 2 diabetes appears to be 
stronger in women then men as observed in some observational studies (2). This gender 
difference may partly be explained by changes associated with menopause which may 
mediate the relation between alcohol and triglyceride levels, the latter being an independent 
risk factor for type 2 diabetes (36). Compared with postmenopausal non-drinkers, 
postmenopausal drinkers have lower triglyceride levels whereas male drinkers have higher 
triglyceride levels compared with male abstainers (37).  
Intervention-associated changes in ADIPOQ mRNA levels in subcutaneous 
adipose tissue correlated with changes in plasma protein levels of total adiponectin. In line 
with are cross sectional studies (38;39) showing associations between subcutaneous 
ADIPOQ mRNA levels with plasma levels of adiponectin. This finding suggests that the 
alcohol-induced increase in plasma adiponectin levels is mediated by de novo synthesis 
rather than decreased renal function (40) or post-transcriptional regulation (41). Changes in 
plasma HMW adiponectin did not correlate with changes in ADIPOQ mRNA levels. 
However, multimer oligomer formation of HMW adiponectin is influenced by several post-
translational modifications (42) which can account for the absence of such a correlation.  
Adiponectin synthesis is under control of the transcription factor PPARγ (20). 
PPARγ ligands induce expression of the adiponectin gene via direct binding of the PPARγ / 
retinoid X receptor heterodimer to the PPAR-responsive element in the human ADIPOQ 
promoter. We indeed observed a trend for increased PPARG mRNA levels after the alcohol 
intervention. However, our sample size of 36 participants was anticipated to detect a 20% 
change in mRNA levels. As the intervention gave rise to only a 9% change in PPARG 
mRNA, our study was underpowered to detect a significant difference in. Besides this trend 
for increased PPARG mRNA levels we also found a strong correlation between 
intervention-associated changes in PPARG and ADIPOQ mRNA levels. Furthermore, 
previous research has shown that PAI-1 expression, and PAI-1 protein levels increases after 
alcohol consumption (21). PAI-1 expression is also regulated by PPARγ (22). It thus seems 
plausible that moderate alcohol use might alter adiponectin gene expression and 
consequently adiponectin protein levels, also in a PPARγ-mediated manner. 
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Consistent with previous findings in young and middle-aged men (8;10), we now 
report that also in postmenopausal women total adiponectin plasma levels increase after 
moderate alcohol consumption. Moreover, we found that also the high-molecular weight 
form of plasma adiponectin increased after six weeks of alcohol consumption. The increase 
in HMW adiponectin after moderate alcohol consumption is in line with a previous study in 
which a trend was observed (11). In the current study, however, we used a more sensitive 
and precise methodology to quantify HMW adiponectin, ELISA instead of quantitative 
Western blotting. 
The observed changes in insulin sensitivity as measured by HOMA-IR did not 
correlate with the alcohol-induced changes in total or with HMW adiponectin, of which the 
latter is proposed to be a better predictor of insulin sensitivity (43). These findings are 
consistent with other lifestyle interventions like weight loss (44) and exercise interventions 
(45) and with previous observations of our group (11;12) which showed increased 
adiponectin plasma levels without changes in insulin sensitivity. In this study we do find an 
alcohol-effect on insulin sensitivity irrespective of changes in adiponectin levels. The 
present results may suggest a possible independent effect of alcohol on insulin sensitivity in 
addition to an adiponectin-mediated effect on insulin sensitivity.  
Looking cross sectional at our data, we did observe correlations between HOMA-
IR and adiponectin levels after both alcohol and placebo treatment (data not shown). This is 
in line with published literature in which consistently associations between adiponectin and 
insulin sensitivity have been shown (14-17). Possibly, increased adiponectin levels partly 
explain the improved insulin sensitivity seen among moderate alcohol consumers (18;19). 
Studies have revealed that circulating adiponectin levels are inversely associated with 
markers of inflammation (39;46;47) whereas a low-grade inflammation is thought to 
contribute to insulin resistance (48). Therefore, adiponectin may lead to improved insulin 
sensitivity through effects on inflammatory markers. 
In conclusion, the results of the present study demonstrate that six weeks of 
moderate alcohol consumption improves insulin sensitivity, and lipid profile in 
postmenopausal women. Furthermore, moderate alcohol consumption increases 
subcutaneous adipose ADIPOQ mRNA levels and plasma levels of adiponectin. This 
suggests that the alcohol-induced increase in adiponectin is attributable at least in part to 
transcriptional alterations in adipose tissue. The observed improvement in insulin 
sensitivity, lipid profile and adiponectin levels when consuming 2.5 standard drinks per day 
may reduce the risk of type 2 diabetes and cardiovascular disease in postmenopausal 
women. Despite these potentially beneficial findings, scientific literature indicates that 
alcohol drinking may also have detrimental health effects (49). Both potential benefits and 
risks should be taken into consideration when counseling on consumption. 
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Background: Moderate alcohol consumption has various acute and longer-term effects on 
low-grade inflammation which may accumulatively affect chronic disease risk. So far, no 
comprehensive, large-scale profiling has been performed to integrate the effects of longer-
term moderate alcohol consumption. 
 
Objective: To describe the effects of moderate alcohol consumption on several circulating 
markers and whole-genome transcriptomics using large-scale profiling of proteins and gene 
expression activity in blood and in blood cells, respectively. 
 
Methods: In a randomized, open-label, crossover trial, 24 young (age: 21-33 y) normal-
weight (BMI: 19-27 kg/m2) men consumed 100 mL vodka (30 g alcohol) with 200 mL 
orange juice or orange juice only (control) daily during dinner for four weeks. After each 4-
week period, blood was sampled for measuring serum lipoproteins, plasma cytokines and 
whole blood gene expression. To determine gene expression profiles whole blood was 
collected in PAXgene tubes and extracted RNA was analyzed on Illumina BeadChips. 
 
Results: Four weeks of vodka increased HDL-cholesterol, associated lipoprotein levels and 
total adiponectin whereas interleukin (IL)-1 receptor antagonist and IL-18 plasma levels 
decreased (all P < 0.05) compared with control. Four weeks of vodka resulted in down-
regulation of 345 genes and up-regulation of 455 genes in blood cells. Pathway analysis 
revealed effects of vodka consumption on the immune response with a down-regulated 
expression of the nuclear transcription factor kappa B (NF-κB) in blood cells. Furthermore, 
a network of expression changes related to lipid metabolism was observed with a central 
role for peroxisome proliferator-activated receptor alpha (PPARα). 
 
Conclusion: An integrated approach of large-scale profiling of proteins and genes showed 
that longer-term moderate alcohol consumption altered immune response and lipid 
metabolism. 
 
Trial registration: Clinicaltrials.gov ID no.: 00918918 
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Introduction 
It is recognized that chronic, low-grade inflammation is an important hall mark in the 
development of both atherosclerosis and type 2 diabetes (1;2). Low-grade inflammatory 
changes have been shown to precede type 2 diabetes by many years (3;4). Moderate alcohol 
consumption has been consistently associated with a reduced risk of both cardiovascular 
diseases (5) and type 2 diabetes (6) compared with abstention possibly due to a lowered 
inflammatory status.  
Alcohol consumption is known to modulate several immune functions and 
inflammatory processes (7). In observational studies moderate alcohol consumption is 
associated with lower levels of inflammatory markers (8) and lowered levels of C-reactive 
protein (CRP) (9-11). Data from randomized trials on inflammatory markers after 
prolonged moderate alcohol consumption are scarce but do suggest lower levels of certain 
cytokines (12) and CRP (13;14) although not consistently (15). Acute moderate alcohol 
consumption has been shown to suppress the production of pluripotent nuclear transcription 
factor kappa B (NF-κB) (16-18) in white blood cells. Activation of NF-κB, induced by a 
wide range of signals including lipopoly-saccharides and viruses, is a pivotal step in the 
induction of several inflammatory cytokines, chemokines and growth factors.  
Besides their important role in inflammatory responses and the immune system, 
white blood cells are also the most readily available tissue for gene expression profiling. 
More importantly, their gene expression profiles have previously been shown to reflect 
dietary-induced changes in several short-term and longer-term intervention trials (19;20).  
Recently, we have shown that the interpretation of a dietary intervention-induced 
changes can be strongly facilitated by the use of an integrative approach of comprehensive 
techniques such protein and gene profiling (21). Hence, we examined the effects of 
prolonged moderate alcohol consumption by means of an integrated approach of gene and 
protein profiling of blood.  
 
 
Methods 
Study Design 
The study used a randomized, open-label, crossover design, consisting of two 4-week 
periods. Subjects consumed two miniatures (50 mL each) of vodka (Smirnoff, U.K.) (30 g 
alcohol) with 200 mL orange juice (Appelsientje, the Netherlands) or only orange juice 
daily for four weeks during dinner. The study was conducted at TNO (a Dutch acronym for 
applied scientific research) Quality of Life, in Zeist, the Netherlands. The study was 
approved by an independent centralized ethics committee (METOPP; Tilburg, the 
Netherlands) and is registered at Clinicaltrials.gov, number NCT 00918918. Allocation to 
treatment order was randomized according to BMI and age. Blood sampling was done on 
the morning after four weeks of each treatment period, after an overnight fast. Compliance 
was monitored by weekly measurement of urinary ethyl glucuronide (EtG), a direct phase II 
metabolite of ethanol formed by action of UDP-glucuronosyl transferase. EtG has been 
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reported to be a superior marker with 100% sensitivity as a biomarker of recent drinking. It 
persists in the urine up to ~75 - 85 h after last intake (22). Cut-off limit to assess 
compliance during juice intervention for urinary EtG values was set at >0.25 mg/mL 
(positive sample), to obtain a high sensitivity but avoid positive results due to unintentional 
ethanol exposure. Cut-off limit during vodka intervention was set at EtG values <0.5 
mg/mL (2.2 μmol/L) (negative sample). Additional measures of compliance were the 
increase of HDL-cholesterol and the return of empty bottles of vodka. 
 
Subjects 
We recruited 24 apparently healthy, non smoking male subjects between 21 and 40 years. 
Subjects were eligible if they consumed between 5 and 28 units of alcohol per week, were 
free of any medication at the beginning of the study, and had a BMI between 18 and 27 
kg/m2 and had no family history of alcoholism. Subjects gave written informed consent and 
received a compensation for their participation. They were instructed to maintain their 
habitual body weight, food pattern and physical activity pattern and were told to refrain 
from any alcoholic products during the entire study except the vodka supplied by TNO. 
 
Blood and urine handling and analysis 
Blood samples were obtained from the anticubital vein of the forearm and collected in tubes 
containing clot activator for serum and in ice-chilled tubes containing or Potassium 
Ethylene Diamine Tetra Acid (K3EDTA) for plasma (Vacutainer Systems, Becton 
Dickinson, Plymouth, U.K.). Blood was centrifuged for 15 minutes at 2.000 g at 4°C, 
within 15 - 30 minutes after collection and stored at -<70°C. Serum clinical chemistry tests 
included the measurement of γ-glutamyltransferase, alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, glucose, insulin, triglycerides, free fatty acids total 
cholesterol, HDL-cholesterol, LDL-cholesterol, and phospholipids were analyzed with 
enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany) on an Olympus 
AU400 clinical chemistry analyzer (Olympus-Diagnostica Europe, Hamburg, Germany). 
Six serum apolipoproteins (apolipoproteins A-I, A-II, B, C-I, C-III and E) and 47 plasma 
proteins (Human InflammationMAP™ 1.0; http://www.rulesbasedmedicine.com/products-
services/Human-InflammationMAP.asp) were analyzed by bead-based multiplexed 
immunoassay at the biomarker testing laboratory Rules Based Medicine (RBM; Austin, 
Texas, U.S.A.). Total adiponectin was measured using MesoScale Diagnostics assays (Cat# 
K151IYC-1) (Meso Scale Discovery; Gaithersburg, MD, U.S.A.). For gene expression 
analysis 2.5 mL blood was collected in PAXgene tubes (BD, Erembodegem, Belgium) and 
stored according to the manufacturer’s instructions. EtG was determined in morning urine 
samples as previously described (23). 
 
 
 
RNA extraction and handling 
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RNA was isolated using PAXgene Blood RNA Kit (Qiagen, Venlo, the Netherlands) 
according to manufacturer’s instructions. The Quality control, RNA labeling, hybridization 
and data extraction were performed at ServiceXS (Leiden, the Netherlands). RNA 
concentration was measured using a Nanodrop ND-1000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, U.S.A.). The RNA quality and integrity was determined 
using Lab-on-Chip analysis on an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., 
Santa Clara, CA, U.S.A.). Average RNA yield of the samples was 10.3 μg (range 1.9 - 28 
μg) and the average RNA Integrity Number (RIN) score was 8.9 (range 6.8 - 9.6). The 
labeling reaction included a globin reduction step. Four different peptide nucleic acids 
(PNAs) were used to block the 3’ends of globin transcripts. Due to the addition of the 
globin PNA sequences to the labeling reaction, the labeling of globin transcripts is 
hampered in favor of the other transcripts, which are typically underrepresented in blood 
cells. As a consequence, the signal strength of non-globin genes is much higher after globin 
reduction. Biotinylated cRNA was prepared using the Illumina TotalPrep RNA 
Amplification Kit (Ambion, Inc., Austin, TX, U.S.A.) according to the manufacturer’s 
specifications starting with 500 ng total RNA. Per sample, 750 ng of cRNA was used to 
hybridise to the Sentrix HumanHT-12 v3 Expression BeadChips (Illumina, Inc., San Diego, 
CA, U.S.A.). Each BeadChip contains twelve arrays. Hybridization and washing were 
performed according to the Illumina standard assay procedure. Scanning was performed on 
the Illumina iScanner (Illumina, Inc., San Diego, CA, U.S.A.). Image analysis and 
extraction of raw expression data was performed with Illumina Genomestudio 2010 Gene 
Expression software with background subtraction and no normalization. Probe level data 
were submitted to quantile normalization in GeneSpring GX 11.0 (Agilent Technologies, 
Santa Clara, CA, U.S.A.) and probes were filtered on detection P value (>0.99 in at least 
one sample). This resulted in normalized data for 19,378 probes.  
 
Statistical analysis  
Serum and plasma variables at the end of the intervention were compared between 
treatments with a mixed analysis of variance model that included terms for treatment, 
period and the interaction between period and treatment (indicating possible carryover 
effects). The so-called 80% rule was applied to the multiplex inflammatory protein dataset 
to retain only those plasma analytes for which ≥80% of the values were above the detection 
limit for ≥1 of the 2 treatment groups (24), resulting in retention of 29 of the 47 antigens 
measured in plasma. Values below the detection limit that remained in the truncated data 
set were replaced by a value of half of the detection limit. Values for remaining samples 
that were not measurable on the standard curve for a specific protein were set at 0.1 times 
the detection limit for that protein. Statistical analyses were performed using the SAS 
statistical software package (SAS version 8.2 and 9, SAS Institute, Cary, NC, U.S.A.). 
Statistical significance was defined as P < 0.05. For gene expression data, an additional 
threshold was applied to select genes that were up-regulated (>0%) in ≥15 subjects or 
down-regulated (<0%) in ≥15 subjects (Figure 5.1). The cut-off of 15 subjects was based on 
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the average number of subjects that showed intervention-induced alterations in significantly 
changed circulating markers. These remaining genes were used for biological interpretation 
and network construction.  
 
Figure 5.1: Flow chart of probe selection and number of probes and specific genes changed between 
the two interventions in the microarray analysis. 
 
 
Biological interpretation 
Functional analysis of the gene expression data was performed by using Ingenuity Pathway 
Analysis version 8.7 (Ingenuity Systems Inc, Redwood City, CA, U.S.A.), identifying 
significantly enriched pathways and gene lists (P < 0.05). Networks were built in MetaCore 
version 6.1 (GeneGo,St Joseph, MI, U.S.A.), using direct interactions or shortest path 
algorithm (max 2 steps and with filter for human data). 
 
Results 
Subjects and compliance 
All 24 men enrolled completed the study without any serious adverse events. Mean (± 
SEM) age and BMI of the men were 25.5 ± 3.3 y and 23.5 ± 2.5 kg/m2. Weekly urinary 
EtG levels were assessed to check individual compliance to treatments. This revealed eight 
positive urine samples during the orange juice-drinking period, although all ≤0.5 mg/mL, 
and seven negative samples during the vodka orange juice-drinking period out of the 192 
samples analyzed (overall compliance of 92%). Another indicator for compliance was the 
8.8% increase in HDL-cholesterol after vodka and juice compared with juice consumption 
(Table 5.1). 
Expressed: 
19,378 probes 
Changed (P < 0.05):  
1,070 probes  
Down-regulated in ≥15 subjects: 
382 probes (345 unique Entrez gene IDs) 
Up-regulated in ≥15 subjects: 
496 probes (455 unique Entrez gene IDs) 
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Table 5.1: Overview of circulating proteins and metabolites that significantly differed (P < 
0.05) between the two 4-week treatments in 24 young men and sampled after an overnight 
fast. 
Data are expressed means (± SEM). 
1 P values obtained from a mixed ANOVA model that included terms for treatment, period and the interaction 
between period and treatment (to assess carryover effects). 
 
 
Serum and plasma measurements 
No significant (P > 0.05) carryover effects as assessed by an interaction between treatment 
and period effect were observed for any plasma or serum measures. As expected HDL-
cholesterol and some HDL-associated apolipoproteins such as apolipoprotein (apo)A-II and 
apoC-I, apoC-III and phospholipids increased (all P < 0.05) after alcohol consumption 
(Table 5.1). Plasma levels of the pro-inflammatory cytokines interleukin (IL)-1 receptor 
antagonist and IL-18 were significantly reduced (both P < 0.05) whereas plasma levels of 
the anti-inflammatory protein adiponectin were increased after vodka consumption (P < 
0.05). 
 
 
 
 
 
Orange 
Juice 
Vodka and 
orange juice 
% 
change 
P value1 
Lipoproteins     
HDL-cholesterol (mmol/L) 1.12 ± 0.04 1.22 ± 0.05 8.8 < 0.001 
Phospholipids (mmol/L) 2.36 ± 0.08 2.52 ± 0.08 6.0 < 0.001 
Apolipoprotein A-II (ng/L) 221 ± 13 243 ± 13 11.6 < 0.01 
Apolipoprotein C-I (ng/L) 239 ± 8 255 ± 8 7.7 0.01 
Apolipoprotein C-III (μg/L) 84 ± 6 94 ± 6 10.4 0.02 
     
Inflammatory markers     
Total adiponectin (μg/mL) 10.6 ± 0.9 11.6 ± 0.9 8.6 < 0.01 
IL-1 receptor agonist (pg/mL) 68 ± 5 52 ± 5 -13.8 < 0.01 
IL-18 (pg/mL) 152 ± 13 143 ± 13 -4.0 0.03 
     
Miscellaneous/liver markers     
γ-glutamyltransferase (U/L) 19.8 ± 2.4 24.3 ± 2.4 18.7 < 0.001 
Ferritin (ng/mL) 125 ± 18 100 ± 18 -13.6 < 0.01 
Alpha-1 antitrypsin (mg/mL) 1.49 ± 0.05 1.39 ± 0.05 -6.0 0.03 
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Table 5.2: Overview of differentially expressed pathways and number of genes changed 
based on Ingenuity Pathway Analysis, ranked on most significantly changed pathway in 
functional group. 
Functional group Pathways / lists P value # changed 
Signaling Glucocorticoid receptor signaling 0.0017 22 
 Acute myeloid leukemia signaling 0.0047 9 
 Estrogen receptor signaling 0.0151 10 
 Chronic myeloid leukemia signaling 0.0158 9 
 PI3K/AKT signaling 0.0204 10 
 Neuregulin signaling 0.0288 8 
 BMP signaling pathway 0.0324 7 
 GNRH signaling 0.0347 10 
 G Beta gamma signaling 0.0372 8 
 Androgen signaling 0.0417 9 
    
Immune response Antigen presentation pathway 0.0028 7 
 
Crosstalk between dendritic cells and natural 
killer cells 
0.0044 10 
 Leukocyte extravasation signaling 0.0095 14 
 Oncostatin M signaling 0.0135 5 
 PKCΘ¸ signaling in T lymphocytes 0.0151 10 
 GM-CSF signaling 0.0155 7 
 B Cell receptor signaling 0.0166 12 
 IL-15 signaling 0.0407 6 
 T Cell receptor signaling 0.0457 8 
 
Role of NFAT in regulation of the immune 
response 
0.0468 12 
    
(Lipid) metabolism 
Mechanism of gene regulation by peroxisome 
proliferators via PPARα 
0.0065 10 
 Citrate cycle 0.0069 5 
 PPARα/RXR activation 0.0257 12 
    
Other Role of NFAT in cardiac hypertrophy 0.0178 14 
 Selenoamino acid metabolism 0.0214 5 
    
Apoptosis Apoptosis signaling 0.0224 8 
 Pro-apoptosis 0.0316 5 
 TNF-R1 signaling 0.0479 5 
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Microarray analysis and pathway analysis 
Microarray hybridization was performed on RNA extracted from whole blood which was 
collected at the end of each 4-week intervention period. All 48 arrays passed the quality-
control criteria. Of the 48,803 probes present on the microarray, 19,378 probes were 
defined as expressed in the white blood cells (Figure 5.1). Four weeks of vodka and juice 
resulted in down-regulation of 382 probes (345 genes with unique Entrez IDs) and up-
regulation of 492 probes (455 genes with unique Entrez IDs) in leukocytes.  
To determine the role of genes that changed after vodka and juice consumption, 
we performed pathway analysis in Ingenuity Pathway Analysis. This revealed changes in 
pathways related to diverse signaling processes, immune response, lipid 
metabolism/PPARα and apoptosis (Table 5.2).  
The functional group ‘signaling’ contained a diversity of the different signaling processes. 
Two of the top four pathways of this functional group involved pathways related to myeloid 
leukemia signaling. Table 5.3 shows the genes involved in these pathways of which 
expression levels were significantly different between the treatments. 
Another functional group that was altered by the alcohol treatment compared to 
the alcohol free treatment was ‘immune response’ and contained among others the pathway 
of antigen presentation, B and T cell receptor signaling and Il-15 signaling. Forty unique 
genes were involved in this functional group. These genes were, together with the 
significantly affected proteins related to immune response/inflammation (e.g. total 
adiponectin, IL-1 receptor antagonist, IL-18, ferritin, and alpha-1 antitrypsin) used for 
network analysis in MetaCore (Figure 5.2). This integrative network analysis of genes and 
proteins revealed coherent effects of moderate alcohol consumption on immune response, 
as indicated by the direct links in the network in Figure 5.2. The figure depicted a central 
role for the transcription factor NF-κB. 
Similarly, a network was created for genes from the pathway category (lipid) 
metabolism together with HDL-cholesterol and the significantly changed HDL-associated 
markers (e.g. apolipoproteins and total adiponectin). Again, this network approach 
illustrated close biological links between the alcohol-induced changes in genes and proteins 
involved with a central role for PPARα (Figure 5.3). 
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Table 5.3: Genes involved in myeloid leukemia signaling (acute and chronic) which 
expression levels differed between treatments1. 
1 P < 0.05 and an additional restriction of up- or down-regulation of the gene expression level in at least 15 of the 
24 subjects. 
 
 
Discussion 
In this study, we assessed changes in gene expression and circulating markers after 
moderate alcohol consumption in a randomized crossover trial in men. With an integrated 
approach of gene and protein profiling of blood, we showed that four weeks of moderate 
alcohol consumption (30 g alcohol per day) resulted in changes related to immune response 
and lipid metabolism. The altered gene expression profiles in immune response were 
predominantly associated with a decreased NF-κB expression whereas changes in lipid 
metabolism were in close connection with PPARα  
Gene description Gene name Entrez ID 
Mean 2 
log ratio 
P 
value 
Histone deacetylase 5 HDAC5 10014 -0.52 0.019 
Runt-related transcription factor 1  RUNX1 861 -0.47 0.020 
Growth factor receptor-bound protein 2  GRB2 2885 -0.26 0.030 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 2 
NFKB2 4791 -0.18 0.043 
Signal transducer and activator of 
transcription 5A  
STAT5A 6776 -0.16 0.011 
Proliferation-associated 2G4 PA2G4 5036 -0.15 0.026 
CCAAT/enhancer binding protein CEBPA 1050 -0.13 0.021 
V-raf-1 murine leukemia viral oncogene 
homolog 1  
RAF1 5894 0.12 0.049 
V-crk sarcoma virus CT10 oncogene 
homolog 
CRK 1398 0.13 0.047 
V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog  
KRAS 3845 0.17 0.033 
Colony stimulating factor 2 receptor CSF2RB 1439 0.57 0.016 
V-kit Hardy-Zuckerman 4 feline sarcoma 
viral oncogene homolog  
KIT 3815 0.60 0.007 
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Figure 5.2: Immune response network with a central role of nuclear transcription factor kappa B (NF-
κB). The network was derived using MetaCore and based on direct interactions between 40 genes 
involved in immune response and 5 plasma proteins. Blue circles/squares indicate down-regulation in 
response to alcohol intervention, red circles/squares indicates up-regulation in response to alcohol 
intervention. Squares denote proteins (measured in plasma), circles represent genes (measured in 
leukocytes). 
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We observed altered expression profiles in white blood cells related to acute and chronic 
myeloma and lymphoma signaling. Expression of the genes encoding for signal transducer 
and activator of transcription 5A (STAT5A) and runt-related transcription factor 1 (RUNX1) 
(a.k.a. AML1, acute myeloid leukemia 1) were down-regulated after moderate alcohol 
consumption compared with the abstention period. Activation of STAT5A has been shown 
to be essential for the tumorigenesis. The altered expression levels in pathways of myeloma 
and lymphoma signaling in our crossover study might provide mechanistic support for 
findings of several observational studies (25;26). In these large prospective cohort studies 
an inverse association between alcohol consumption and risk of non-Hodgkin lymphoma 
was reported. 
 
 
 
Figure 5.3: Network around peroxisome proliferator-activated receptor alpha (PPARα).  
The network was derived using MetaCore and based on shortest path (max 2 steps) between 11 
genes involved in PPAR regulated pathways or citrate cycle and 4 plasma proteins. Blue 
circles/squares indicate down-regulation in response to the alcohol intervention, red circles/squares 
indicate up-regulation in response to alcohol intervention. Squares denote proteins (measured in 
plasma), circles represent genes (measured in leukocytes). 
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We observed a down-regulation of NF-κB after prolonged moderate vodka and 
juice consumption compared to juice only consumption. The various direct connections of 
NF-κB with other immune-related gene expression and protein levels underlined the 
pleiotropic regulator function of NF-κB in inflammatory responses. Our findings of 
prolonged alcohol consumption on NF-κB are in concord with observations after acute 
consumption in which is shown that acute alcohol prevents NF-κB activation which lead to 
an inhibition in pro-inflammatory cytokines such as TNF-α an IL-1ß at the protein as well 
as the mRNA level (18). We did observe lower IL-18 levels after moderate alcohol 
consumption, in line with a previous study among diabetic men (27). 
We and others have previously reported increased circulating adiponectin 
concentrations after moderate alcohol consumption (28-30). Adiponectin was present in 
both the immune response and PPARα /lipid metabolism networks. This adds to the notion 
that adiponectin might be an important link between inflammation and lipid metabolism. 
Indeed several lines of evidence suggest an inverse association between adiponectin and 
markers of inflammation (31) and with favorable lipid profiles (32) in observational studies. 
Gene expression of ADIPOQ in these white blood cells did not change between treatments, 
despite the increased levels after moderate alcohol consumption. However, adiponectin is 
predominantly expressed in the adipose tissue. The alcohol-induced increase of the protein 
can largely be attributed to increased expression of the adiponectin gene in adipose tissue 
(23). 
We found a substantial decrease in plasma ferritin concentrations after the vodka 
treatment compared with the control treatment. Ferritin is one of the key proteins regulating 
iron homeostasis. Growing evidence has shown that even moderately increased iron stores, 
represented by high-normal ferritin concentrations, are associated with insulin resistance 
(33) and type 2 diabetes. The results of our randomized trial are in contrast with 
observational research which shows a positive association with alcohol consumption and 
ferritin concentrations (34-36). If confirmed in other trials, decreased ferritin concentrations 
might be a new and relatively unexplored mechanism that may explain the lowered risk of 
type 2 diabetes associated with moderate consumption. Gene expression of ferritin in white 
blood cells did not change between treatments, probably because the protein is 
predominantly expressed in liver tissue. 
The observations of increased HDL-cholesterol and apolipoproteins after alcohol 
consumption are consistent with previous findings in 132 healthy men (37). Previous 
studies by our group showed similar increases of HDL-cholesterol in young men (38) and 
middle-aged men (39;40) and women (41) after alcohol consumption.  
Strong points of the study are its randomized crossover design, the high 
compliance to the treatments throughout the study and the integrated approach of both 
proteins and gene expression profiles. However, several limitations warrant consideration. 
First, we used a specific type of tissue, i.e. white blood cells, for gene profiling. Although 
these cells might not be representative for all tissues directly affected by alcohol 
consumption (e.g. liver and adipose tissue), these cells were chosen because of their 
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important roles in inflammatory responses and the immune system. Furthermore, their 
expression profiles have previously been shown to reflect metabolic changes due to short-
term and longer term nutritional adaption in healthy humans (20;21). Second, whole blood 
was collected for RNA isolation. As globin RNA was removed from the samples the gene 
expression profiles can be assigned to the white blood cell population. Since the white 
blood cell population consists of a range of cell types present in the blood samples, it can 
not be completely excluded that changes in gene expression might reflect changes in white 
blood cell type distribution in blood. Third, we only measured specific proteins based on a 
priori expected changes (inflammatory markers and lipoproteins) which might have biased 
our results. However, the analysis of whole-genome expression data and subsequent 
pathway analyses were relatively unbiased, since all genes were measured and this analysis 
indicated the same processes being affected. Furthermore, the network analysis revealed 
integrated effects (shown by the direct connections in both immune response and 
lipid/lipoprotein metabolism network) which might represent a close biological connection 
between the changes in genes and proteins due to alcohol consumption. 
In conclusion, a comprehensive and integrated approach of gene and protein 
profiling of blood showed that moderate alcohol consumption resulted in changes in 
immune response and lipid metabolism. Our integrated and large-scale profiling revealed 
potential new functional pathways and physiological mechanisms that may explain some of 
the health effects that moderate alcohol consumption exerts.  
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Background: Moderate alcohol consumption is associated with a reduced risk of type 2 
diabetes. It also increases concentrations of adiponectin, a hormone inversely associated 
with type 2 diabetes risk. However, the rate at which this increase occurs is unclear.  
 
Objective: To examine the effect of moderate alcohol consumption on the weekly 
alterations in levels of both total and high-molecular weight (HMW) adiponectin and 
associated markers of glucose and lipid metabolism. 
 
Methods: In a randomized, open-label, crossover trial, 24 normal-weight, premenopausal 
women who were regular alcohol consumers, received 66 cL of beer (~26 g alcohol) or 66 
cL of alcohol-free beer (<0.5 g alcohol) daily for 3 weeks preceded by a 1-week washout. 
Blood samples were collected weekly after an overnight fast for measurement of plasma 
total and HMW adiponectin and markers of glycemia and lipid metabolism. 
 
Results: There was a significant interaction (P < 0.05) between the two treatments over 
time for both plasma HWM and total adiponectin concentrations. Within three weeks, 
moderate alcohol consumption significantly increased plasma total (8.2%; P = 0.01) and 
HMW (8.2%; P = 0.02) adiponectin levels compared with abstention. Changes over time in 
total adiponectin were positively associated with changes in HMW adiponectin during the 
nonalcoholic beer (r = 0.80; 95% confidence interval (CI): 0.55, 0.92) and beer (r = 0.82; 
95% CI: 0.58, 0.93) intervention. Alcohol consumption did not affect the ratio HMW to 
total adiponectin nor serum glucose, insulin, hemoglobin A1c or triglyceride levels 
compared with abstention during the 3-week intervention periods. 
 
Conclusions: Moderate alcohol consumption concomitantly increases plasma total and 
HMW adiponectin concentrations compared to abstention in premenopausal women. These 
effects were evident after at least three weeks of consumption. No changes were observed 
in other markers of insulin sensitivity.  
 
Trial registration: Clinicaltrials.gov ID no.: NCT00524550.  
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Introduction 
Moderate alcohol consumption is associated with a reduced risk of type 2 diabetes (1;2). 
This association could – in addition to improved insulin sensitivity and favorable changes 
in triglycerides (3;4) – partially be explained by increased circulating adiponectin levels (5). 
Adiponectin is an adipose tissue-specific adipokine involved in glucose and lipid 
metabolism (6). It is positively associated with insulin sensitivity (7) and inversely with 
inflammatory markers (8). Moreover, higher adiponectin levels have been consistently 
associated with a lower risk of type 2 diabetes (9) and cardiovascular disease (10).  
In observational studies alcohol consumption has been positively associated with 
adiponectin concentrations (11-13), an effect confirmed in short-term randomized trials of 
alcohol administration (14-17).  
Acute alcohol consumption, however, does not alter postprandial levels of 
adiponectin (18;19) suggesting a longer period of alcohol consumption is needed to 
increase adiponectin levels. Also, almost all of these short-term trials only included men 
whereas adiponectin levels differ between men and women (20) and lower levels are 
observed in premenopausal compared to postmenopausal women (21;22). Moreover, the 
majority of these trials investigated only total adiponectin levels, whereas the high-
molecular weight (HMW) isomer of adiponectin has been proposed as the most active 
metabolic form (23-25). 
Hence, this trial was designed to investigate the weekly alterations in levels of 
both HMW and total adiponectin and associated markers of glucose and lipid metabolism 
by changes in alcohol consumption over a 3-week period in a group of premenopausal 
women. 
 
 
Methods 
Study design 
The study used a randomized, open label, placebo-controlled, crossover design, consisting 
of two 3-week periods, each preceded by a one week washout. Subjects daily consumed 
two cans (66 cL) of beer (~26 g alcohol) or two cans of alcohol-free beer (Amstel, the 
Netherlands) for three weeks during dinner. The study was conducted at TNO (a Dutch 
acronym for applied scientific knowledge) Quality of Life (Zeist, the Netherlands). Subjects 
were instructed to maintain their habitual body weight, food and physical activity pattern 
and were told not to consume any additional alcohol during the entire study (including 
washout periods). Body weight was measured weekly wearing indoor clothing, without 
shoes, wallet and keys using a digital weight scale with a precision of 0.1 kg (SECA, model 
701, Germany). Blood and urine sampling was done weekly for eight weeks after an 
overnight fast. Compliance was monitored by weekly measurement of ethyl glucuronide, a 
direct phase II metabolite of alcohol consumption in the urine and increase in serum HDL-
cholesterol. Cut-off limit to assess compliance during alcohol free intervention for urinary 
ethyl glucuronide values was set at >0.25 mg/mL (positive sample), to obtain a high 
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sensitivity but avoid positive results due to unintentional ethanol exposure. Cut-off limit 
during the beer intervention was set at ethyl glucuronide values <0.5 mg/mL (2.2 μmol/L) 
(negative sample) (4). 
 
Study subjects 
Subjects were recruited from a pool of volunteers of TNO Quality of Life. Eligible 
premenopausal women consumed between 5 and 21 units of alcohol per week, were 
apparently healthy, between 20 to 40 years, used phase I or II oral contraceptives, had a 
BMI between 19 and 25 kg/m2, refrained from smoking and had no family history of 
alcoholism. They gave written informed consent and received compensation for their 
participation. The study was approved by an independent centralized ethics committee 
(METOPP, Tilburg, the Netherlands). This trial is registered at Clinicaltrials.gov, number 
NCT00524550. 
 
Handling and analysis of blood and urine samples 
Ethyl glucuronide samples in morning urine were sampled and treated as described 
previously (4). Blood samples were obtained weekly from the anticubital vein of the 
forearm and collected in tubes containing clot activator for serum and in ice-chilled tubes 
containing or potassium ethylene diamine tetra acid (K3EDTA) for plasma (Vacutainer 
Systems, Becton Dickinson, Plymouth, U.K.) and were centrifuged for 15 minutes at 2.000 
g at 4°C, within 15 - 30 minutes after collection and stored at <-70°C. Biochemical 
determinations in blood were performed at TNO Quality of Life using Olympus analytical 
equipment and reagents except for adiponectin. Plasma total and HMW adiponectin 
concentrations were determined by an enzyme-linked immunosorbent assay (ELISA) 
(Catalogue number: 47-ADPHU-E01; Alpco Diagnostics, Salem, NH, U.S.A.). The intra-
assay coefficients of variation for the two forms of adiponectin were 5.4% for total and 
5.0% for HWM adiponectin. 
 
Statistics 
Variables over time were compared between treatments using a mixed analysis of variance 
model that included fixed terms for treatment, time, treatment sequence (indicating possible 
carry-over effects), and the interaction between treatment and time and random terms for 
subject and period. Body weight was included in the model as a random factor to correct for 
potential fluctuations in body weight. Orthogonal polynomials were used to test for linear 
or quadratic trends. Regression analyses were performed to describe the slopes of the time 
trend curve for both beverages. For the correlation between changes over time in 
adiponectin and HMW adiponectin, a Fisher’s z transformation was applied on individual 
correlations to correct for deviations from the normal distribution and a 95% confidence 
intervals (CI) were calculated. Statistical analyses were performed using the SAS statistical 
software package (SAS version 8, SAS Institute, Cary, NC, U.S.A.). Data are presented as 
mean ± SEM unless specified otherwise. Statistical significance was defined as P < 0.05. 
Alcohol and alterations in adiponectin | 
 107 
Results 
All 24 enrolled women completed the study (Table 6.1). Mean age and BMI of the women 
were 23.9 ± 4.3 y and 22.2 ± 1.6 kg/m2 respectively. No carryover effects were seen in any 
outcome measure. Analysis of urinary ethyl glucuronide revealed two negative samples 
during the beer-intervention and no positive samples during the alcohol free beer 
intervention or washout period out of the 191 samples analyzed (overall compliance of 
99.0%). Another measure of compliance was the increase (P < 0.01) in HDL-cholesterol 
after three weeks of beer compared with non-alcoholic beer consumption (Table 6.2).  
 
 
Table 6.1: Baseline characteristics of twenty-four premenopausal women after an overnight 
fast. 
Variable Mean ± SD Range 
Body weight (kg) 67.6 ± 6.5 54.4 - 79.4 
Glucose (mmol/L) 4.95 ± 0.28 4.39 - 5.39 
Insulin (pmol/L) 41.7 ± 16.0 20.1 – 81.3 
HDL-cholesterol (mmol/L) 1.61 ± 0.33 1.06 - 2.17 
LDL-cholesterol (mmol/L) 2.62 ± 0.46 1.70 - 3.40 
Triglycerides (mmol/L) 1.11 ± 0.40 0.42 - 1.98 
Alanine aminotransferase (units/L) 16.9 ± 6.4 9 – 30 
Aspartate aminotransferase (units/L 21.0 ± 5.7 13 – 41 
Alkaline phosphatase (units/L) 62.6 ± 15.6 33 – 86 
γ-Glutamyltranspeptidase (units/L) 19.0 ± 9.1 7.6 - 39.2 
 
 
 
Mean body weight was slightly higher during the 3-week beer drinking period 
(67.9 ± 1.3 kg vs. 67.6 ± 1.3 kg, P < 0.01). Results were adjusted for this difference in body 
weight, but did not essentially change. Therefore, unadjusted results are presented. Plasma 
levels of total and HMW adiponectin over time differed between the two treatments 
(Pinteraction < 0.05; Figure 6.1). After the first two weeks, adiponectin levels did not differ 
between treatments. However, after three weeks, both HMW (3.73 ± 0.36 μg/mL vs. 3.47 ± 
0.36 μg/mL, P = 0.02) and total (7.24 ± 0.51 μg/mL vs. 6.77 ± 0.51 μg/mL, P = 0.01) 
adiponectin levels were 8.2% higher after consuming beer compared with consuming non-
alcoholic beer. No differences between treatments over time or between treatments were 
observed in the ratio HMW to total adiponectin or levels of serum glucose, insulin, 
triglycerides or free fatty acids (data not shown). 
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Table 6.2: Characteristics of twenty-four premenopausal women after three weeks of 
consuming beer or alcohol-free beer after an overnight fast. 
 Alcohol-free Beer P value1 
Glycemic markers    
Glucose (mmol/L) 4.79 ± 0.11 4.84 ± 0.11 0.36 
Insulin (pmol/L) 45.7 ± 4.0 46.1 ± 4.0 0.90 
Hemoglobin A1c (%) 5.0 ± 0.04 4.9 ± 0.04 0.16 
    
Lipid profile    
HDL-cholesterol (mmol/L) 1.52 ± 0.07 1.62 ± 0.07 < 0.01 
LDL-cholesterol (mmol/L) 2.40 ± 0.07 2.37 ± 0.07 0.77 
Triglycerides (mmol/L) 1.27 ± 0.08 1.25 ± 0.08 0.61 
Free fatty acids (mmol/L) 0.34 ± 0.03 0.29 ± 0.03 0.26 
    
Liver enzymes    
Alanine aminotransferase (units/L) 10.8 ± 1.8 10.0 ± 1.8 0.21 
Aspartate aminotransferase (units/L 17.8 ± 2.0 17.8 ± 2.0 0.95 
Alkaline phosphatase (units/L) 56.9 ± 6.5 57.8 ± 6.5 0.68 
γ-Glutamyltranspeptidase (units/L) 16.5 ± 2.2 18.5 ± 2.2 0.01 
Data are expressed as mean ± SEM. 
1 Mixed ANOVA model on baseline values that included terms for treatment, period and the interaction between 
period and treatment (to assess carryover effects). 
 
 
The orthogonal polynomial describing the linear time trend for each adiponectin 
form was significantly different between the two interventions (Pinteraction < 0.01). During 
the 3-week abstention period, the slope for HMW was -0.27 ± 0.09 μg/mL (P < 0.01) and 
for total adiponectin levels -0.54 ± 0.13 μg/mL (P < 0.001) whereas the slopes of the two 
adiponectin forms during the alcohol period did not differ from zero. Changes over the 
weeks in total adiponectin were positively associated with changes in HMW adiponectin 
during the nonalcoholic beer (r = 0.80; 95% CI: 0.55, 0.92) and beer (r = 0.82; 95% CI: 
0.58, 0.93) intervention. Changes over time in the two adiponectin forms were not 
associated with changes in serum glucose, insulin, triglycerides and free fatty acids. 
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Figure 6.1. Mean ± SEM weekly plasma concentrations of total adiponectin and high-molecular 
weight adiponectin during a 3-week intervention with daily beer (●) or alcohol-free beer consumption 
(○) each preceded by a 1-week washout among twenty-four normal-weight premenopausal women. 
* P < 0.05 between beer and alcohol-free beer consumption at time-point during the intervention. 
 
 
Discussion 
The present study showed that among young, normal-weight women moderate alcohol 
consumption, consumed daily with dinner, increased both HMW and total adiponectin 
concentrations compared with abstention. These increases were evident after at least three 
weeks of consumption. Furthermore, the changes over time in HMW and total adiponectin 
levels during each treatment were correlated, which suggest that these changes occurred 
concomitantly. No changes were observed in markers of glycemia or lipid metabolism in 
these women. 
A trial by Imhof and colleagues (14) investigated the effects on total adiponectin 
levels after three weeks of daily alcohol consumption among women (20 g alcohol/day) and 
men (30 g/day). They reported increased adiponectin levels after red wine but not after beer 
consumption in women and higher levels after beer and ethanol but not after red wine 
consumption in men. The authors hypothesized that drinking preferences of participants 
might substantially have affected the findings by incomplete adherence to the study 
protocol as women preferred to drink wine whereas men preferred to drink beer. Other 
experimental studies have consistently reported similar robust increases in circulating total 
adiponectin levels in young (17) and middle-aged men (15;16) and postmenopausal women 
(4), irrespective of beverage type. Moreover, we have previously reported that alcohol 
intervention-associated changes in mRNA levels of the gene encoding for adiponectin in 
adipose tissue correlated with changes in plasma protein levels of total adiponectin (4). This 
implies that the alcohol-induced increase in plasma adiponectin levels might be mediated 
by de novo synthesis providing further support that the alcohol itself is responsible for 
increases in circulating adiponectin levels rather than an alcoholic beverage-specific 
constituent. 
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The data revealed that the difference in adiponectin levels between the two 
treatments are mainly due to a decrease in adiponectin levels during abstention rather than 
an increase during alcohol consumption. This, and the fairly similar mean HDL-cholesterol 
levels prior to the interventions compared to after the alcohol intervention, might confirm 
that the women were indeed habitual drinkers (which was an inclusion criterion for the 
present study). Furthermore, the ratio of HMW to total adiponectin over the weeks did not 
differ between treatments. This, also reflected by the high correlations between changes in 
HMW and total adiponectin, points out that the intervention-induced changes in HMW and 
total adiponectin levels occur concurrently. Despite different physiological mechanisms, the 
observed adiponectin-kinetics resemble in part the alcohol-induced increase in 
apolipoprotein A-I and HDL-cholesterol, although in these cases higher levels were already 
seen after 5 and 10 days of alcohol consumption, respectively, compared with abstention 
(26). 
In line with previous clinical trials with other groups of young and relatively 
healthy subjects, we did not observe changes in markers of insulin sensitivity (27;28) or 
triglycerides levels (29) after moderate alcohol consumption. Studies that did find an effect 
on insulin levels after alcohol consumption were performed in middle-aged, relatively less 
insulin-sensitive (3;30) or diabetic subjects (31-33) and lasted between four weeks to up to 
a year. This suggests that the effect of moderate alcohol intake on markers of glycemia 
occurs after a longer period of alcohol administration and/or in subjects with (slightly) 
impaired glucose tolerance rather than in young and insulin sensitive subjects.  
Strong points of the study are its randomized crossover design, the high 
compliance to the treatments throughout the study and the measurement of HMW and total 
adiponectin with a more sensitive and precise method (Enzyme-linked immunosorbent 
assay (ELISA)) instead of quantitative western blotting (17) and within the same ELISA 
(4). Some limitations warrant consideration. The study duration of three weeks of alcohol 
consumption was relatively short. May be more profound differences would have appeared 
in adiponectin levels or markers of glycemia if the study persisted longer. Secondly, the 
women investigated were relatively young and healthy and thus at low risk for type 2 
diabetes. However, studies have shown that the association between moderate alcohol 
consumption and a lower risk of type 2 diabetes also holds in younger women (34) and 
among subjects already at low risk for diabetes on the basis of multiple combined low-risk 
lifestyle behaviors (30). 
In conclusion, daily moderate alcohol consumption for at least three weeks 
concomitantly increased total and HMW adiponectin compared with abstention in 
premenopausal women. Increased circulating adiponectin levels may contribute to a 
reduced risk for type 2 diabetes in moderate drinkers, not only in postmenopausal women 
and young and middle-aged men but also among normal-weight, premenopausal women. 
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Background: Circulating high-density lipoprotein (HDL)-cholesterol and its associated 
surface lipids apolipoprotein A-I (apoA-I) and phospholipids have been shown to play an 
important role in the detoxification of lipopolysaccharides (LPS). Moderate alcohol 
consumption increases HDL-cholesterol, apoA-I and phospholipids.  
 
Objective: to the study was to investigate whether the alcohol-induced increase in 
lipoproteins attenuates the inflammatory response after a low-dose in vivo endotoxin 
challenge.  
 
Design: In a randomized, crossover trial, 22 men (age: 21-31 y) consumed vodka (30 g/day 
alcohol) with orange juice or orange juice for four weeks. After each four-week period, 
subjects were intravenously challenged with a low-dose endotoxin (0.06 ng/kg body 
weight) bolus. Blood was sampled before and for six hours after the LPS bolus.  
 
Results: Four weeks of vodka consumption increased HDL-cholesterol (10.3%; P < 0.001), 
apoA-I (11.9%; P < 0.001), apolipoprotein C-I (7.4%; P < 0.001) and phospholipids (7.8%; 
P < 0.001) compared with juice consumption. Inflammatory cytokine and leukocyte 
responses after the LPS bolus did not differ between treatments. However, tolerance to 
endotoxin was observed in leukocyte (P < 0.05) and TNF-α responses (P < 0.01) during the 
second challenge with LPS.  
 
Conclusions: Despite improved lipoprotein profiles, alcohol consumption did not attenuate 
the inflammatory response after a low dose in vivo endotoxin challenge. 
 
Trial registration: Clinicaltrials.gov ID no.: NCT 00918918 
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Introduction 
In addition to the well-recognized function of lipoproteins in cholesterol and lipid transport, 
a large body of evidence has demonstrated that lipoproteins also play an important role in 
the host defense system (1). Lipopolysaccharide (LPS) (also called endotoxin), a 
component of the gram-negative bacterial cell wall, is among the most potent modulators of 
the host’s innate immune system. Although all lipoproteins have been demonstrated to bind 
LPS, it mainly binds to high-density lipoprotein (HDL)-cholesterol (60%) in addition to 
low-density lipoprotein (LDL)-cholesterol (25%) and very low-density lipoprotein 
(VLDL)-cholesterol (12%) when added to whole human normal blood (2;3). Increasing 
circulating HDL-cholesterol levels has shown to attenuate the inflammatory effect of 
endotoxin both in men (4) and mice (5). Conversely, lowering lipoprotein levels rendered 
animals more susceptible to LPS-induced lethality (6). Studies in both animals and humans 
suggest that, not HDL-cholesterol itself, but the associated surface apolipoprotein A-I 
(apoA-I) (7-9) and the phospholipids (2;5;10) are largely responsible for the protective 
effect against endotoxin-evoked infection. Moreover, increasing phospholipid content of 
circulating lipoproteins has been shown to decrease the adverse effects of endotoxin in 
rabbits (11) and mortality in pigs (12). 
Moderate alcohol consumption is well-known for its HDL-raising properties, 
(13;14) which may account for 50% of the protective effect observed in the relation 
between alcohol consumption and cardiovascular disease (15;16). Besides the increase in 
HDL-cholesterol, alcohol consumption also increases its associated surface lipids apoA-I, 
and phospholipids independent of type of beverage (17). Theoretically, this alcohol-induced 
increase in lipoproteins could increase the scavenging capacity of endotoxin, thereby 
minimizing the amount of endotoxin available to elicit inflammatory activation. 
The injection of a dose of endotoxin into humans has been used for decades as a 
model to study the interrelationships between infection and the host response (18-20). 
Using this well-established model of endotoxemia in apparently healthy volunteers, we 
compared the impact of the alcohol-induced increase in HDL-cholesterol and its associated 
surface lipids on the sensitivity toward a low-dose in vivo endotoxin challenge in men. 
 
 
Materials and Methods 
Study design 
The study used a randomized, open label, crossover design, consisting of two four-week 
periods. Subjects consumed two miniatures (50 ml each) of vodka (Smirnoff, U.K.) (30 
g/day alcohol; ~2 drinks according to the U.S. Department of Agriculture (USDA) 
guidelines (21)) with 200 ml orange juice (Appelsientje, the Netherlands) or only orange 
juice for four weeks during dinner. The study was conducted at TNO (a Dutch acronym for 
applied scientific research) Quality of Life, in Zeist, the Netherlands. The study was 
approved by an independent centralized ethics committee (METOPP; Tilburg, the 
Netherlands) and is registered at Clinicaltrials.gov, number NCT 00918918. Allocation to 
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treatment order was randomized according to BMI and age. Blood sampling was done on 
the morning after four weeks of each treatment period, after an overnight fast.  
Compliance was monitored by weekly measurement of urinary ethyl glucuronide 
(EtG), a direct phase II metabolite of ethanol formed by action of UDP- glucuronosyl 
transferase. EtG has been reported to be a superior marker with 100% sensitivity as a 
biomarker of recent drinking. It persists in the urine up to ~75 - 85 h after last intake (22). 
Cut-off limit to assess compliance during juice intervention for urinary EtG values was set 
at >0.25 mg/mL (positive sample), to obtain a high sensitivity but avoid positive results due 
to unintentional ethanol exposure. Cut-off limit during vodka intervention was set at EtG 
values <0.5 mg/mL (2.2 μmol/L) (negative sample). Additional measures of compliance 
were the increase of HDL-cholesterol and the return of empty bottles of vodka. 
 
Subjects 
We recruited 24 apparently healthy, non smoking male subjects between 21 and 40 years. 
Subjects were eligible if they consumed between 5 and 28 units of alcohol per week, were 
free of any medication at the beginning of the study, and had a BMI between 18 and 27 
kg/m2 and had no family history of alcoholism. Subjects gave written informed consent and 
received a compensation for their participation. They were instructed to maintain their 
habitual body weight, food pattern and physical activity pattern and were told to refrain 
from any alcoholic products during the entire study except the vodka supplied by TNO. 
 
Experimental protocol 
On the morning after each intervention, after an overnight fast, study participants came to 
the premises. Blood pressure and heart rate were measured by means of OMRON HEM-
7080IT-E (Kyoto, Japan). A catheter was inserted in an antecubital vein. At t = 0, blood 
was drawn for baseline measurements. Subsequently, subjects received a bolus infusion of 
0.06 ng/kg body weight of endotoxin (Escherichia coli lipopolysaccharide, Catalog 
Number: 1235503, lot G3E069; United States Pharmacopeial Convention Inc, Rockville, 
MD, U.S.A.) in the antecubital vein. Heart rate and blood pressure were recorded and blood 
samples were collected at t = 0, 1, 2, 3, 4, 5 and 6 hours after endotoxin challenge.  
 
Blood and urine analysis 
Blood samples were obtained from the anticubital vein of the forearm and collected in tubes 
containing clot activator for serum and in ice-chilled tubes containing or Potassium 
Ethylene Diamine Tetra Acid (K3EDTA) or lithium heparin for plasma and whole blood 
(Vacutainer Systems, Becton Dickinson, Plymouth, U.K.). Blood was centrifuged for 15 
minutes at 2.000 g at 4°C, within 15 - 30 minutes after collection and stored at <-70°C.  
Clinical chemistry, high sensitive C-reactive protein (hsCRP), phospholipids and 
total leukocytes were analyzed by ADVIA 120/2120 Hematology system (Bayer 
Diagnostics, U.S.A.). Apolipoproteins in serum were analyzed by bead-based multiplexed 
immunoassay at the biomarker testing laboratory Rules Based Medicine (RBM; Austin, 
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Texas, U.S.A.). Tumor Necrosis Factor alpha (TNF-α) was measured by Ultra-Sensitive 
ELISA (Invitrogen, Paisley, U.K.) and Interleukin (IL)-6 by Luminex using Bio-plex Pro-
Assays (Bio-Rad Laboratories, Hercules, CA, U.S.A.), both in plasma according to the 
manufacturers' specifications. Plasma total adiponectin and lipoprotein binding protein 
(LBP) were measured using MesoScale Diagnostics assays (Cat# K151IYC-1 and 
K151BXC-1) (Meso Scale Discovery; Gaithersburg, MD, U.S.A.) and plasma soluble 
CD14 (sCD14) was measured by means of an immuno-enzymometric (Cat# DC140) (R&D 
systems; Abingdon, U.K.). EtG was determined was analyzed using a triple quadrupole 
Ultra Performance LC/MS in MRM mode (Waters, Saint-Quentin en Yvelines, France) as 
previously described (23).  
 
Statistical analyses  
Statistical analyses were performed using the SAS statistical software package (SAS 
versions 8.2 and 9.1, SAS Institute, Cary, NC, U.S.A.). Variables at the end of the 
intervention were compared between treatments with a mixed analysis of variance model 
that included terms for treatment, period and the interaction between period and treatment 
(indicating possible carryover effects). The inflammatory responses over time between 
treatments were compared with a mixed analysis of variance model that included terms for 
treatment, time, period the interaction between time and treatment and the interaction 
between period and treatment. Correlation coefficients were computed according to 
Pearson’s correlation coefficient or Spearman rank order (for non-normally distributed 
variables) to assess associations in intervention-induced relative changes between 
lipoproteins and apolipoproteins and to asses associations between lipoproteins and 
endotoxin-induced peak response of inflammatory markers. Data are presented as means 
and SEM unless otherwise specified. Statistical significance was defined as P < 0.05. 
 
 
Results 
Intervention 
Two of the 24 subjects underwent just one LPS challenge and were excluded for further 
analyses. Mean age and BMI of the 22 men were 25.0 y (range: 21 - 31 y) and 23.3 kg/m2 
(range: 19.1 - 27.2 kg/m2). Compliance to treatments was assessed by weekly urinary EtG 
levels revealing eight positive samples during the juice-drinking period (although all <0.5 
mg/mL) and five negative samples during the vodka-drinking period out of the 176 samples 
analyzed (overall compliance of 93%).  
No carryover effects were observed for any outcome measures. HDL-cholesterol 
significantly increased by 10.3% (P < 0.001) after the vodka juice compared to juice 
consumption. Also, apoA-I (11.6%; P < 0.001), apolipoprotein C-I (apoC-I) (7.4%; P < 
0.001), phospholipids (7.8%; P < 0.001) and total adiponectin (11.3%; P < 0.001) increased 
significantly after the vodka juice intervention. Baseline levels of other markers after each 
four-week period did not differ between treatments (Table 7.1). 
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Table 7.1: Lipoprotein profile, inflammatory markers, and clinical chemistry at the end of a 
4-week intervention period of daily orange juice or vodka (30 g alcohol) with orange juice 
in 22 young, normal-weight men after an overnight fast. 
Values shown are mean ± SEM or median [inter quartile range].  
Apo, apolipoprotein;  
1 Mixed ANOVA model on baseline values that included terms for treatment, period and the interaction between 
period and treatment (to assess carryover effects). 
 
 
Endotoxin challenge 
Endotoxin infusion did not cause any notable adverse events among the subjects. Heart rate 
and diastolic blood pressure decreased after endotoxin infusion. Heart rate dropped on 
average from 67 ± 2 beats/min at baseline to 58 ± 2 beats/min at 2 hours whereas diastolic 
blood pressure dropped from 73 ± 2 mmHg at baseline to 70 ± 2 mmHg at 4 hours (both P 
 Orange juice Vodka and 
orange juice 
P value1 
Lipoprotein profile    
HDL-cholesterol (mmol/L) 1.08 ± 0.04 1.18 ± 0.04 < 0.001 
Phospholipids (mmol/L) 2.29 ± 0.07 2.46 ± 0.07 < 0.001 
ApoA-I (mg/mL) 0.21 ± 0.01 0.24 ± 0.01 < 0.001 
ApoC-I (ng/mL) 233 ± 7.8 249 ± 7.8 < 0.001 
LDL-cholesterol (mmol/L)  2.57 ± 0.16 2.61 ± 0.12 0.60 
ApoB (mg/mL) 1.08 ± 0.06 1.10 ± 0.06 0.56 
ApoE (μg/mL) 35.2 ± 2.4 36.7 ± 2.4 0.32 
    
Inflammatory markers    
Total adiponectin (μg/mL) 10.6 ± 1.0 11.8 ± 1.0 < 0.001 
TNF-α (pg/mL) 0.93 ± 0.11 0.77 ± 0.11 0.11 
IL-6 (pg/mL) 1.24 ± 0.12 1.26 ± 0.12 0.85 
hsCRP (mg/L) 0.40 [0.33-1.36] 0.49 [0.24-1.46] 0.50 
Total leukocyte count (106/mL) 5.8 ± 0.3 6.0 ± 0.3 0.33 
LPS binding protein (μg/mL) 5.3 ± 0.4 5.0 ± 0.4 0.33 
Soluble CD14 (μg/mL) 1.23 ± 0.04 1.29 ± 0.04 0.20 
    
Clinical chemistry    
Glucose (mmol/L) 5.30 ± 0.09 5.27 ± 0.09 0.57 
Insulin (pmol/L) 60.0 ± 6.9 53.4 ± 6.9 0.33 
Triglycerides (mmol/L) 1.19 ± 0.15 1.28 ± 0.15 0.28 
Free fatty acids (mmol/L) 0.41 ± 0.03 0.35 ± 0.03 0.13 
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< 0.05 for time main-effect). Systolic blood pressure did not change over time but was on 
average slightly increased after the vodka intervention compared with the juice intervention 
(117 ± 1 vs. 115 ± 1 mmHg; P < 0.05). 
When challenged with endotoxin, total leukocyte count and percentage of 
neutrophils increased significantly (P < 0.001) and reached its peak at four 4 after bolus 
infusion (Figure 7.1). In addition, percentage lymphocytes significantly decreased (P < 
0.001) after endotoxin infusion to a nadir at 4 hours. The response in circulating total 
leukocytes or percentages of lymphocytes or neutrophils did not differ between treatments 
(All P > 0.45). However, we observed attenuated total cytokine count (P < 0.05) and 
percentages of lymphocytes and neutrophils (both P < 0.001) responses on the second visit 
after the LPS challenge (Figure 7.1). 
The effects on endotoxin infusion on TNF-α and IL-6 levels are shown in Figure 
7.2. Both cytokines significantly increased over time (P < 0.001) and reached their peak 
approximately three hours after administration of the LPS bolus. TNF-α (P = 0.52) and IL-
6 (P = 0.24) levels did not differ between treatments. In line with the leukocytes, TNF-α 
response (P < 0.01) was significantly lower during the second time of LPS administration 
(Figure 7.2). IL-6 response also tended to be lower after the second time, although not 
significantly (P = 0.16). 
 
Correlations 
Independent of treatment, serum HDL-cholesterol was tightly correlated with serum apoA-I 
levels whereas serum LDL-cholesterol was highly associated with serum apoB after each 
treatment (All r > 0.82; P < 0.0001). Also intervention-induced percent changes in apoA-I 
and HDL (ρ = 0.43; P < 0.05) and apoB and LDL-cholesterol (ρ = 0.75; P < 0.001) levels 
where significantly correlated. The relative changes in HDL-cholesterol were also 
significantly correlated with changes in phospholipids (ρ = 0.58; P < 0.01) and borderline 
significant with changes in apoC-I (ρ = 0.40; P = 0.07) but inversely correlated with 
changes in apolipoprotein E (apoE) (ρ = -0.43; P < 0.05).  
Due to the significant period effect, correlations between HDL-cholesterol and 
endotoxin-induced peak levels in inflammatory markers were investigated after the first 
period only. No correlations were observed between HDL-cholesterol (or associated 
apolipoproteins) and peak levels of TNF-α at three hours or with IL-6 or total leukocyte 
count at 4 hours after the LPS bolus at the first challenge.  
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Figure 7.1: Effect of low-dose in vivo endotoxin challenge on cytokine response after a 4-week 
intervention of vodka and orange juice (●) or orange juice only (○) and after the first 4-week 
intervention (□) or the second 4-week intervention (■) in 22 men. Data are expressed as mean ± SEM. 
Responses of total leukocytes count (P < 0.05) and percentages of lymphocytes and neutrophils (both 
P < 0.001) were significantly lower during the second period after LPS administration (right panels). 
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Figure 7.2: Effect of low-dose in vivo endotoxin challenge on leukocyte response after a 4-week 
intervention of vodka and orange juice (●) or orange juice only (○) and after the first 4-week 
intervention (□) or the second 4-week intervention (■) in 22 men. Data are expressed as mean ± SEM. 
TNF-α response was significantly lower (P < 0.01) during the second period after LPS administration 
(upper right panel). 
 
 
Discussion 
After 4 weeks of moderate vodka and juice consumption, HDL-cholesterol, apoA-I, apoC-I, 
phospholipids and total adiponectin levels were increased whereas LDL-cholesterol, apoB, 
apoE and several inflammatory markers remained unchanged compared with juice among 
young, normal-weight men. However, we observed no effect of alcohol consumption on the 
LPS-induced responses in leukocyte subpopulations or cytokines. 
The observations of increased HDL-cholesterol and apoA-I but unaffected LDL, 
apoB and apoE levels by alcohol consumption are consistent with previous findings in 132 
healthy men (24). Previous studies by our group showed similar increases of ~11% in 
HDL-cholesterol and apoA-I in young men (25) and middle-aged men (14;26) and women 
(27) after alcohol consumption. Moreover, we noted strong correlations between HDL-
cholesterol and apoA-I and between LDL-cholesterol and apoB. Even intervention-induced 
changes in HDL-cholesterol and apoA-I (26) and LDL-cholesterol and apoB were 
significantly associated. These findings are in line with a recent meta-analysis among more 
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than 300,000 people which showed that HDL-cholesterol and apoA-I had very similar 
shape and magnitude of associations with risk of vascular diseases, as did LDL-cholesterol 
and apoB (28).  
Besides increased HDL-cholesterol and apoA-I, we also found increased levels of 
apoC-I and total adiponectin. Similar to apoA-I and phospholipids, several human studies 
suggest that apoC-I can function as part of the innate host defense mechanism against 
infection. In old age high plasma levels of apoC-I protect against mortality from infection 
independent of HDL-cholesterol (29). Moreover, apoC-I levels are also correlated with 
increased survival in patients with severe sepsis (30). In concord with previous findings 
(23;31;32), we also found higher adiponectin levels after regular moderate alcohol 
consumption compared with abstention. Adiponectin levels are inversely associated with 
markers of inflammation (33;34). Moreover, it has been shown that adiponectin exerts anti-
inflammatory effects via macrophages, suppressing the production of pro-inflammatory 
cytokines in response to LPS (35). 
Despite the increases in HDL-cholesterol and several associated surface markers 
important for LPS detoxification, the inflammatory response after the LPS bolus did not 
differ between treatments. Possibly, a potential anti-inflammatory effect could have 
counteracted by a pro-inflammatory effect after moderate alcohol consumption. 
Concentrations of increased lipopolysaccharide-binding protein (LBP), soluble CD14 
(sCD14) and endotoxin levels (36), suggestive of increased permeability or ‘leaky gut’ 
(37), and a decreased endotoxin-binding capacity of whole blood (38) have been reported in 
persons with chronic alcohol misuse. Both LBP and CD14 play a role in the response to 
gram negative compounds depending on their concentration and environment (39;40). For 
example, they transfer LPS to the signaling receptor complex MD-2/Toll-like receptor 4 
(TLR4) on macrophages. However, plasma LBP or sCD14 levels were unaffected by 
moderate alcohol consumption. Also, in observational research moderate amounts of 
alcohol, comparable as used in our study, were not associated with endotoxemia in 
apparently healthy men (41).  
Alternatively, the unaltered response after LPS administration between treatments 
might be due to tolerance to the endotoxin. Peak and averaged values of total leukocyte and 
cytokine responses were lower the second administration compared to the first 
administration. These are strong indications for tolerance. Although tolerance to LPS has 
been described before in humans  after days (42;43) or 2 weeks (44), it has never been 
described as late as 4 weeks after a previous challenge. This tolerance could have obscured 
potential treatment effects due to the randomized crossover design of our study. We 
compared treatments taking into account results after the first LPS administration period 
only. This did not materially change our findings (data not shown). However, our study was 
not designed for such a comparison and was therefore highly underpowered. 
Regardless of possible increased anti-inflammatory properties of HDL-cholesterol 
and its associated surface lipids, a functional consequence of the alcohol-induced elevation 
in HDL is an increased cholesterol efflux. The improved cholesterol efflux is mediated by 
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stimulating early steps in reverse cholesterol transport (17) and by ATP-binding cassette 
transporter protein A1 (ABCA1) (26). Furthermore, increased paraoxonase (PON) activity 
has been observed after moderate alcohol consumption (14;27). PON, an enzyme entirely 
complexed to HDL-cholesterol, may protect against atherosclerosis by its anti-oxidative 
properties (45).  
Experimental endotoxemia can provide unique insights into the relationship of 
inflammation and metabolic disturbances (20;46). Nevertheless, several limitations of this 
model warrant consideration. Based on previous research that showed HDL-mediated 
decreases in inflammatory responses in humans (4;7;10), we chose LPS as an inductor of 
inflammation. It should be noted that endotoxin is just one of many ways to activate the 
immune system. Second, the dose of endotoxin might have been too low to pick up 
differences in HDL-cholesterol’s anti-inflammatory potential, compared with previous 
research where they used 1-4 ng/kg body weight (4;7;19;46). Fourth, structural differences 
in LPS derived from different strains exist. However, both the dose (0.06 ng/kg 
bodyweight) and strain of LPS have been used before (44;47) and give physiological 
relevant rather than supra physiological elevations of TNF-α. With this model we 
succeeded to mimic a more naturally occurring endotoxemia, as seen in humans e.g. after a 
high fat meal (48). Finally, we induced a more acute rather than chronic low-grade 
inflammation. Especially the latter has been proposed to be associated with several diseases 
states. Therefore, low-dose endotoxin administration for a longer period might more closely 
mimic this low-grade inflammatory state. 
To summarize, moderate alcohol consumption (approximately two to three drinks 
a day) for four weeks increases serum HDL-cholesterol, apoA-I, apoC-I and phospholipids, 
which all have been linked to play important roles in the detoxification of LPS. This 
improvement of lipoprotein profile did not attenuate the inflammatory response after a low 
dose of LPS bolus, possibly due to tolerance to the endotoxin. Whether the increase in 
HDL-cholesterol and its associated surface lipids after moderate alcohol consumption has 
potent anti-inflammatory properties in vivo warrants further clarification. 
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Background: Preingestive or cephalic phase responses, triggered by sensory stimulation of 
nutrients, influence the organism’s digestive and endocrine responses and substrate 
mobilization. Whether oral sensory stimulation with alcohol elicits cephalic phase 
responses is uncertain. 
 
Objective: To determine whether oral alcohol exposure, in the form of white wine, 
provokes cephalic phase responses in normal-weight and overweight subjects. 
 
Design: In a semi-randomized, crossover trial, eleven normal-weight (BMI 19-25 kg/m2) 
and eleven overweight (BMI 27-35 kg/m2) postmenopausal women sham-fed, after an 
overnight fast under three separate conditions four weeks apart, 41 g cake (750 kJ), 25 cL 
white wine (750 kJ; ~26 g alcohol) and 25 cL water. Blood was drawn prior to and for 30 
min after two 3-minute episodes of modified sham feeding (MSF). Blood samples were 
analyzed for free fatty acid (FFA), triglyceride, glucose, pancreatic polypeptide (PP), 
insulin and alcohol concentrations. 
 
Results: Incremental area under the curves (IAUC) of FFA concentrations differed 
significantly (P < 0.001) between the three treatments but not between BMI categories (P = 
0.11). After MSF with white wine, FFA concentrations dropped to a minimum of 77 ± 3% 
of baseline concentrations at t = 12 ± 2 min after baseline and returned to baseline after ~30 
min, whereas after MSF with cake and water FFA concentrations gradually increased. 
IAUC of triglycerides, glucose, PP and insulin concentrations did not differ between the 
three treatments (All P > 0.05). 
 
Conclusions: Short-term oral white wine exposure substantially and temporarily decreases 
FFA concentrations suggesting a cephalic phase response of alcohol. This effect occurred 
regardless of BMI. 
 
Trial registration: Clinicaltrials.gov ID no.: NCT00652405. 
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Introduction 
The digestion of food is generally being divided into the cephalic, gastric, and intestinal 
phases. Cephalic phase responses are physiologic changes in response to food cues such as 
thought, smell, sight and taste of palatable food. These preingestive responses are rapid 
(occurring within minutes after stimulation), transient (returning to near baseline within 
minutes) and relatively small compared to the magnitude achieved when food is actually 
being ingested (1). The main function of the cephalic phase may be essentially adaptive, 
preparing the digestive system for the reception, digestion and absorption of the nutrients 
from food (2). 
The primary metabolic changes occurring during this phase are gallbladder 
contraction (3), gastric acid production (4), and stimulation of both the exocrine and 
endocrine pancreas (5). Its physiological relevance in response to meal ingestion becomes 
apparent when blocking (6) or bypassing (7) the cephalic phase, which has detrimental 
effects on postprandial glycemia and insulinemia. Moreover, modified sham feeding 
(MSF), a method to provoke cephalic phase responses, with fatty foods alters mobilization 
of free fatty acids (FFA), triglycerides and glucose in the postprandial state (8-12). These 
effects are absent when sham feeding with water (9;11).  
Cephalic phase responses are thought to be mediated by the efferent component of 
the vagus nerve, which in turn induces changes in substrate utilization. Vagal stimulation 
can be measured indirectly by pancreatic polypeptide (PP) release after MSF (13). Sham 
feeding with foods rich in protein and fat and carbohydrates (13;14) indeed exert cephalic 
phase PP responses. Furthermore, oral fat (9;11;12) and carbohydrate exposure (15) have 
been shown to induce a cephalic phase insulin release. 
Whether and to what extent tasting alcohol affects cephalic phase responses 
remains unclear. Since the cephalic phase plays a role in provoking physiological changes 
pivotal for food digestion, appetitive sensations (11;12) and food intake (14) it is important 
to know whether alcohol could exert a cephalic phase response (CPR). With this study we 
therefore wanted to investigate the effects on substrate mobilization and hormone release 
after oral white wine exposure. 
 
 
Methods 
The study used a semi-randomized, open-label, crossover design. It was part of an 
intervention in which subjects daily consumed white wine (~70 kcal/100 mL, ~26 g 
alcohol; Droë Steen; South Africa), followed by mineral water (Vittel, France) or vice 
versa. Subjects consumed these study substances for four weeks during dinner. Allocation 
to treatment order was randomized according to BMI category. The study was conducted at 
TNO (a Dutch acronym for applied scientific research) Quality of Life, in Zeist, the 
Netherlands. This study was conducted according to the guidelines laid down in the 
Declaration of Helsinki and all procedures involving human subjects were approved by an 
independent centralized ethics committee (METOPP; Tilburg, the Netherlands). Written 
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informed consent was obtained from all subjects. This trial is registered at clinicaltrail.gov 
as NCT00652405. 
 
Subjects 
We recruited 24 nonsmoking women from a pool of volunteers of TNO Quality of Life. We 
chose postmenopausal women to prevent possible effects of the menstrual cycle on CPR. 
Eligible subjects were apparently healthy, free of any medication use, had an absence of 
menses for at least 2 years, a BMI between 19 and 25 for normal-weight or 27 and 35 kg/m2 
for overweight subjects and no family history of alcoholism. The overweight group had a 
BMI of 27 and higher to increase the potential contrast between the two BMI groups. BMI 
groups were matched for age and restraint eating score on the Dutch Eating Behavior 
Questionnaire (16) as differences may exit in cephalic phase response between restraint and 
unrestraint eaters (17). 
 
Experimental protocol 
Each subject was subjected to three experimental conditions 4 weeks apart from each other. 
The conditions were administered in a semi-counterbalanced order after a 10 h overnight 
fast: (a) sham-feeding cake (positive control), (b) sham-feeding 25 cL of water (negative 
control) and (c) sham-feeding 25 cL of white wine (13% vol). For logistic reasons the cake 
condition was always first. The order of sham feeding water or wine was the same as the 
treatment order of the intervention. All three stimuli were served at room temperature 
(isothermic). The energy content of the 41 g cake (Albert Heijn, The Netherlands; 5% 
protein, 41% carbohydrates and 54% fat) equaled the energy content of the 25 cL of white 
wine (~100% alcohol). High fat cake was chosen as it has been demonstrated to elicit a 
cephalic phase PP release (14). 
Each test morning, an indwelling cannula was placed in the forearm for venous 
blood draws. During the experimental days subjects took, at t = 0 min (baseline), a bite or 
sip of the food, oral processed it without swallowing for as long as the stimulus felt 
comfortable in their mouth, and then expectorated the stimulus. Subjects repeated this 
procedure for a 3-min period in which half of the stimulus portion size was sham-fed. In a 
second 3-min period, from t = 4 min onwards, the other half of the stimulus was sham-fed. 
Taken together, a 6 min-stimulation period with a one min break for blood sampling was 
given. After each 3-min sham feed period, subjects were allowed to rinse their mouth once 
with water. Stimuli were weighed (Mettler Toledo, Switzerland) before and after sham 
feeding to check whether subjects had accidentally swallowed parts of the sham feed 
stimuli. Blood sampling for FFA, triglycerides glucose, PP and insulin took place at t = 0, 
4, 8, 12, 16, 20 and 30 min. At t = 8 min additional blood and saliva were sampled to 
determine alcohol concentrations. Unstimulated saliva (to avoid possible CPR due to 
chewing) was collected for four minutes after t = 8 min. 
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Blood and saliva sample analysis 
Blood samples were obtained from the anticubital vein of the forearm and collected in tubes 
containing clot activator for serum and in ice-chilled tubes containing or Potassium 
Ethylene Diamine Tetra Acid (K3EDTA) for plasma (Vacutainer Systems, Becton 
Dickinson, Plymouth, U.K.). Blood was centrifuged for 15 minutes at 2.000 g at 4°C, 
within 15 - 30 minutes after collection and stored at -80 °C. FFA, triglyceride, glucose and 
insulin determinations in serum were performed using Olympus analytical equipment and 
reagents. PP determinations in serum were performed using radioimmunoassay by using a 
commercially available kit (Euro-diagnostica, Sweden) with a detection limit of 3.1 pmol/L 
and intra-assay and inter-assay coefficient variations of 3.5% and 2.6% respectively. 
Alcohol concentrations in plasma and saliva were determined by headspace gas 
chromatography (18). The detection limit of the alcohol concentration in blood and saliva 
was 0.1 mmol/L. Concentrations below the detection limit were set at half the detection 
limit. 
 
Statistical analyses 
The rationale for the sample size was based on a previous study in women with a very 
similar experimental design to elicit a cephalic phase PP release (14). Cumulative changes 
in serum FFA, triglycerides, glucose, PP, and insulin responses were quantified as the 
incremental (delta from baseline) area under the 30 min time-concentration curve using the 
trapezoidal rule. Baseline values and incremental area under the curves (IAUCs) of each 
metabolite/hormone and alcohol concentrations were compared with a mixed analysis of 
variance (ANOVA) model that included terms for treatment, BMI category and their 
interaction. If a significant treatment effect occurred, a post hoc Tukey test was used and 
for IAUCs summary statistics such as time to peak / nadir (and percentage difference from 
each subject’s own baseline value (to compensate for baseline differences between normal-
weight and overweight subjects) were computed. In case of a significant treatment effect, a 
responder was defined as having an increase or decrease of >14% from baseline serum 
concentration at two consecutive time points within 16 min after initiation of MSF. We 
used SAS statistical software package (SAS version 8, SAS Institute, Cary, NC, U.S.A.) to 
perform the statistical analyses. P values < 0.05 were considered statistical significant. 
Results are presented as mean (± SEM) unless otherwise specified. 
 
 
Results 
One normal-weight subject dropped out due to study-unrelated reasons, one overweight 
subject was left out of the analysis as she had swallowed parts of the sham feed stimuli on 
all three occasions. Overweight subjects had a significant higher BMI (mean ± standard 
deviation: 29.8 ± 2.6 vs. 22.8 ± 1.4 kg/m2; P < 0.0001) but did not differ in age (55.6 ± 3.0 
vs. 56.0 ± 2.7 y; P = 0.82) or restraint eating score (2.7 ± 0.7 vs. 2.7 ± 0.7; P = 0.90) 
compared with normal-weight subjects respectively. 
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At baseline (t = 0 min) there were no differences in values of metabolites and hormones 
between the three treatments (Table 8.1). Overweight subjects had higher levels of FFA, 
glucose and insulin compared with normal-weight subjects at baseline (All P < 0.05). 
 
Expectorated stimuli weights and alcohol concentrations 
Stimuli weights after MSF increased by a mean of 13.9 ± 1.3 g after sham feeding cake, 
15.8 ± 1.9 g after sham feeding white wine and 0.2 ± 1.3 g after sham feeding water due to 
the added weight of the saliva. 
At t = 8 min, mean saliva (SAC) and blood alcohol concentrations (BAC) differed 
significantly between treatments (both P < 0.0001) but not between BMI categories (both P 
>0.80). SAC and BAC after wine exposure reached a mean of 152 ± 13 mmol/L and of 0.16 
± 0.02 mmol/L (Range: <0.1 - 0.44 mmol/L) respectively whereas no detectable alcohol 
levels were found after cake and water exposure (all <0.1 mmol/L). Three women (one 
normal-weight and two overweight women) had plasma alcohol levels below the detection 
limit (<0.1 mmol/L) at t = 8 min after MSF with white wine. 
 
Metabolites 
Mean serum FFA concentrations dropped after MSF with white wine and returned to near 
baseline values after MSF stopped whereas FFA concentrations after sham feeding cake 
and water resulted in a gradual increase over the 30 min time span (Figure 8.1). IAUC of 
serum FFA concentrations differed significantly (P < 0.001) between the three treatments. 
Post hoc analyses showed that IAUC of FFA after MSF with white wine differed 
significantly from IAUC of water (P < 0.001) and cake (P < 0.001), whereas water and 
cake did not differ (P = 0.79). The nadir of FFA concentrations after MSF white wine 
reached its minimum at t = 12 ± 2 min after baseline (12 ± 2 min for normal-weight and 12 
± 2 min for overweight women). At this time point, mean FFA concentrations dropped to 
77 ± 3% of baseline values (79 ± 5% for normal-weight and 74 ± 4% for overweight 
women). Eighty-two percent (18/22; 9 normal- and nine overweight subjects) of the women 
could be marked as a responder after oral alcohol exposure (based on a drop of >14% in 
basal FFA concentration at two consecutive time points within 16-min after MSF). The 
effect even occurred in two of the three subjects who had no detectable blood alcohol 
concentrations at t = 8 min. Only 5% (1/22) and 0% (0/22) of the subjects showed such a 
decrease after orosensory stimulation with water and cake respectively. No main effect for 
BMI category (P = 0.11) or interaction effect for BMI category x treatment (Pinteraction = 
0.35) were observed (Figure 8.1). 
Mean serum triglyceride concentrations after the three MSF treatments remained 
close to fasting concentrations (Figure 1). IAUC of serum triglycerides concentrations did 
not differ between the three treatments (P = 0.66) and BMI categories (P = 0.72). Also no 
interaction effect for BMI category x treatment (Pinteraction = 0.51) was observed. 
Mean serum glucose concentrations after the three MSF treatments remained close 
to fasting concentrations (Figure 8.1). IAUC of serum glucose concentrations did not show 
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a treatment (P = 0.69) or BMI category x treatment effect (Pinteraction = 0.63). However, 
overweight women had lower glucose IAUC after all three MSF treatments compared to 
normal-weight women (P = 0.03). 
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Figure 8.1: Mean (± SEM) serum free fatty acid, triglyceride and glucose response curves in women 
(N = 22) and incremental area under the curve (IAUCs) in normal-weight (N = 11) and overweight (N 
= 11) women after modified sham feeding (MSF) cake, water or white wine for two 3-minute 
episodes.  
* Significantly different from water and cake, P < 0.001 (Mixed ANOVA on IAUCs, followed by a 
post hoc Tukey test). 
Significant main effect for BMI category in glucose IAUCs, P = 0.03 (Mixed ANOVA on IAUCs). 
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Hormones 
Three women (one normal-weight and two overweight women) had PP concentrations 
below the detection limit of the assay throughout all three test conditions. Excluding them 
from the analysis did not essentially change the results. Therefore, unadjusted results are 
presented here. 
Mean serum PP response curves after the three treatments showed increased PP 
concentrations towards the end (at t = 30 min) after all three MSF procedures (Figure 8.2). 
IAUC for serum PP concentrations did not differ between the three MSF treatments (P = 
0.38). Also no BMI category effect (P = 0.51) or BMI category x treatment interaction 
(Pinteraction = 0.71) were observed.  
Mean serum insulin response curves after the three MSF treatments remained 
close to fasting concentrations (Figure 2). IAUC for serum insulin concentrations did not 
show a treatment (P = 0.22), BMI category (P = 0.84) or BMI category x treatment 
interaction effect (Pinteraction = 0.28) (Figure 8.2). 
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Figure 8.2: Mean (± SEM) serum pancreatic polypeptide (PP) and insulin response curves in women 
(N = 22) and incremental area under the curve (IAUCs) in normal-weight (N = 11) and overweight (N 
= 11) women after modified sham feeding (MSF) cake, water or white wine for two 3-minute 
episodes.  
No main or interaction effects, P > 0.05 (Mixed ANOVA on IAUCs). 
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Discussion 
The present study demonstrates that short-term oral exposure to white wine substantially 
and robustly decreases serum FFA concentrations, irrespective of BMI. This effect was 
rapid (occurring within minutes of MSF), transient (returning to baseline after ~20 min 
when MSF stopped) and small (relative to the magnitude achieved when alcohol is actually 
being ingested; 23% reduction compared to 47% reduction (19) in FFA concentrations), 
indicating a cephalic phase response (1). No alterations were observed in other metabolites 
or hormones. 
To further ascertain that the decrease in FFA concentrations was a cephalic effect 
rather than a gastric or intestinal effect, several additional markers were evaluated. The 
weight, albeit crude, before and after mastification was determined, which indicated that 
little or none of the white wine was inadvertently swallowed during MSF. Furthermore, 
alcohol levels in saliva and plasma were measured. Despite a very small increase in mean 
plasma alcohol concentrations they remained ~60 times lower compared to ingestion of a 
similar amount of alcohol (19). Furthermore, triglyceride and glucose concentrations 
remained close to fasting concentrations after MSF with wine (Figure 8.1). It is well-
documented that acute alcohol ingestion not only lowers FFA (19-22) but also strongly 
elevates triglyceride (19;23-25) and lowers glucose concentrations (23;26). We did not 
notice an increase in triglyceride or a decrease in glucose concentrations after MSF with 
alcohol. It thus seems unlikely that the relatively low and clinically irrelevant blood alcohol 
concentration could have evoked this substantial drop in FFAs without affecting 
triglycerides or glucose. 
Despite evidence of a substantial decrease in FFA concentrations after MSF with 
wine, we did not document any changes in vagal activity. This is in line with a recent study 
in which MSF with both sweet and salty solutions did not increase PP (27). The lack of 
significant increases in cephalic phase PP levels in response to liquid stimuli suggests that 
in humans, chewing may be a required stimulus for vagal activation. However, also after 
MSF with cake, a stimulus that needs to be chewed, no significant increase in PP release 
was observed in our study. Prior observations showed that chewing gum, whether 
unflavored or flavored with a non-nutritive sweetener or the sweetener paired with a mint 
flavor, also did not significantly increase PP levels (27). Perhaps the amount of MSF 
stimuli might have been too little (14) and or the duration of MSF might have been too 
short (12;28) for a significant PP release. In three women serum PP concentrations even 
failed to reach the detection limit of the assay throughout all three treatments. This finding 
is in accordance with observations of others where healthy adults also had PP 
concentrations below the detection limit of the assay (29). Furthermore, in another study 
some men and women even lacked PP responses after swallowing a meal (13). We 
observed increased PP concentrations at the end of all three treatments in our study. This 
indicated that PP secreting cells were intact in our subjects and it also provided evidence 
that the analytical method was able to measure changes in PP concentrations. 
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Whatever the mechanism from wine in the oropharyngeal cavity may be, it must 
elicit responses that increase FFA absorption from the bloodstream or decrease FFA supply 
from the adipose tissue to account for the decline in FFA concentrations after oral alcohol 
exposure. Increased storage of FFA is under control of acylation-stimulating protein (ASP). 
This stimulates storage of free fatty acids (FFA) as triglycerides in adipose tissue, but also 
increases glucose uptake (30). Since no changes in glucose were observed after MSF with 
wine, it seems unlikely that increased ASP activity could have explained this finding. A 
decreased supply of FFAs via lipoprotein lipase, out of chylomicron triglycerides is not 
very likely to be the cause, as this action predominantly occurs in the postprandial period 
(31). A plausible mechanism may be due to the altered activity of hormone-sensitive lipase 
(HSL), an enzyme responsible for hydrolysis of stored triacylglycerols in adipose tissue 
(32). HSL activity in adipose tissue is known to also be under control of the vagal nerve 
(33). Lowered activity of HSL results in a reduction in the rate of FFA release from adipose 
tissue stores. 
Given the facts that the drop in FFA is preingestive and that the FFA response 
curve shows all characteristics of a cephalic phase response based on the magnitude and 
time span in which the effect occurred one can consider the effect cephalic rather than a 
gastric or intestinal. Furthermore, irrespective whether the effect is a ‘true’ cephalic phase 
effect or not, it still is of physiological relevance as the decrease in FFAs was substantial, 
robust and it occurred after stimulation durations likely to be encountered in normal 
drinking (~6 min). It implies that mere oral wine exposure without ingestion already 
triggers metabolism and may serve as a feed-forward system to optimize the absorption and 
utilization of dietary constituents such as alcohol.  
As cephalic phase responses are known to affect satiation (34) and satiety (11;12) 
the sudden drop in FFA after oral wine exposure might possibly be associated with 
increased appetite sensations and energy intake as observed after alcohol consumption (35).  
The acute drop in FFAs after oral exposure might also improve insulin sensitivity 
as observed after both acute alcohol consumption (21) and prolonged consumption (36). 
Acute decreases in serum FFA concentrations are directly related to improved insulin 
signaling (37) and glucose metabolism (38). It has been proposed that acute FFA reductions 
could reflect the improved insulin sensitivity observed after acute moderate alcohol 
consumption (21;39). 
This study has only been executed with white wine. Whether similar findings will 
be found with other alcoholic beverages has yet to be investigated. It seems likely, 
however, that this would be the case for several reasons. FFA concentrations are decreased 
after acute alcohol consumption per se (19-22), and not only after white wine consumption. 
Secondly, other physiological effects described after alcohol consumption (e.g. increase in 
HDL-cholesterol (40)) are observed for all three types of alcoholic beverages. 
Strong points of the study are its crossover design, its relatively large and 
homogenous group of subjects and the incorporation of both hormones and metabolites. 
Several limitations warrant consideration. The white wine differed in structure (liquid vs. 
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solid compared to the cake) and energy content (compared to water). However, differences 
in structure or amount of calories between stimuli are unlikely to have caused this robust 
and substantial drop in FFA concentrations after MSF with wine since both after sham 
feeding cake and water FFA concentrations gradually increased; a process that naturally 
occurs with prolonged fasting. Another control might have been a non-alcoholic wine or 
ethanol in water. We choose cake rather than an ethanol-related control solely to have an 
expected positive control for cephalic phase PP release.  
We conclude that mere oral exposure to white wine is capable of reducing serum 
free fatty acid concentrations, regardless of BMI. Furthermore, this study demonstrates that 
stimulation durations likely to be encountered in normal drinking are sufficient to elicit 
such a temporarily but substantial and robust response. Further study of the cephalic phase 
response of alcohol, also in other beverages, on its physiological implications such as 
appetite and insulin sensitivity is warranted. 
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The research described in this thesis aimed to contribute to a better understanding of the 
association between alcohol consumption and type 2 diabetes risk that has previously been 
found. To this end, two main research strategies were followed. First observational studies 
were applied to extend the evidence of this relation. Second, underlying physiological 
mechanisms were further investigated in controlled study settings. 
This final chapter starts with a brief overview of the main findings, followed by a 
section on methodological considerations, a reflection of the findings and comparison with 
other studies. Finally, implications for public health and recommendations for future 
research are given. 
 
Main findings 
The main findings of the observational and experimental studies conducted and described 
within this thesis are summarized in Table 9.1. 
 
Prospective cohort studies 
The effect of change in alcohol consumption over time on diabetes risk depended on initial 
consumption level in U.S. middle-aged men. Only among initially rare and light drinkers, 
increases in alcohol consumption over time were associated with increased levels of total 
adiponectin and with a lower risk of type 2 diabetes. When considering these endpoints, 
men already consuming alcohol in moderation did not gain further health benefit from 
increased consumption. In line with data obtained from the general population, we found 
that moderate alcohol consumption is associated with a lowered risk of type 2 diabetes in 
Dutch men and women already at lower risk due to favorable lifestyle characteristics. In 
these subjects who carry a relatively low risk of developing diabetes on the basis of other 
lifestyle characteristics, alcohol consumption provided a considerably further decrease 
(about 40% or more) in the risk of diabetes.  
 
Randomized controlled trials 
The randomized intervention studies carried out showed that moderate alcohol consumption 
increased both total and high-molecular weight adiponectin levels by about 10% compared 
to abstention. These effects were not depending on beverage type (beer, wine or spirits), 
age (young and middle-aged subjects) or gender. Moreover, the increase in adiponectin 
concentrations could be attributed to increased de novo syntheses in adipose tissue as 
intervention-induced changes in total adiponectin protein levels correlated to changes in 
expression of the gene encoding adiponectin. Furthermore, the weekly alterations in both 
total and HMW adiponectin occurred concomitantly and were evident within three weeks 
of moderate alcohol consumption compared with abstention.  
Among postmenopausal women, we observed favorable changes in fasting insulin 
and triglyceride levels after six weeks of moderate alcohol consumption but not in younger 
women and men after three and four weeks, respectively. An integrated approach of large-
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scale profiling of proteins and genes revealed that moderate alcohol consumption for four 
weeks altered gene expression profiles of white blood cells and circulating proteins both 
related to immune response and lipid metabolism. However, we could not confirm that four 
weeks of moderate alcohol consumption resulted in a lower inflammatory response induced 
by a low dose in vivo endotoxin bolus, despite a 10% increase in HDL-cholesterol and 
several HDL-associated apolipoproteins in men. Finally, we found that short-term oral 
exposure of white wine without swallowing provoked a substantial decrease in circulating 
free fatty acid concentrations in normal-weight and overweight postmenopausal women. 
The free fatty acid concentrations returned to near baseline values in less than half an hour 
after the exposure to the wine stopped. 
 
 
Methodological considerations 
This section discusses methodological considerations which are important to take into 
account when interpreting the results. The research described in this thesis consisted of 
prospective cohort studies and randomized controlled trials, both subject to certain 
strengths and limitations. Although these have been pointed out in the discussion sections 
of each chapter, several general but iterative aspects will be briefly commented on to put 
the observed findings into perspective.  
 
Prospective cohort studies 
Compared with randomized trials results of prospective cohort studies can be easily 
generalized as they are based on the natural development of a trait in a real-life setting. The 
observational studies described in this thesis had several strengths, such as a prospective 
and long follow-up, large samples sizes, and verified cases of a hard end point: incident 
type 2 diabetes. However, there are, as with any prospective studies, certain limitations. In 
the following section some limitations specifically of interest in prospective studies on 
alcohol consumption will be addressed. 
 
Reference group 
One of the concerns related to observational studies with alcohol is also known as the "sick-
quitter" hypothesis. It was proposed by Shaper and colleagues in 1988 (1) and substantiated 
later (2;3). This hypothesis argues that abstainers are an inappropriate control population 
because at least some of these people may abstain because of illness or former alcohol 
abuse or because alcohol interacts with prescription drugs they are taking. Obviously, 
comparisons of healthy drinkers with abstainers who take prescription drugs or who have 
underlying illnesses that raise one's risk for chronic diseases will produce a biased result in 
favor of the alcohol-consuming subjects. Because an individual’s health status informs such 
a decision, comparing current with former drinkers can be biased. This “sick-quitter” effect 
may also explain a small portion of the benefit attributed to alcohol in some studies on type 
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2 diabetes as shown in the meta-analysis by Baliunas and colleagues in which they found 
lower risk reductions when only lifelong abstainers were included in the reference group 
(4). Our results, however, are not likely to be influenced by such bias. In the Dutch cohort, 
we used lifelong abstainers as referent. In this particular study, former drinker and thus 
potential ‘sick-quitters’ were included in the light drinking category. In parts of the 
analyses of changes in alcohol consumption we used current stable drinkers as a referent 
category instead of current non drinkers thereby bypassing this potential bias. Furthermore, 
in sensitivity analyses we removed current nondrinkers (which include people who might 
have given up drinking for health reasons) with minimal effect on the risk estimates. 
Therefore it is unlikely that our results are biased by the effect of sick-quitters. 
 
Confounding 
The results presented could be in part influenced by differences in (lifestyle) factors other 
than alcohol consumption that are associated with both exposure and disease but that do not 
lie in the causal pathway between the exposure and the outcome, i.e. confounding. In 
general, moderate drinkers tend to be leaner and eat better, exercise more and have a higher 
social economic status (5;6). However, drinkers are also more likely to be smokers and 
smoking is a risk factor for diabetes. Thus, it is overly simplistic to suggest that alcohol 
consumption is completely intertwined with a healthy lifestyle. In the two cohort studies 
presented, we indeed noted that moderate drinkers were likely to exercise and smoke more 
and were less likely to have a family history of diabetes. Also among females, but not 
among males, moderate drinkers tended to be leaner than abstainers. Finally, moderate 
drinkers were higher educated in the Dutch cohort. However, in the U.S. cohort all men 
were health professionals (e.g. dentists, optometrists, osteopaths, pharmacists, podiatrists, 
and veterinarians) and thus highly educated, which substantially reduced the potential 
confounding due to social economic status in this group. We therefore adjusted for a large 
number of important risk factors of type 2 diabetes such as age, body mass index (BMI), 
physical activity, smoking, family history of diabetes and several nutritional factors in both 
studies. 
In the observational study on alcohol consumption and lifestyle factors among 
Dutch men and women, we examined the association of alcohol intake with risk of type 2 
diabetes in strata of separate lifestyle behaviors based on body mass index, physical activity 
level, smoking, and adherence to a healthy diet and in strata of combined low-risk lifestyle 
behaviors. In the separate strata of each of the four individual lifestyle behaviors and in the 
strata of joint lifestyle behaviors, moderate alcohol consumers had consistently lower risk 
of type 2 diabetes compared to abstainers. This makes a compelling case that the inverse 
association between moderate alcohol and diabetes risk is not confounded by other lifestyle 
behaviors.  
In the study on changes in alcohol consumption, we accounted for changes in 
several potential confounding factors. First we controlled for changes in hypertension, 
hypercholesterolemia, and CVD by including terms for these factors at the beginning and 
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end of the period of change in alcohol consumption in the model. Thus, our results 
accounted for changes in these risk factors and indirectly for risk factors strongly related to 
them. In sensitivity analyses, we accounted for the differences in BMI that may have 
occurred during the four-year periods between assessments of alcohol consumption by 
including BMI pre- and post- the period of change in alcohol consumption. This did not 
materially alter the results. We used the exact same approach to assess the effect of changes 
in physical activity, another important diabetes risk factor. Again, this yielded similar 
results. There was not sufficient variation in smoking status in this cohort, as the prevalence 
of current smokers was ~10%, to adjust for change in smoking status. Hence change in 
smoking was unlikely to be an important confounder. Our approach for dietary risk factors 
also inherently accounted for change in intake over time. For each dietary factor, we 
calculated a cumulative average over the period of follow-up, thus including both time 
points in the models. Because individual dietary factors are substantially less strongly 
associated with diabetes risk than are BMI and physical activity, it is unlikely that any 
remaining uncontrolled confounding that is not already accounted for drove the observed 
findings. Nevertheless, we cannot completely rule out the possibility of residual 
confounding. Although some residual confounding may attenuate the observed association, 
it is unlikely that a confounder of this magnitude would have remained undetected.  
 
Assessment of alcohol intake 
In the population based studies, we relied on self-reported alcohol consumption which was 
assessed by a food frequency questionnaire (FFQ). It is known that self-reported alcohol 
intake is generally being under-reported (7;8). Despite this and obvious other limitations, 
the FFQ is accepted as the standard tool for dietary assessment in large studies on diet and 
chronic disease. The FFQs used in our studies were validated against 24-hour recalls 
showing high correlations of over 0.7 (9-11). To further validate the self-reported alcohol 
intake, we also determined the relation between alcohol intake and HDL-cholesterol in a 
6.5% sub-cohort of Dutch men and women. In line with previous observations, this analysis 
showed a linear association between alcohol intake and HDL-cholesterol concentrations in 
both men and women (12). This means that for alcohol intake an FFQ may be a reasonably 
valid method for ranking subjects according to intake rather than to estimate absolute 
amounts of intake although the actual amount and frequency of alcohol consumed by the 
subjects in these studies may differ from that reported. However, any misclassification due 
to the FFQ is unlikely to affect this rank order of alcohol consumption.  
 
 
Randomized crossover trials 
Mainly due to the limitations of observational studies, such as uncontrolled or residual 
confounding, findings from randomized trials are generally believed to provide the highest 
level of evidence. However, conducting large-scale, long-term, randomized controlled trials 
with hard endpoints such as type diabetes may be impossible due to obstacles in costs, 
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logistics and ethical issues. Strictly controlled short-term alcohol feeding studies on 
intermediates of type 2 diabetes are considered to provide an alternative strategy. 
 
Design of the trials 
All intervention studies described in this thesis used a randomized, crossover design. The 
term ‘randomized’ means that the subjects are randomly assigned to a sequence of 
treatments (e.g. alcohol vs. non-alcohol or vice versa) and ‘crossover’ means that all 
subjects participated in the different test conditions. This allowed for within subject 
comparison of effects, thereby controlling many unpredictable individual variables possibly 
related to outcome measures and increasing statistical power to detect significant 
differences. A possible issue with this design is potential ‘carryover’ effects between 
treatments, which could confound the estimates of the treatment effects. In the statistical 
models, we checked whether statistical significant carryover effects occurred but this was 
not the case. Therefore, the presented results are unlikely to be biased by carryover effects. 
 
Dose and type of study substance 
The amount of alcohol, which was provided in the form of white wine, beer or vodka to 
participants in the randomized trials, averaged around 25 g/day for women and 30 g/day for 
men. This amount equals 2.5 to 3 Dutch units or around 2 U.S. units and exceeds current 
recommendations. However, these guidelines are directed at prevention of all chronic 
diseases rather than on a maximum risk reduction of type 2 diabetes. Moreover, the amount 
used in the experimental trials represented the nadir of the association between alcohol 
consumption and type 2 diabetes based on several meta-analyses (4;13;14). In concert, 
daily alcohol administration of 30 g of alcohol/day for eight weeks improved insulin 
sensitivity among postmenopausal women compared with 15 g or 0 g of alcohol per day 
(15). Furthermore, our clinical intervention studies aimed to provide an underlying 
mechanism for the observed association and are not meant to directly translate in a public 
health message. Finally, since the interventions comprised a relatively short period of time, 
such an elevated dose ensured sufficient contrast between treatments to find significant 
differences in relevant outcome parameters. 
We used commercially available alcoholic beverages and most of the times their 
most comparable control as study substances for the trial in order to mimic regular alcohol 
consumption. Nonetheless differences between study substances exits. However, both 
observational studies and short-term controlled trials comparing beer, wine and spirits 
found that the observed effects on type 2 diabetes risk or mediating markers such as 
adiponectin were independent from beverage type and thus due to the alcohol itself. 
Nevertheless we cannot rule out the fact that certain beverage-specific constituents other 
than alcohol (e.g. polyphenols in wine, juice or B vitamins in beer) may have affected 
specific anti-inflammatory processes or insulin sensitivity despite the fact that we selected 
comparable non alcoholic beverages as counterparts in most of the studies (e.g. white grape 
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juice vs. white wine and non-alcoholic beer vs. beer). Taken together, we do not think that 
choice of beverage has materially influenced our results to a large extent. 
 
Study population of the trials:  
Participants in the studies consisted of postmenopausal women and younger women and 
men who consumed alcohol on a regular basis. Therefore, the results may not readily be 
generalized to middle-aged men or abstainers. However, previous intervention trials of our 
group have shown that e.g. adiponectin levels are also increased after alcohol consumption 
in middle-aged men (16;17). Moreover, even among initial abstainers, increases in alcohol 
consumption were associated with an increment in adiponectin levels, as described in 
chapter 2. It is thus unlikely that, the findings, especially concerning the increased 
adiponectin, are limited to the investigated groups of subjects. 
 
Compliance to treatments: 
In any intervention study compliance to study treatments is key to obtain valid results. First 
compliance was monitored by weekly measurement of urinary ethyl glucuronide, a direct 
phase II metabolite of ethanol formed by action of UDP-glucuronosyl transferase. Ethyl 
glucuronide has been reported to be a superior marker with 100% sensitivity as a biomarker 
of recent drinking (18) and persists in the urine up to ~75 to 85 h after last intake. 
Additional measures of compliance were increase of serum HDL-cholesterol, daily 
questionnaires, and return of empty bottles. All of these measures suggested a high 
compliance to the study procedures.  
 
Sample sizes and duration of the trials 
The number of subjects in study, in addition to dose and intervention length, is crucial for 
statistical power to detect relevant differences. Most of the samples sizes were based on 
previous research either with moderate alcohol consumption or a comparable intervention, 
which enabled us to estimate realistic detectable differences in outcome measures between 
treatments. Furthermore, we also had a low drop-out rate during the studies which added to 
the retention of sufficient statistical power. 
 
Outcome measures  
Adiponectin and markers of inflammation and insulin sensitivity in blood were the main 
parameters measured in all interventions. These measures are thought to be important 
intermediates in the development of type 2 diabetes. Blood samples were obtained from the 
anticubital vein of the forearm and collected in tubes. Samples were centrifuged for 15 
minutes at 2.000 g at 4°C, within 15 - 30 minutes after collection and stored at <-70°C. 
Samples were determined using validated assays according to the manufacturers’ 
specifications. Intra-assay and inter-assay variation usually were below 5%.  
Besides circulating markers we also measured gene expression levels in various 
tissues by means of RT-PCR or microarray analysis. RNA quantity and quality were 
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verified and no serious deviations were observed. Labeling and hybridization of RNA for 
each tissue was conducted by the same person to minimize variation.  
Finally, we did not measure insulin sensitivity according to the golden standard: the 
euglycemic, hyperinsulinemic clamp technique. Instead, we used an indirect measure based 
on fasting levels of glucose and insulin (HOMA-IR) which correlates with the clamp 
technique (19). 
 
 
Comparison with other studies and interpretation of the findings 
 
Prospective cohort studies 
In concert with previous prospective population-based studies from different geographical 
regions (20-52), we observed an inverse association between moderate alcohol 
consumption and risk of type 2 diabetes among U.S. men and Dutch men and women. In 
contrast we did not observe an increased risk of diabetes in heavier consumption categories 
as was expected based on the reported U-shaped association. In the Dutch cohort, heavier 
alcohol intake was defined as any intake above current guidelines. This may have obscured 
a potential U-shaped curve since alcohol intake levels up to about 50 g of alcohol/day 
(4;14) are still protective against diabetes. In the U.S. cohort, we found a linearly inverse 
association between alcohol and diabetes, despite a more sophisticated categorization of 
alcohol intake which should have enabled us to detect a U-shaped curve. 
 
Changes in risk of type 2 diabetes were evident within a 4-year period following changes in 
alcohol intake (chapter 2). This is in line with observations of change in alcohol intake and 
subsequent change in risk of cardiovascular diseases (53-55) and mortality (56), although 
some inconsistency exists (57;58). Our findings suggest that the effect of alcohol 
consumption on diabetes risk has a relatively short latency time but may also be transient 
and reversible. Furthermore, the temporality of the relation between alcohol and diabetes 
risk may imply a causal association between alcohol intake and diabetes risk. 
 
Consistent with previous findings, we found that the association between alcohol 
consumption and type 2 diabetes appeared to be independent of other single (25;32;38) or 
joint (48;59) lifestyle factors related to diabetes risk. Our results (chapter 3) reflect similar 
additional protection from alcohol consumption for type 2 diabetes among otherwise 
healthy subjects as was previously shown for heart disease by Mukamal and colleagues 
(60). The results of these two studies together indicate that the relation is not likely to be 
explained by a healthier lifestyle of moderate drinkers in general. Also, it shows that the 
common suggestion by some that alcohol should be avoided since the same protection 
against theses diseases can be caused by other lifestyle habits may not be completely valid. 
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For the interpretation of observational data on alcohol consumption, one should 
bear in mind that such results are based on studies where individuals report their average 
intake as drinks per day, month or year which is in turn transformed into average 
intake/day. It is unlikely that most individuals drink every day. Yet, current guidelines do 
not reflect this in the definition for moderation and are based on this exact threshold of “1 
drink per day for women or two drinks per day for men” instead of a general “average” 
metric over the course of a week or month instead. One can thus argue whether these 
observational data are optimal to derive absolute values for intake recommendations, as 
misjudgments with respect to the health effects of alcohol intake might occur. 
 
 
Randomized crossover trial 
Whether alcohol consumption improves markers of insulin sensitivity has been examined in 
several randomized trials of which an overview is given in chapter 1 (Table 1.1). The only 
two studies that did report significant changes in markers of insulin sensitivity had 
intervention periods of 8 weeks and were conducted with older and less insulin-sensitive 
but non-diabetic men and women (61) or postmenopausal women (15). In line with the 
latter (15), we also found (chapter 4) lowered fasting serum insulin and triglyceride levels 
and an improvement in insulin sensitivity as estimated by the homeostasis model 
assessment of insulin resistance (HOMA-IR) among postmenopausal. 
However, the majority of the published studies did not find an improvement in 
(markers of) insulin sensitivity attributed to moderate alcohol consumption. These studies 
generally used younger adults (age <50 y) (62-67) or had a relatively short treatment period 
of alcohol consumption (all ≤4 weeks) (16;17;68). Hence, it was no surprise that we did not 
find changes in fasting serum insulin levels or other markers of insulin sensitivity in 
relatively young and insulin sensitive adults after 3 or 4 weeks of alcohol consumption 
compared with abstention (chapters 5 and 6). However, it should be noted that a myriad of 
other differences in designs between studies were present (e.g. difference in measurement 
of insulin sensitivity, dose of alcohol, beverage type, frequency of consumption, amount of 
participants). Therefore, it cannot be ruled out that experimental factors other than study 
population and duration are not important. 
 
In line with previous research, (16;17;66;69) moderate alcohol consumption increased 
circulating adiponectin levels (chapters 4-6). This effect was irrespective of beverage type 
suggesting it is the alcohol that provokes the effect. We could not confirm that alcohol 
particularly increased the high-molecular weight form of adiponectin, as previously shown 
(66). The increases in adiponectin after moderate alcohol consumption in the different 
studies were about 10%, which is a stronger effect than what can be obtained by similar 
changes in other macronutrients (i.e., a 10% shift in calories) (70;71). 
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Several lines of evidence suggest an inhibition of the pluripotent transcription factor 
nuclear factor kappa B (NF-κB) in white blood cells after acute alcohol consumption 
(72;73). In concord, we observed in chapter 5 down-regulation of the NF-κB and several 
physiologically related genes under its control after prolonged moderate alcohol 
consumption. Activation of the transcription factor NF-κB is a critical step in monocytes 
inflammatory cytokine production after exposure to bacterial stimuli such as LPS. Yet we 
did not observe an attenuated cytokine response after a low dose endotoxin administration 
in men after four weeks of alcohol consumption despite an improved lipoprotein profile 
(chapter 7). 
 
To the best of our knowledge, the preprandial effects of alcohol after mere oral exposure as 
described in chapter 8 have never been studied. However several studies on moderate 
alcohol consumption with a meal have shown several beneficial acute postprandial effects 
on glycemia (74;75) but also on free fatty acid (FFA) levels and insulin sensitivity (76). 
The temporary but substantial drop in FFA levels observed in the preprandial study could 
acutely improve insulin sensitivity and may in turn accumulatively over time result in a 
lower risk of type 2 diabetes. 
 
 
Public health implications: to drink or not to drink? 
The results in this thesis again underline that moderate alcohol consumption lowers the risk 
of type 2 diabetes. In addition, the results showed that the association is affected by change 
in consumption over time and that the association is not confounded by lifestyle behaviors 
that influence diabetes risk.  
Although our results might be seen as suggesting that some individuals should consider 
adopting regular and moderate intake of alcohol, our findings, even if proven to be causal, 
are limited to a single outcome of type 2 diabetes. Besides reduced diabetes risk there is 
also compelling evidence that moderate alcohol intake affects several other health outcomes 
which should be taken into account. An average daily intake of one to two alcoholic 
beverages is associated with the lowest all-cause mortality (77) and a reduced risk of 
cardiovascular diseases (78;79) but also with higher risk of breast cancer among women 
(80) especially with risk of hormone-sensitive breast cancers (81;82). Besides these effects 
with moderate alcohol consumption, there is evidence for a positive associations between 
heavy alcohol consumption and risk of unintentional injuries (83), liver cirrhosis (84), some 
forms of cancer (85), and addiction which should also be taken into consideration. Current 
guidelines acknowledge this by recommending that if any alcohol is consumed at all, it 
should be consumed in moderation, and only by adults. Moreover, studies suggest adverse 
effects at even moderate amounts of alcohol consumption in specific individuals and 
situations. According to the U.S. National Institute of Alcohol Abuse and Alcoholism (86) 
and the Netherlands Health Counsel (87) people who should abstain include:  
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• Children and adolescents. 
• Women who are pregnant or planning to become pregnant. 
• Individuals with specific medical conditions (e.g. liver disease, pancreatitis). 
• Individuals taking medications that can interact with alcohol. 
• Individuals who plan to engage in activities that require alertness and skill (such as 
driving a car). 
• Individuals who cannot restrict their drinking to moderate levels or are recovering 
from alcoholism. 
 
For teetotalers it is undesirable to advise picking up the habit of consuming alcoholic 
beverages in moderation. Usually they have their motives to abstain (e.g. religion or family 
history of alcoholism). 
 
Some argue that moderate alcohol intake is only effective in middle-aged and older people 
to prevent chronic diseases. This seems especially the case for outcomes like cardiovascular 
diseases and type 2 diabetes that appear to be more malleable over the course of a lifetime 
than e.g. cancer. Indeed, research in this thesis has shown that adopting moderate alcohol 
intake later in life could reduce the risk of type 2 diabetes as is the case for risk of 
cardiovascular diseases (53;56). For younger adults there may be less health benefit from 
alcohol drinking throughout adulthood because the preventive effect of moderate alcohol 
consumption on these diseases can only work if there is an actual risk. These risks become 
evident at about middle age whereas risks associated with the negative consequence of 
alcohol consumption are prevalent throughout adulthood. On the other hand, although risks 
of chronic diseases become actual at older age, it has been generated by a series of events in 
the previous decades. It might therefore, be overly simplistic to ignore the fact that earlier 
signs of e.g. atherosclerosis (such as fatty streaks) can already be observed during 
adolescence. Furthermore, there is evidence that alcohol consumption does reduce the risk 
of type 2 diabetes (38) and cardiovascular diseases (88) among younger adults. Thus, it 
may be somewhat premature to suggest that only middle-aged and older adults can benefit 
from light or moderate alcohol consumption. Especially, since a fundamental principle of 
dietary guidelines is the concept that a healthy diet starting from a young age can mitigate 
such processes and hence reduce the risk of chronic diseases in later life. 
 
Guidelines for a healthy lifestyle generally do not recommend moderate alcohol 
consumption because of the risks associated with heavy alcohol consumption. Usually other 
lifestyle features are emphasized. A drawback with such an approach is that healthy 
lifestyle behaviors are often inter-correlated and may be most effective when present in 
combination and generally should not be considered mutually exclusive. Possibly, light to 
moderate alcohol consumption could be an additional part of such a healthy lifestyle.  
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However caution is warranted and tailored advice on alcohol consumption is essential. 
Heavy or excessive drinking should always be discouraged, whereas moderate alcohol 
consumption could be regarded as a complement, rather than an alternative, to other low-
risk lifestyle habits. Guidelines and personal advice on alcohol consumption should 
consider the full range of benefits and risks to the individual including the consistent harms 
to the individual and society of drinking that exceeds recommended limits. A discussion 
with a health care provider is strongly advised for all people considering a change in their 
drinking habits. 
 
 
Future research recommendations 
 
Observational studies 
Genetic predisposition  
It is recommended to pay more attention to the genetic variation in genes coding for 
enzymes involved in alcohol metabolism since large-scale clinical trials with hard 
endpoints such as type 2 diabetes are not feasible in this field. An individual’s genetic 
composition does not change over time and is less likely to be associated with confounding 
factors. Therefore, research on the effect modifying potential of genetic variants, for 
example ADH and ALDH, which favor a casual relationship between alcohol intake and 
disease, may provide more insight. Along this line, a more sophisticated approach could be 
to compose a gene score based on some a priori chosen gene variants that predicts alcohol 
consumption. If this score is associated with both alcohol consumption and diabetes risk in 
another, independent cohort this would provide compelling evidence for a causal 
relationship between alcohol consumption and type 2 diabetes. 
 
 
Biomarkers mediating of the association between alcohol consumption and diabetes 
Although the association between moderate alcohol consumption and decreased risk of type 
2 diabetes has been reported consistently, limited observational data are available on 
potential underlying mechanisms. For alcohol consumption and cardiovascular disease this 
relation may be mediated through HDL-cholesterol and non HDL-cholesterol factors, such 
as insulin sensitivity, inflammatory markers, lipid and haemostatic factors (12;89-91). For 
type 2 diabetes, adiponectin appeared to explain about 25% of the relation between alcohol 
and diabetes risk whereas circulating biomarkers of inflammation, endothelial dysfunction, 
and fasting insulin did not explain a substantial part of this association (92). However, this 
specific study solely consisted of middle-aged women, had a case control design, and was 
performed with a limited number of potential mediators. For example, triglyceride 
concentrations were not included in this model despite being an independent risk factor for 
diabetes (93). Compared with postmenopausal non-drinkers, postmenopausal drinkers have 
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lower triglyceride levels whereas male drinkers have higher triglyceride levels compared 
with male abstainers (94).  
Nevertheless, studies like these may help to clarify the possible mechanisms 
underlying the observed association between moderate alcohol intake and diabetes. 
Therefore, future research should confirm the mediating effect of adiponectin, not only in 
women but also in men. Furthermore, additional potential mediators such as triglycerides 
and inflammatory markers such as TNF-α should be taken into account in these analyses 
besides the more traditional glycemic and inflammatory markers. 
 
Drinking pattern 
Measures of overall volume of alcohol consumption obscure the relative contributions of 
drinking frequency (how often alcohol is consumed), drinking quantity (how much alcohol 
is typically consumed on those days), and their individual contributions to diabetes risk 
have not been thoroughly investigated. Therefore, the effect of drinking pattern should be 
examined further in future studies.  
 
 
Randomized trials 
The physiological mechanisms that could account for the risk reduction in type 2 diabetes 
associated with moderate alcohol consumption are not completely understood. However, 
several theories have been proposed such as an improved insulin sensitivity, increased 
adiponectin levels, lowered inflammatory status and improved glycemic control.  
In order to provide more definite answers, future randomized trials with prolonged 
moderate alcohol consumption might consider using: 
• subjects with slightly impaired insulin sensitivity of increased risk of type 2 
diabetes (and thus more likely to benefit from alcohol consumption),  
• sufficiently long treatment periods (preferably over six weeks of moderate alcohol 
consumption to find improvements in insulin sensitivity), 
• other or more convincing intermediates of type 2 diabetes e.g.  
- Profiling of other tissues besides blood that might be relevant tissues in the 
etiology of type 2 diabetes such as (visceral) adipose or liver tissue. 
- β-cell function and secretion of related incretin hormones such as glucagon-
like peptide-1 (GLP-1) and gastric inhibitory peptide / glucose-dependent 
insulinotropic polypeptide (GIP).  
- Challenges of homeostasis (oral glucose tolerance test or euglycemic clamp 
to challenge insulin sensitivity /glycemic control or an endotoxin challenge to 
characterize the inflammatory or immune response. 
• an integrated approach of metabolic, protein, and gene profiling of different tissues 
for the discovery of potential new biomarkers.  
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Finally, investigating the more acute effects associated with moderate alcohol consumption 
on e.g. preprandial (cephalic phase) or postprandial responses and its subsequent 
consequences could help to elucidate the relation between alcohol and insulin sensitivity or 
glycemia which in turn could accumulatively affect diabetes risk. 
 
 
Concluding remarks 
In conclusion, research presented in this thesis confirmed the reduced risk of type 2 
diabetes associated with moderate alcohol consumption in two separate populations. 
Furthermore, it extended the association by showing the temporality of the association, and 
by expanding this relation to subjects already at lower risk of type 2 diabetes. Finally, it 
provided several plausible physiological mechanisms that may account for the lower risk of 
type 2 diabetes. 
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Moderate alcohol consumption has been associated with a reduced risk of type 2 diabetes 
compared with abstention. Despite overwhelming evidence for this relation from 
observational studies and to some extent from clinical trials on intermediate endpoints, 
several questions concerning this relation remain. This thesis thus aimed to substantiate the 
evidence of the inverse association between moderate alcohol consumption and type 2 
diabetes in different populations in observational studies and to provide underlying 
physiological mechanisms in clinical intervention studies. 
 
Observational studies 
Changes in alcohol consumption over time are associated with subsequent changes in risk 
of cardiovascular diseases and mortality but whether changes in alcohol consumption 
influence future diabetes risk was uncertain. Thus in chapter 2 we investigated among 
38,031 middle-aged U.S. men if four-year changes in alcohol consumption affected 
subsequent type 2 diabetes risk. Among initially rare and light drinkers, moderate increases 
in alcohol consumption over a four-year time period were associated with a lower risk of 
type 2 diabetes. However, individuals already consuming alcohol in moderation did not 
receive further benefit from increased consumption. The results suggest that the effects of 
alcohol consumption on type 2 diabetes risk have a relatively short latency time but are also 
transient and reversible. 
 
Whether the lower risk of type 2 diabetes among subjects who consume alcohol is due to 
the alcohol drinking itself or whether, to some extent, it is due to other healthy lifestyle 
factors of drinkers is a continuing question. In chapter 3, we determined if alcohol 
drinking, in addition to having optimal weight, being physically active, nonsmoking, and 
consuming a healthy diet, had an effect on the risk of developing type 2 diabetes among 
35,625 Dutch men and women. The results showed that even among subjects who are at 
lower risk of developing diabetes on the basis of other lifestyle characteristics, alcohol 
consumption provided considerably further decrease of about 40% in the risk of type 2 
diabetes. 
 
Intervention studies 
Although moderate alcohol consumption has consistently been associated with a decreased 
risk of type 2 diabetes compared with abstaining it remains uncertain whether it improves 
insulin sensitivity. In chapter 4, we describe the results of a randomized, crossover trial 
among thirty-six apparently healthy postmenopausal women who received white wine (~25 
g alcohol/day) or white grape juice daily during dinner for six weeks. Moderate alcohol 
consumption for six weeks improved insulin sensitivity by about 11% and adiponectin 
levels by about 12% in postmenopausal women. Furthermore, these data suggested a 
transcriptional mechanism leading to the alcohol-induced increase in adiponectin plasma 
levels. 
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Moderate alcohol consumption has several acute effects on gene expression of white blood 
cells but longer term effects on gene expression are largely unknown. Thus in chapter 5 we 
examined with large-scale profiling of proteins and genes the effects of four weeks of 
moderate vodka (~30 g alcohol/day) consumption on inflammatory markers and gene 
expression profiles in blood of twenty-four younger men. This integrated approach of large-
scale profiling of proteins and genes revealed that moderate alcohol consumption for four 
weeks altered gene expression profiles of white blood cells and circulating markers related 
to inflammation. 
 
Previously, we have shown that moderate alcohol consumption increased levels of 
adiponectin, a hormone inversely associated with type 2 diabetes risk. However, the rate at 
which this increase occurs is unclear and if this increase differs for specific forms of 
adiponectin was also uncertain. In chapter 6, we therefore examined the effect of moderate 
alcohol consumption on the weekly alterations in levels of both total and high-molecular 
weight (HMW) adiponectin in twenty-four premenopausal women. We observed that 
moderate beer consumption (~26 g alcohol/day) increased both the high-molecular weight 
form as the total adiponectin from by about 8% after at least three weeks of consumption 
compared with alcohol-free beer consumption. Alcohol consumption did not preferentially 
change the molecular weight distribution of adiponectin in these younger women.  
 
Circulating high-density lipoprotein (HDL)-cholesterol and its associated surface lipids 
apolipoproteins have been shown to play an important role in the detoxification of a 
specific endotoxin named LipoPolySaccarides (LPS). Moderate alcohol consumption 
increases HDL-cholesterol and several apolipoproteins. In chapter 7, we aimed to study 
whether the alcohol-induced increase in lipoproteins attenuated the inflammatory response 
after a low-dose in vivo endotoxin challenge. After four weeks of moderate vodka juice 
consumption (~30 g alcohol/day) several lipoproteins were increased by approximately 
10% compared with four weeks of juice consumption in twenty-two men. However, we did 
not observe an attenuated inflammatory response over time after a low-dose in vivo 
endotoxin bolus. 
 
Preingestive or cephalic phase responses, triggered by sensory stimulation of 
macronutrients, influence the organism’s endocrine responses and substrate mobilization. 
However whether oral sensory stimulation with alcohol elicits cephalic phase responses 
was unknown. In chapter 8, we investigated whether short-term (~6 min) oral alcohol 
exposure, in the form of white wine(~25 g alcohol), provoked cephalic phase responses in 
eleven normal-weight and eleven overweight subjects. Oral white wine exposure in the oral 
cavity substantially (-20%) and temporarily (~20 min) decreased serum free fatty acid 
concentrations compared with water exposure regardless of BMI. This suggests a cephalic 
phase response of alcohol. 
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The main findings, methodological considerations and interpretation of the findings of the 
studies described in this thesis are discussed in chapter 9. Directions for further research 
and implications for public health are mentioned 
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Het is al langere tijd bekend dat er een relatie is tussen matige alcoholconsumptie* en een 
lager risico op het krijgen van diabetes mellitus type 2 (kortweg diabetes type 2*) in 
vergelijking met geheelonthouding of overmatige alcoholconsumptie. Ondanks veelvuldig 
bewijs was het nog steeds niet helemaal duidelijk of dit verband daadwerkelijk veroorzaakt 
wordt door de alcoholconsumptie of door andere factoren, die gepaard gaan met matige 
alcoholconsumptie. Ook was het nog grotendeels onbekend wat alcohol in het lichaam doet 
om de verlaging in het risico op diabetes type 2 te kunnen verklaren.  
 
Het doel van dit proefschrift is tweeledig: 
1) Het bewijs voor de relatie tussen matige 
alcoholconsumptie en diabetes type 2 verder 
uit te breiden door middel van bevolkings-
onderzoek met diabetes type 2 als eindpunt. 
2) Mogelijk onderliggende mechanismen te 
onderzoeken, welke het verband vanuit een 
biologisch oogpunt kunnen verklaren. Dit is 
gedaan met behulp van interventiestudies 
met belangrijke voorspellers van diabetes 
type 2 als uitkomst. 
 
Algemene inleiding 
In hoofdstuk 1 bespreken we de definitie van matige alcoholconsumptie. Ook geven we in 
dit inleidende hoofdstuk een omschrijving van 
diabetes type 2 en het ontstaan ervan. Daarnaast 
geven we een overzicht van de meest recente 
uitkomsten uit bevolkingsonderzoek waaruit 
blijkt dat er een verband is tussen alcohol-
consumptie en een verlaging van het risico op 
diabetes type 2. Verder bespreken we de mogelijk 
onderliggende mechanismen op basis van eerder 
uitgevoerde interventiestudies. Tenslotte 
beschrijven we de doelstellingen en de opbouw van dit proefschrift. 
 
Bevolkingsonderzoek 
Met bevolkingsonderzoek bedoelen we een studieopzet waarbij in een grote groep mensen 
wordt nagegaan in welke mate een bepaalde ziekte onder de bevolking vóórkomt en welke 
factoren dit mogelijk in de hand werken of juist voorkómen. In dit proefschrift kijken we 
specifiek naar alcoholconsumptie maar houden daarbij ook rekening met leeftijd, 
leefstijlfactoren zoals lichaamsgewicht, beweging, voedingspatroon en rookgedrag, en 
andere belangrijke factoren zoals familiegeschiedenis van diabetes en opleidingsniveau. 
Statistische analyses van vaak grote databestanden zijn daarbij een belangrijk hulpmiddel. 
* Matige alcoholconsumptie 
Matige alcoholconsumptie wordt door 
richtlijnen omschrijven als maximaal 
één standaard glas voor vrouwen en 
maximaal twee standaard glazen per 
dag voor mannen. 
Dagelijks 2 tot 3 glazen alcohol gaat 
samen met het laagste risico op 
diabetes type 2. Daarom definiëren we 
in dit proefschrift deze hoeveelheid als 
matige alcoholconsumptie. 
* Diabetes type 2
Diabetes type 2, ofwel ouderdoms-
suikerziekte, is een ziekte die wordt 
gekenmerkt door een verhoogd glucose 
(= suiker) gehalte in het bloed. Bij dit 
type diabetes produceert het lichaam 
wel insuline maar is het lichaam minder 
gevoelig voor insuline geworden. 
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Effect van verandering in alcohol op diabetes 
Een relatief nieuwe methode om na te gaan hoe ´hard´ het veronderstelde verband tussen 
matige alcoholconsumptie en diabetes type 2 is, is om de ´tijdelijkheid´ van dit verband te 
onderzoeken. Met andere woorden: hoe beïnvloedt een toename of afname in alcohol-
consumptie in een bepaalde tijdsperiode het risico op diabetes type 2? In hoofdstuk 2 
hebben we beschreven hoe dit zich gedurende twintig jaar bij 38.031 Amerikaanse mannen 
van middelbare leeftijd ontwikkelt. Hierbij hebben we specifiek gekeken of veranderingen 
in de alcoholconsumptie over periodes van vier jaar een effect hadden op het risico op 
diabetes type 2 in de daaropvolgende vier jaar. Hierbij hebben we ook rekening gehouden 
met andere relevante veranderingen die mogelijk van invloed zijn, zoals lichaamsgewicht, 
lichaamsbeweging, rookgedrag en voedingspatroon. Uit het onderzoek bleek dat wanneer 
personen die slechts incidenteel alcohol dronken hun consumptie van alcoholhoudende 
drank verhoogden tot een matig niveau, dit leidde tot 10% hogere gehaltes van 
adiponectine* in het bloed en tot een 22% lagere 
kans op diabetes type 2. Omgekeerd, wanneer 
matige drinkers hun alcoholconsumptie 
verlaagden, nam het risico op diabetes type 2 toe 
tot een niveau dat vergelijkbaar was met het risico 
van mensen die aanvankelijk incidenteel 
alcoholhoudende dranken consumeerden. Bij 
mensen die bij aanvang van de studie matig 
dronken en in de loop der tijd hun consumptie 
verhoogden, bleek er echter geen sprake te zijn 
van extra bescherming tegen diabetes type 2. Deze resultaten laten zien dat het effect van 
alcohol op het risico op diabetes type 2 na een relatief korte tijd (vier jaar) zijn beslag 
krijgt, maar ook dat het effect in een zelfde tijdsperiode teniet gedaan kan worden wanneer 
de consumptiehoeveelheid veranderd. 
 
Nog effect van alcohol op diabetes bij een gezonde leefstijl? 
Diabetes type 2 kan veelal worden voorkomen door een gezonde leefstijl. Belangrijke 
elementen van een gezonde leefstijl zijn: het voorkómen van overgewicht, voldoende 
lichaamsbeweging, niet roken en een uitgebalanceerd voedingspatroon. Of bij mensen die 
er al een gezonde leefstijl op na hielden, matige alcoholconsumptie toch nog een 
toegevoegd gunstig effect heeft op het risico op diabetes type 2 was nog niet eerder 
onderzocht. In hoofdstuk 3 is beschreven hoe we dit bij 35.625 Nederlandse mannen en 
vrouwen tussen de 20 en 70 jaar gedurende 10 jaar hebben onderzocht. De resultaten lieten 
zien dat personen die zich hielden aan ten minste drie van de bovengenoemde 
beschermende leefgewoonten én daarnaast een matige hoeveelheid alcoholhoudende drank 
consumeren, 40% minder kans hebben op het ontwikkelen van diabetes type 2 dan 
geheelonthouders met een gezonde leefstijl.  
 
* Adiponectine
Adiponectine is een hormoon dat 
vrijwel alleen wordt gemaakt en 
afgegeven door het vetweefsel. Hoge 
gehaltes van dit hormoon in het bloed 
hangen samen met een hoge insuline-
gevoeligheid, een lage ontstekingsgraad 
en een lager risico op diabetes type 2 en 
hart- en vaatziekten. 
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Interventiestudies 
Bij interventiestudies wordt aan een relatief kleine groep proefpersonen een bepaalde stof 
of behandeling gegeven. In de beschreven interventiestudies in dit proefschrift werden 
alcoholhoudende dranken en alcoholvrije controle dranken aan de proefpersonen gegeven. 
De interventiestudies duurden 8 tot 12 weken en zijn uitgevoerd volgens een zogenaamde 
'gerandomiseerde cross-over' opzet. Dat betekent dat alle proefpersonen beide dranken 
(alcohol vs. alcoholvrij) hebben gekregen (= cross-over) maar in een willekeurige volgorde 
(= gerandomiseerd). Mannen dronken bij de avondmaaltijd dagelijks 3 standaard glazen en 
vrouwen 2,5 glazen. Een standaard glas bevat ongeveer 10 gram pure alcohol, ongeacht het 
type drank (bier, wijn of gedistilleerd). Aan het einde van beide periodes werd 
lichaamsmateriaal (bloed, vetweefsel, urine of speeksel) afgenomen om veranderingen in 
uitkomstmaten te bestuderen. 
 
Veranderingen in insulinegevoeligheid door alcohol 
Hoewel uit een groot aantal onderzoeken blijkt dat mensen die een matige hoeveelheid 
alcohol consumeren een verlaagd risico hebben op diabetes type 2 in vergelijking met 
geheelonthouders, was het nog onduidelijk of 
alcoholconsumptie de insulinegevoeligheid* van 
het lichaam verhoogt. In hoofdstuk 4 beschrijven 
we de resultaten van een klinische interventie-
studie onder 36 vrouwen van middelbare leeftijd 
(na de overgang) die gedurende zes weken witte 
wijn en wit druivensap hebben gedronken. Matige 
alcoholconsumptie bleek de insulinegevoeligheid 
met 11% en het gehalte adiponectine in het bloed met 12% te laten toenemen in 
vergelijking met zes weken onthouding van alcoholhoudende drank. Bovendien bleek dat 
de toename van adiponectine in het bloed toe te schrijven was aan een toegenomen 
aanmaak van adiponectine in het vetweefsel. 
 
Effect van alcohol op witte bloedcellen 
Matige alcoholconsumptie heeft verschillende korte termijn effecten op de genexpressie (= 
het tot uitdrukking komen van erfelijke eigenschappen) van witte bloedcellen. Deze cellen 
spelen een belangrijke rol bij een ontsteking* en 
bij de afweer van het lichaam. De effecten van 
matige alcoholconsumptie op deze witte 
bloedcellen op een wat langere termijn zijn nog 
grotendeels onbekend. Om dit te onderzoeken 
hebben we in hoofdstuk 5 beschreven hoe we de 
veranderingen in eiwitten in bloed en in genexpressie van witte bloedcellen hebben 
onderzocht. Hiervoor hebben 24 jonge mannen vier weken lang dagelijks een mix van jus 
d’orange met wodka gedronken en vier weken alleen jus d’orange gedronken. De 
* Ontsteking
Een beschermende reactie van 
lichaamsweefsel op een schadelijke 
prikkel, vaak gekenmerkt door een 
rode, warme, pijnlijke zwelling. 
* Insulinegevoeligheid
Dit betekent de gevoeligheid van 
weefsels zoals lever en spieren voor 
insuline. Insuline zorgt ervoor dat 
glucose in de weefsels komt. Een 
verlaagde insulinegevoeligheid kan een 
voorspeller zijn van diabetes type 2. 
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veranderingen in zowel eiwitten als genexpressie liet zien dat na de periode van 
alcoholconsumptie verschillende processen op het gebied van ontsteking en vetmetabolisme 
waren veranderd. Deze veranderingen gaven inzicht in de manier waarop alcohol mogelijk 
de kans op diabetes type 2 verlaagt. 
 
Effect van alcohol op het hormoon adiponectine 
Eerder onderzoek heeft aangetoond dat matige alcoholconsumptie bij jonge mannen en bij 
mannen en vrouwen van middelbare leeftijd het adiponectinegehaltes in het bloed verhoogt 
(zie hoofdstuk 4). Of alcoholconsumptie ook bij jongere vrouwen de adiponectinewaarden 
in het bloed laat stijgen was nog niet eerder onderzocht. Ook de snelheid waarmee dit 
gebeurt, was nog onduidelijk. Bovendien was nog onvoldoende bekend of deze stijging na 
alcoholconsumptie ook optreedt voor de hoogmoleculaire vorm van adiponectine. 
Aangenomen wordt dat vooral deze vorm de ‘biologisch actieve’ vorm is. Daarom hebben 
we in hoofdstuk 6 bij 24 jonge vrouwen de wekelijkse veranderingen in de totale als de 
hoogmoleculaire vorm van adiponectine gemeten. We zagen dat in vergelijking met 
alcoholvrij bier, alcoholhoudend bier zowel het gehalte van de totale als de 
hoogmoleculaire vorm van adiponectine met ongeveer 8% liet toenemen. Deze stijgingen 
waren pas waarneembaar na minimaal drie weken van matige alcoholconsumptie.  
 
Effect van alcohol op kunstmatige ontstekingsreactie 
Matige alcoholconsumptie verhoogt de bloedwaardes van het HDL-cholesterol, ook wel het 
‘goede’ cholesterol genoemd. Naast andere functies speelt dit HDL-cholesterol ook een 
belangrijke rol in de afvoer van schadelijke stoffen. Sommige van die schadelijke stoffen 
kunnen een ontstekingsreactie kunnen veroorzaken. In hoofdstuk 7 hebben we daarom 
onderzocht of de toegenomen waarde van HDL-cholesterol na alcoholconsumptie bij de 
proefpersonen leidt tot een lagere ontstekingsreactie. Hiervoor hebben 22 mannen 
gedurende vier weken dagelijks een mix van jus d’orange met wodka of alleen jus d’orange 
gedronken. Aan het einde van beide periodes werd bij de proefpersonen een milde 
ontstekingsreactie opgewekt door het toedienen van een schadelijke stof. Hoewel het HDL-
cholesterol na vier weken matige alcoholconsumptie 10% hoger was dan na de vier weken 
zonder alcoholconsumptie, bleek er geen verschil te zijn in de ontstekingsreactie na beide 
periodes. 
 
Effect van proeven van alcohol op vrije vetzuren 
Het proeven van voedsel prikkelt bepaalde zintuigen in de mond. Deze prikkel bereidt het 
lichaam voor op het voedsel dat doorgeslikt gaat worden. In hoofdstuk 8 hebben we bij 22 
vrouwen van middelbare leeftijd (na de overgang) onderzocht of het proeven van witte wijn 
gedurende 6 minuten zonder het door te slikken ook een dergelijke reactie opwekt. Na het 
proeven was de hoeveelheid vrije vetzuren (= een bron van kant-en-klare energie) in het 
bloed van de wijnproevers 20% lager dan in het bloed van de waterproevers. De daling in 
vrije vetzuren door het proeven van de wijn was tijdelijk (20 minuten). Mogelijk leidt de  
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daling van vrije vetzuren in het bloed ten gevolge van het proeven van alcohol tot een 
tijdelijke verhoging van de insulinegevoeligheid. 
 
Algemene discussie 
Tot slot wordt in hoofdstuk 9 een kort overzicht gegeven van de belangrijkste bevindingen 
van dit proefschrift. Ook worden de voor- en nadelen van de gebruikte 
onderzoeksmethoden besproken en worden de gevonden resultaten vergeleken met eerdere 
bevindingen in de wetenschappelijke literatuur. Vervolgens wordt de relevantie van de 
uitkomsten voor de volksgezondheid beschreven. Tenslotte, worden suggesties gedaan voor 
verder onderzoek op het gebied van matige alcoholconsumptie en diabetes type 2. 
 
Kortom, dit proefschrift heeft het verband tussen matige alcoholconsumptie en een lager 
risico op diabetes type 2 uitgebreid door in bevolkinsonderzoek aan te tonen dat: 
• het verband ook geldt voor mensen die door hun leefstijl al een verlaagde kans op 
diabetes type 2 hebben 
• een toename in alcoholconsumptie tot een matig niveau leidt tot een daaropvolgende 
verlaging in het risico op diabetes type 2. 
De toegenomen adiponectinegehaltes en insulinegevoeligheid en de veranderingen in 
ontstekingsprocessen na matige alcoholconsumptie in de interventiestudies kunnen de 
verlaging in risico op diabetes type 2 mogelijk verklaren. 
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